Drug, bio-affecting and body treating compositions inventions 12/08

20080318834 - Antimicrobial lactoferrin compositions for surfaces, cavities, and foodstuff: The present invention relates to a method and composition for decontaminating surfaces, in particular surfaces in the oral cavity or wounded skin, inert surfaces such as from surgical instruments, or food stuffs, such as meat, wherein the method consists of treating the surface with a solution of lactoferrin of acid... Agent: The Webb Law Firm, P.C.

20080318839 - Ligand activated transcriptional regulator proteins: Fusion proteins for use as ligand-dependent transcriptional regulators are provided. The fusion proteins include a nucleotide binding domain operatively linked to a ligand-binding domain. They also can include a transcription regulating domain. The nucleotide binding domain is a zinc-finger peptide that binds to a targeted contiguous nucleotide sequence of from... Agent: Bell, Boyd & Lloyd LLP

20080318835 - Novel integrin ligand itgl-tsp: ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retmopathy), restenosis,... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080318838 - Peptides: G

20080318837 - Pharmaceutical formation for increased epithelial permeability of glucose-regulating peptide: What is described is a pharmaceutical formulation comprising a mixture of a pharmaceutically effective amount of glucose-regulating peptide (GRP) and enhancers, wherein the pharmaceutical formulation is used in the treatment of a metabolic syndrome.... Agent: Brooks Kushman P.C.

20080318836 - Scd fingerprints: The present invention relates to the use of cluster of differentiation (CD) molecules in detecting the presence and progression of one or more disease states in an individual. In particular it relates to the use of profiles of shed CD (sCD) molecules in detecting an assessing the progress of one... Agent: Edwards Angell Palmer & Dodge LLP

20080318840 - Compositions of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer: The invention relates to novel compositions comprising alpha-fetoprotein (AFP) and methods for preventing, treating or inhibiting a malignant neoplasm expressing an alpha-fetoprotein receptor (AFPR) with or without multidrug resistance. Compositions comprising a non-covalent complex of an exogenous AFP, and at least one apoptosis-inducing agent selected from the group comprising mitochondrial... Agent: Dann, Dorfman, Herrell & Skillman

20080318841 - Method for preparing a factor h concentrate and the use thereof in the form of a drug: The invention relates to the use of a factor H for producing a drug for treating Uremic Haemolytic Syndrome (UHS), to a method for purifying the factor H from a frozen fresh plasma and to a factor H concentrate obtainable by said method.... Agent: Marsh, Fischmann & Breyfogle LLP

20080318842 - Cyclic isodityrosine derivatives: wherein R1 represents a hydrogen atom, an amido group, a Boc group, a Cbz group, an Fmoc group, a BocNH(CH2)5CO— group, a BocNHCH(CH2C6H5)CO— group, or a linear or branched alkyl group; R2 represents a benzoyl group, a benzyl group, a modified benzyl group, or a linear or branched alkyl group;... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080318843 - Device and method for the delivery of drugs for the treatment of posterior segment disease: Hydrogel lenses are infused with a drug for the treatment of posterior segment disease. The lenses are placed in contact with the subject's cornea. Drugs can be passively released from the hydrogel and can migrate around the globe of the eye to the posterior segment.... Agent: Grossman, Tucker, Perreault & Pfleger, PLLC

20080318844 - Composition and method for the treatment of diseases affected by histone deacetylase inhibitors: The present invention includes methods of treatment and compositions for treating diseases related to the activity of a histone deacetylase in a subject by administering to the subject an effective amount of a modified FK228 compound comprising an amino acid conjugate which constitutes an amino thiol, a hydroxy thiol, a... Agent: Chalker Flores, LLP

20080318849 - Kahalalide f and related compounds: A process is provided for preparing kahalalide F and which leads to other kahalalide mimic compounds having useful biological activity.... Agent: King & Spalding

20080318845 - Selective vpac2 receptor peptide agonists: The present invention relates to peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.... Agent: Eli Lilly & Company

20080318846 - Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists: Methods to sensitize tumor cells to radiation therapy through the administration of an endothelin agonist such as the ETB agonist IRL1620.... Agent: K&l Gates LLP

20080318847 - Use of antagonist of oxytocin and/or vasopressin in assisted reproduction: The present invention relates to the use of antagonists of oxytocin, antagonists of oxytocin and vasopressin, or antagonists of vasopressin, or their pharmaceutically accepted salts, or their combinations with other drugs for the manufacture of a medicament which main profile of action is inhibition of oxytocin and/or vasopressin receptors in... Agent: Merchant & Gould PC

20080318851 - Acid-labile subunit (als) of insulin-like growth factor binding protein complex: e

20080318857 - Compositions and methods for the intracellular disruption of vegf and vegfr-2 by intraceptors: The present invention provides an intraceptor that interacts with and decreases activity of with VEGF and/or a VEGFR for the treatment of angiogenesis-related conditions. The present invention further provides pharmaceutical compositions, and methods of use thereof, for the treatment and prevention of an angiogenesis-related condition using said intraceptors. The invention... Agent: Sutherland Asbill & Brennan LLP

20080318862 - Crosslinkable polymeric materials and their applications: The present invention relates to a novel composition for dental, orthopedic and drug delivery purpose. Specifically, it relates to composition comprising an admixture of a resorbable bone substitute and a crosslinkable prepolymer. It also relates to the composition formed by crosslinking the admixture.... Agent: Darby & Darby P.C.

20080318853 - Diagnostic and therapeutic use of a novel growth factor, neublasmin: The present invention relates to the field of diagnostic and therapeutic use of proteins and genes, in particular to the diagnostic and therapeutic use of a secreted human hormone/growth factor, Neublasmin, and use or the gene coding for Neublasmin in the diagnosis and treatment of testicular disorders, in particular diagnosis... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080318855 - Dna encoding for recombinant polypeptide emutants of human stromal cell-derived factor 1: This invention is generally directed to a recombinant method of producing SDF-1 receptor antagonists. More particularly, the invention is directed to the isolated and/or recombinant polynucleotide sequences encoding analogs of human SDF-1 alpha or beta and, in particular, SDF-1 analogs having the proline at residue position number 2 replaced with... Agent: Tips Group C/o Intellevate LLC

20080318852 - Epitopes related to coeliac disease: The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.... Agent: Pepper Hamilton LLP

20080318850 - Glycopegylated factor ix: The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a... Agent: Morgan, Lewis & Bockius LLP (sf)

20080318860 - High activity growth factor mutants: The application relates to novel biosynthetic growth factor mutants, derived from GDF-5, which exhibit improved biological activity. Mutations at positions 453 and 456 of human GDF-5 are disclosed, as well as use of these mutants in therapy of diseases associated with tissue degeneration/destruction.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080318863 - Ischemia therapeutic agent: The present invention provides a ischemia therapeutic agent that contains vascularization induction factor and gelatin hydrogel, and gradually releases vascularization induction factor, which is useful in treating ischemia accompanying peripheral circulatory disorders etc. encountering as complications of arteriosclerosis obliterans, Buerger's disease, diabetes and collagen disease.... Agent: Osha Liang L.L.P.

20080318858 - Isolated recombinant vaccinia virus complement control protein (hrvcp) polypeptide: An isolated recombinant vaccinia virus complement control protein (hrVCP) polypeptide comprises a modified amino acid sequence comprising one or more amino acid substitutions to an amino acid sequence as set forth in SEQ ID NO: 2. The hrVCP polypeptide exhibits a complement activation regulatory activity greater than a complement activation... Agent: Stites & Harbison, PLLC

20080318866 - Medicament for treatment of non-insulin dependent diabetes mellitus, hypertension and/or metabolic syndrome: A substance including the chemical structures of bicyclo [3.2.1]octan or the chemical structures of kaurene for the use in a dietary supplementation or as a constituent in a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The unique chemical structures of bicyclo [3.2.1]octan alone... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080318854 - Method for regulating neurite growth: This invention relates to a method of inhibiting neuronal cell death, including protecting neronal cells from cell death and the effects of stress, such as high or low pH, comprising administering to the cells an effective amount of Teneurin C-terminal Associated Peptide (TCAP). The invention provides the use of TCAP... Agent: Mccarthy Tetrault LLP

20080318864 - Methods and compositions regarding polychalcogenide compositions: The present invention concerns the use of polychalcogenide compositions on cells, tissue, organs, and organisms to enhance their survivability. It includes compositions, compounds, methods, articles of manufacture and apparatuses for enhancing survivability and for protecting them from or treating them for injury or damage. In specific embodiments, there are also... Agent: Fulbright & Jaworski L.L.P.

20080318859 - Methods for tissue engineering: The invention relates to the use of parathyroid hormone-related protein (PTHrP) in the prevention of hypertrophy in chondrogenic cells for cartilage replacement. A method for engineering three dimensional cartilage constructs from chondrogenic cells is provided, said method comprising a step of treating the chondrogenic cells or immature constructs with PTHrP... Agent: Edwards Angell Palmer & Dodge LLP Peter C. Lauro, Esq.

20080318856 - Monomer protein with bone morphogenetic activity and medicinal agent containing the same for preventing and treating diseases of cartilage and bone: This invention provides for a protein of the TGF-β superfamily in which the cysteine involved in the normal formation of homodimers is changed to another amino acid. These mutant proteins, as monomers, display higher bone morphogenetic activity than the wild-type protein dimers. Also provided is a method for producing and... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080318861 - Mucosal delivery of stabilized formulations of exendin: What is described is a pharmaceutical formulation for intranasal administration of exendin to a mammal, wherein the formulation comprises a therapeutically effective amount of an exendin, a viscosity enhancer, methyl-β-cyclodextrin, a surfactant, tartrate buffer to control pH and a chelating agent for cations, and wherein such exendin dosage form exhibits... Agent: Brooks Kushman P.C.

20080318865 - Stabilized pharmaceutical peptide compositions: Method for increasing the shelf-life of a pharmaceutical composition comprising a glucagon-like peptide which is prepared from a peptide product that has been dried at a pH above neutral pH.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080318867 - Virulent phages to control listeria monocytogenes in foodstuffs and in food processing plants: The present invention relates to virulent (lytic) Listeria monocytogenes phage from the Myoviridae family, preferably P100, alone or in combination with other virulent phages. P100 and the endolysin from P100 can be administered to food products, to the components that will be added to food products, and/or to the infrastructure... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080318868 - Use of mycobacterial mannosylated lipoglycans peptide mimotopes for treating inflammation: The present invention is based on the discovery that biological peptide-based mimotopes of mannose-containing cell-wall compounds of Mycobacterium tuberculosis, specifically, ManLAM, have an anti-inflammatory effect and immunoregulator effect in animal models of inflammation. Such models include animal models of allergic peritonitis, allergic asthma and septic shock model (mice injected with... Agent: The Nath Law Group

20080318869 - Method to promote wound healing: Wound healing is impaired in irradiated animals. Substance P and its active analogs promote wound healing in irradiated animals. Substance P and its analogs can be used to treat animals irradiated by a nuclear weapon, a nuclear accident, or a therapeutic regimen, for example. Wounds which are susceptible to such... Agent: Jones Day

20080318870 - Synthetic bile acid compositions and methods: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.... Agent: Foley & Lardner LLP

20080318871 - Treatment of neurological disorders: The description relates to the treatment of the inflammatory component of neurological disorders or so called neuroimmune disorders such as schizophrenia, manic depression and other bipolar disorders, multiple sclerosis, post-partum psychosis and autism, herein also called inflammatory neurological disorders. Provided are methods for modulating a neurological disorder in a subject... Agent: Trask Britt

20080318872 - Antigen determinant of rheumatoid arthritis-specific autoantibody and use thereof: where A is —NH2, B is —O—, D is —NH—, F is —NHCO—, or —NR—, where R is hydrogen or acyl, G is —CONH—, or —COOR, wherein R is alkyl, E is (CH2)n′, wherein n′ is an integer from 1 to 6, S is —SH, or —SS—, on the condition... Agent: Mchale & Slavin, P.A.

20080318873 - Camptothecin derivatives as chemoradiosensitizing agents: Camptothecin-based compounds are useful for treating a neoplasm in mammalian subjects by administering such compound to the subjects in combination with radiotherapy, i.e., the treatment of tumors with radioactive substances or radiation from a source external to the subject. Camptothecin-based compounds are modified by positioning at least one electron-affinic group... Agent: Foley & Lardner LLP

20080318874 - Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes: Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080318875 - Core 2 glcnac-t inhibitors: The present invention relates to the use of known and novel compounds as inhibitors of UDP-GlcNAc:Galβ1,3GaINAc-R (GlcNAc to GalNAc) β1,6-N-acetylglucosaminyl transferase (core 2 β1,6 N-acetylaminotransferase, core 2 GlcNAc-T-EC 2.4.1.102). Such inhibitors have applications in therapy for diseases associates with raised activity of core 2 GlcNAc-T, in particular inflammatory diseases, atherosclerosis,... Agent: Nixon & Vanderhye, PC

20080318876 - Use of ginsenosides in the treatment of aids: e

20080318877 - Purifications of pomegranate ellagitannins and their uses thereof: Compositions of purified and biologically active ellagitannins are provided by separation from pomegranate husk using a method of extraction and purification using a solid polymeric adsorbent and the uses of the said compounds... Agent: Bozicevic, Field & Francis LLP

20080318878 - Antibacterial agents: The present invention provides acylide derivatives, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed to by Gram-positive, Gram-negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp., Chlamydia spp., Mycoplasm, Legionella... Agent: Jayadeep R. Deshmukh, Esq. Ranbaxy Inc.

20080318879 - Method for the preparation of polymeric conjugates of doxorubicin with ph-controlled release of the drug: A method for the preparation of polymeric conjugates of N-(2-hydroxypropyl)methacrylamide and a methacryloylaminoacylhydrazone of doxorubicin with pH-controlled release of the drug, comprising the following three steps of synthesis: a. preparation of a monomeric methacryloylaminoacylhydrazine, wherein the aminoacyl is derived from an amino acid or oligopeptide, by reaction of a methacryloyl... Agent: Pearl Cohen Zedek Latzer, LLP

20080318880 - Neoadjuvant treatment of breast cancer: Neoadjuvant treatment of inflammatory or T3 to T4 breast cancer is carried out by administering to such patients a number of cycles of chemotherapy treatment in which DPPE first is administered followed by a combination of anthracyclines and taxanes.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080318881 - Liquid compositions for treating plant propagation materials: The present invention includes a fast-drying liquid composition comprising at least one fungicide and at least one insecticide. The present invention further includes a method for treating plant propagation materials, especially cut seeds, including tubers, against pests, a method for promoting suberization in cut seeds, a method for decreasing the... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080318883 - Anti-aging supplement: An anti-aging supplement is disclosed having effective amounts of β1,3D glucan, deoxyribonucleic acid, and body's hyaluronan-yielding row material composed of at least one amino sugar selected from a group consisting of N-acetylglucosamine and glucosamine salts.... Agent: Nixon & Vanderhye, PC

20080318887 - Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin: Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in... Agent: Morgan, Lewis & Bockius LLP (sf)

20080318888 - Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin: Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in... Agent: Morgan, Lewis & Bockius LLP (sf)

20080318889 - Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin: Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in... Agent: Morgan, Lewis & Bockius LLP (sf)

20080318890 - Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin: Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in... Agent: Morgan, Lewis & Bockius LLP (sf)

20080318891 - Antisense oligonucleotides against thymidylate synthase: Antisense oligonucleotides targeted to sequences in thymidylate synthase (TS) mRNA. In particular the invention relates to antisense oligonucleotides targeted to sequences in the 3′ end of TS mRNA, which are both cytostatic on their own when administered to human tumour cell lines, and which also enhance the toxicity of anticancer... Agent: Gary M. Nath The Nath Law Group

20080318893 - Blockade of calcium channels: Knock-down of L-type calcium channel beta subunit (LTCCβ) attenuates the hypertrophic response both in vitro and in vivo without compromising systolic performance. Knock-down can be accomplished by administration of a vector encoding a short hairpin RNA which specifically modulates expression of LTCCβ. Suppression of the LTCCβ expression represents a therapeutic... Agent: Banner & Witcoff, Ltd.

20080318895 - Intranasal delivery of nucleic acid molecules: Aerosol delivery of nucleic acids to the lungs using viral vectors, polymers, surfactants, or excipients has been described. Compositions for intranasal administration are described that contain nucleic acids without viral or plasmid vectors and with little to no polymers, surfactants, or excipients. In one embodiment, the composition for intranasal delivery... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080318885 - Method for modulating responsiveness to steroids: The present invention makes it possible to enhance steroid efficacy in a steroid refractory patient afflicted with an inflammatory condition not responding or responding poorly or inadequately to anti-inflammatory treatment, by administering an effective amount of an oligonucleotide having the sequence 5′-Xm-TTCGT-Yn-3′ to 5 said patient, wherein X is A,... Agent: Dla Piper LLP (us)

20080318882 - Method of delivery of nucleic acids to peripheral neurons: The invention provides for methods for delivering a nucleic acid into a peripheral neuron by identifying a target neuron in a dorsal root ganglion and intrathecally delivering a vector comprising the nucleic acid to the dorsal root ganglion neuron. The nucleic acid may encode a neurotrophic factor that may be... Agent: Klarquist Sparkman, LLP

20080318896 - Methods and compositions for controlling of efficacy of rna silencing: Based at least in part on an understanding of the mechanisms by which small RNAs (e.g., naturally-occurring miRNAs) mediate RNA silencing in plants, rules have been established for determining, for example, the degree of complementarity required between an RNAi-mediating agent and its target, i.e., whether mismatches are tolerated, the number... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080318892 - Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad: Pharmaceutical and cosmetic formulations and methods for optimizing the intracellular concentrations of NAD are provided. The present methods and compounds relate to the use of PBEF, PRPP and various forms of nicotinamide, individually or in combination, for therapeutic, cyto-protective, cosmetic and anti-aging purposes. PBEF, PRPP and nicotinamide, individually or in... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080318884 - Methods for altering gene expression and methods of treatment utilizing same: The present disclosure describes methods for altering the expression of a target gene comprising a rare cluster of codons, including, but not limited to, trinucleotide repeats. The method utilizes, in part, on amino acid deprivation or the limiting of specific charged tRNAs. The methods for altering target gene expression may... Agent: Bradley Arant Rose & White, LLP Intellectual Property Department-nwj

20080318886 - Methods of increasing cancer sensitivity to chemotherapeutic agents using chimeric isf35: A method of treating cancer by administering ISF35 or analogous constructs. The treatment can allow an increased sensitivity to treatment with a chemotherapeutic agent.... Agent: Wilson Sonsini Goodrich & Rosati

20080318894 - Rna antagonist compounds for the modulation of her3: The invention relates to oligomer compounds (oligomers), which target HER3 mRNA in a cell, leading to reduced expression of HER3 and/or HER2 and/or EGFR. Reduction of HER3 and/or HER2 and/or EGFR expression is beneficial for a range of medical disorders, such hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions... Agent: Dechert LLP

20080318897 - Composition containing swelling agent composed of swellable water-soluble polysaccharide, and food, anti-obesity agent and constipation alleviator each containing the composition: [Means for Solution] A composition comprises a swelling agent composed of a water-soluble polysaccharide swellable in Japanese Pharmacopoeia first fluid or Japanese Pharmacopoeia second fluid and water; and a swell inhibitor operative to control the swell of the swelling agent. The swelling agent and the swell inhibitor are mixed in... Agent: Trexler, Bushnell, Giangiorgi, Blackstone & Marr, Ltd.

20080318898 - Inclusion complexes of butylphthalide with cyclodextrin or its derivatives, a process for their preparation and the use thereof: The present invention relates to the inclusion complexes of butylphthalide, which is D, L-mixed or levorotatory, with cyclodextrin or cyclodextrin derivatives, to a process for their preparation and the use thereof. In the invention, the butylphthalide is complexed with cyclodextrin or cyclodextrin derivatives, preferably with hydroxypropyl-β-cyclodextrin in order to increase... Agent: Ip Group Of Dla Piper US LLP

20080318900 - Cosmetic compositions comprising at least one bis-urea derivative: and at least one oil with a solubility parameter δa ranging from 0 to 7.00 (J/cm3)1/2, for example from 0 and 5.00 (J/cm3)1/2. The present disclosure also relates to a process for making up or caring for keratin materials, comprising applying to the keratin materials at least one composition as... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080318899 - Pyridazine compounds, compositions and methods: The invention relates to novel chemical compounds and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways... Agent: Millen, White, Zelano & Branigan, P.C.

20080318903 - Methods for treating cancer: The present invention relates to novel Triheterocyclic Compounds, compositions comprising a Triheterocyclic Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Triheterocyclic Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or... Agent: Wilson Sonsini Goodrich & Rosati

20080318901 - Novel lysophosphatidic acid receptor selective antagonists: The present invention is directed to compositions comprising lysophosphatidic acid analogs and methods of using such analogs as agonist or antagonists of LPA receptor activity. In addition the invention is directed to LPA receptor agonists that vary in the degree of selectivity at individual LPA receptors (i.e. LPA1, LPA2 and... Agent: University Of Virginia Patent Foundation

20080318902 - Triheterocyclic compounds and compositions thereof: The present invention relates to novel Triheterocyclic Compounds, compositions comprising a Triheterocyclic Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Triheterocyclic Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or... Agent: Wilson Sonsini Goodrich & Rosati

20080318904 - Deuterium-enriched tenofovir: The present application describes deuterium-enriched tenofovir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080318905 - Prodrugs and methods of making and using the same: Prodrugs of parent drugs and methods of making and using the same are described. The prodrugs comprise an amine-containing parent drug moiety and a prodrug moiety, such as methoxyphosphonic acid or ethoxyphosphonic acid. The prodrugs may be employed in therapy for the treatment of various indications, such as pain, and... Agent: Morrison & Foerster LLP

20080318906 - Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases: Bisphosphonate compounds and related methods of making and using are disclosed, including pyridinium-1-yl, quinolinium-1-yl, and related compounds. The activity of compounds is disclosed in the context of functional assays such as Leishmania major farnesyl diphosphate synthase (FPPS) inhibition, Dictyostelium discoideum growth inhibition, human gamma delta T cell activation, and bone... Agent: Greenlee Winner And Sullivan P C

20080318907 - Nitroxide free radical synergized antineoplastic agents: Nitroxide free radicals attached to antineoplastic agents can synergize their potencies to cancer cells. This invention relates to any antineoplastic agents and their derivatives chemically attached with nitroxide free radicals, such as TEMPO and its radical derivatives. This invention also relates to precursors of such compounds, as well as the... Agent: MastermindIPLaw PC

20080318848 - Kahalalide compositions: The present invention is directed to new kahalalide antitumoral compounds, in particular to analogs of kahalalide F, useful as antitumoral, antiviral, and antifungal agents.... Agent: King & Spalding

20080318908 - Use of gaba and gabab agonists: The present invention provides methods of stimulating tissue growth, including islet cell growth, by administering GABA or a GABA agonist to act on GABAB receptors and GABAB-like receptors to activate cell replication.... Agent: David S. Resnick

20080318909 - Use of linoleic compounds against heart failure: Linoleic acid and related cardiolipin products are used as dietary supplements that provide cardiac benefits against a variety of cardiac related symptoms and diseases. For example, the disclosed compositions and methods may be used to treat or prevent hypertension, ischemic cardiomyopathy, heart disease, Barth Syndrome and heart failure.... Agent: Lathrop & Gage Lc

20080318910 - Controlled-release oral dosage form: A controlled-release oral dosage form suitable for administration to a mammal. The dosage form comprises a drug and an organic acid or a salt thereof. The dosage form releases no more than 60% the total amount of the drug within about a first hour, the remaining amount of the drug... Agent: Bereskin And Parr

20080318911 - 20-cyclopropyl, 26,27-alkyl/haloalkyl vitamin d3 compounds and methods of use thereof: The invention provides vitamin D3 analogs of cholecalciferol, substituted at carbon 20 with cycloalkyl, e.g., cyclopropyl, wherein carbon-16 is a double bond, and carbon-23 is a single, double, or triple bond. Various alkyl or haloalkyl substitutions are incorporated as carbon-25. The invention provides pharmaceutically acceptable esters, salts, and prodrugs thereof.... Agent: Edwards Angell Palmer & Dodge LLP

20080318913 - Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases: There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.... Agent: Morgan Lewis & Bockius LLP

20080318912 - Medicaments for treating chronic respiratory disease: There is provided the use of a methylxanthine compound and a steroid in a synergistic combination for the treatment of a respiratory disease, wherein the methylxanthine compound is administered at a dose, which, in isolation, is not effective to treat said disease.... Agent: Morgan Lewis & Bockius LLP

20080318914 - Methods for the treatment of a traumatic central nervous system injury: Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of... Agent: Foley And Lardner LLP Suite 500

20080318915 - Deuterium-enriched fluticasone propionate: The present application describes deuterium-enriched fluticasone propionate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080318916 - Novel alpha glucosidase inhibitors from lichens: This invention is directed to a novel method for the inhibition of α-glucosidase enzyme and thus treating diabetes, viral infections, fungal infections, autoimmune function disorders and obesity using compounds derived as lichen metabolites; more specifically, this includes the therapeutic applications of methylorsellinate (2,4-dihydroxy-6-methylbenzoate, Compound I), methyl-β-orinolcarboxylate (2,4-dihydroxy-3,6-dimethylbenzoate, Compound II) and... Agent: Sarfaraz K. Niazi

20080318917 - Polyethylene glycolated superoxide dismutase mimetics: Compounds and methods for utilizing compounds comprising a superoxide dismutase mimetic covalently linked to polyethylene glycol. Methods are also provided for preparing a superoxide dismutase mimetic covalently linked to a polyethylene glycol, the methods comprising reacting an activated polyethylene glycol with a superoxide, dismutase mimetic, or alternatively, reacting a superoxide... Agent: Sonnenschein Nath & Rosenthal LLP

20080318918 - Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into the middle ear: Methods for treating and preventing middle ear infections by transmembrane administration of medicament-containing transmembrane carrier compositions comprising a nonionic polymer surfactant, such as an alkyl aryl polyether alcohol (e.g., tyloxapol) to the tympanic membrane. The medicaments delivered according to the methods of the invention include antibiotic, antiviral, anti-fungal and anti-inflammatory... Agent: Dla Piper LLP (us)

20080318919 - Cefquinome compositions and methods of their use: This invention is directed generally to cefquinome compositions, processes for making such compositions, uses of such compositions to make medicaments, kits for making such compositions, and methods for using such compositions and kits to treat infections.... Agent: Intervet/schering-plough Animal Health Patent Department

20080318920 - Deuterium-enriched ezetimibe: The present application describes deuterium-enriched ezetimibe, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080318921 - Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors: The present invention provides a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.... Agent: Wyeth Patent Law Group

20080318923 - 1,3-dihydro-2h-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle: It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug... Agent: Sughrue Mion, PLLC

20080318922 - Bicyclic pyrrole derivatives:

20080318925 - Compounds and uses thereof - 849:

20080318924 - Phenoxypyridine derivative salts and crystals thereof, and process for preparing the same: The invention provides acid addition salts of the compounds represented by formula (1) or (2), or crystals thereof, and processes for preparing the same. The salts or crystals have HGFR inhibitory activity and excellent physical properties (solubility, safety, etc.) and are therefore useful as anti-tumor agents, angiogenesis inhibitors and inhibitors... Agent: Birch Stewart Kolasch & Birch

20080318926 - Methods of treating mood disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives: An aminomethylpyridyloxymethyl/benzisoxazole substituted azabicyclic compound, a pharmaceutical composition comprising same, and a method of treating a mood disorder selected from the group consisting of Somatization Disorder, Borderline Personality Disorder, Narcissistic Personality Disorder, Suicidal Ideation, and Antisocial Personality Disorder.... Agent: Pfizer Inc Steve T. Zelson

20080318927 - Substituted monocyclic cgrp receptor antagonists: (wherein variables A1, A2, A2, A4, m, n, J, Q, R4, Ea, Eb, Ec, R6, R7, Re, Rf, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as... Agent: Merck And Co., Inc

20080318928 - Bengamides with a substituted caprolactam cycle, method for the preparation thereof, compositions containing them and use thereof: The invention relates to the preparation of substituted caprolactams, a method for the preparation thereof, compositions containing them and the use thereof as a medicament, particularly as anticancer agents.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080318929 - Pyrimidine derivatives useful as inhibitors of pkc-theta: Disclosed are novel compounds of formula (I) wherein R1, R2, R3, and R4 and A are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080318930 - Sulfonyl compound as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1: Sulfonyl derivatives of structural formula I are selective inhibitors of the 11β-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome or Syndrome X, and other symptoms associated with NIDDM.... Agent: Merck And Co., Inc

20080318932 - Sodium channel blocker compositions and the use thereof: Methods of treating or preventing chronic pain or convulsion are disclosed by administering to an animal a sodium channel blocker and at least one of gabapentin and pregabalin. Also disclosed are pharmaceutical compositions and kits for the treatment or prevention of chronic pain or convulsion.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080318931 - Treatment of disorders and diseases of the colon: A method and a composition for the treatment of an Inflammatory Bowel Disease (IBD) or intestine polyposes is described. The method includes the local administration to the colon of a therapeutically effective amount of at least one Selective Serotonin Reuptake Inhibitor (SSRI) or at least one tricyclic antidepressant (TCA).... Agent: The Nath Law Group

20080318933 - 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders: m

20080318934 - Diazepinoes: The invention relates to compounds of the formula (I), to the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular tumours and/or diseases in the development or course of which kinases are involved.... Agent: Millen, White, Zelano & Branigan, P.C.

20080318935 - Substituted imidazoheterocycles: e

20080318936 - Substituted 5-phenyl-3,6-dihydro-2-oxo-6h-1,3,4-thiadiazines: Compounds of the formula (I), in which R1, R2, m, Q and B have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20080318937 - Tricyclic delta-opioid modulators: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.... Agent: Philip S. Johnson Johnson & Johnson

20080318938 - Methods for treating aberrant cell proliferation disorders: The invention relates in part to methods for inhibiting proliferation of cancer cells and treating one or more cell proliferative conditions using compounds described herein.... Agent: Morrison & Foerster LLP

20080318939 - Methods for treating ophthalmic disorders: The invention relates in part to methods for treating ophthalmic conditions using compounds described herein. The conditions to be treated include various ocular cancers. The compositions employed include a polycyclic quinolinone derivative or related heteroaromatic analog thereof.... Agent: Morrison & Foerster LLP

20080318940 - Quinazolinone derivatives as vanilloid antagonists: e

20080318941 - 4' substituted compounds having 5-ht6 receptor affinity:

20080318943 - Compounds and uses thereof - 848:

20080318942 - Fredericamycin derivatives: The invention relates to new fredericamycin derivatives, to pharmaceutical drugs containing them or their salts, and to the use of the fredericamycin derivatives for the treatment of diseases, especially tumor diseases.... Agent: Connolly Bove Lodge & Hutz, LLP

20080318944 - N-aroyl cyclic amine derivatives as orexin receptor antagonists: e

20080318945 - Novel compounds:

20080318946 - Di-amino-substituted heterocyclic compounds and methods of use:

20080318947 - Inhibitors of akt activity: Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080318948 - Organic compounds: v

20080318949 - Pyrazolopyrimidinone derivatives, their preparation and their use: It has been proved by pharmacological experiment that the said pyrazolopyrimidinone derivatives have high inhibitory activity against PDE5, and parts of them have a much stronger potency against PDE5 than against PDE6. Most of the compounds show low toxicity. The pyrazolopyrimidinone derivatives can be used in clinics for the palliative... Agent: Sughrue Mion, PLLC

20080318951 - Dual-acting benzoimidazole antihypertensive agents: wherein: Ar, r, n, X, R2-3 and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates... Agent: Theravance, Inc.

20080318950 - Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof: The present invention relates to a novel quinazoline derivative and a pharmaceutically acceptable salt thereof as a multiplex inhibitor, a method for the preparation thereof, and a pharmaceutical composition and a therapeutic composition comprising same as an active ingredient. The inventive quinazoline derivative as a multiplex inhibitor can selectively and... Agent: Anderson, Kill & Olick, P.C.

20080318952 - Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators: Certain diaryl-substituted tetrahydroisoquinoline compounds are histamine H3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and/or serotonin-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20080318953 - Substituted pyridine derivatives: The present invention relates to pyridine derivatives of the general formula (I) and their use as openers of the KCNQ family potassium ion channels for the treatment of CNS disorders.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20080318954 - Compounds: The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts thereof, wherein: Z1: 1 is N or CH; Z2 and Z3 are each independently N or CR7; R1, R2, R3, R4, R5, R6, and R7 are each independently H, R8, or R9; each R8 is independently... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080318955 - Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists: The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.... Agent: Dickstein Shapiro LLP

20080318956 - Inflammatory cytokine release inhibitor: e

20080318957 - Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof: Disclosed are compounds having polybasic functionalities. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism.... Agent: Knobbe Martens Olson & Bear LLP

20080318958 - New utilities of tricyclic compounds: in which X1 and X1 are independently an aryl or heteroaryl that may be optionally substituted, a hydrogen, a halogen, or the like; ring A is a benzene ring or 6-membered aromatic heterocyclic ring containing 1 to 3 N atoms that may be optionally condensed with another aromatic ring; R1... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080318959 - Compounds that inhibit hiv particle formation: The present invention describes novel methods of identifying compounds which inhibit HIV particle formation and Rev-dependent HIV production. The present invention also provides methods and compounds for inhibiting HIV particle formation and or treating patients infected with HIV.... Agent: University Of Virginia Patent Foundation

20080318961 - Drugs comprising chymase inhibitors and ace inhibitors as effective ingredients: It is an object of the present invention to provide drugs which are effective for treatment of hypertension, cardiac disease (cardiac hypertrophy, cardiac failure, myocardial infarction, etc.), cerebral apoplexy, nephritis and the like. The invention also provides circulatory disease treatment agents in forms that allow combined use of chymase inhibitors... Agent: Sughrue Mion, PLLC

20080318960 - Par2-modulating compounds and their use:

20080318963 - 1-[6,7-substituted alkoxyquinoxalinyl) aminocarbonyl]-4-(hetero) arylpiperazine derivatives: The present invention relates to novel quinoxaline-piperazine compounds, 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives and their pharmaceutically acceptable salts, a process for their preparation thereof, and compositions containing such compounds. Therapeutic methods for the treatment of hyperproliferative disorders, including cancers, by administering quinoxalin-piperazine compounds are also included.... Agent: Frommer Lawrence & Haug

20080318965 - Derivatives of alpha2-adrenergic receptor agonist: The present invention relates to alpha2-adrenergic receptor agonist nitrooxyderivatives having improved pharmacological activity and enhanced tolerability. They can be employed for the treatment of ocular diseases, in particular high intraocular pressure and glaucoma.... Agent: Arent Fox LLP

20080318964 - Deuterium-enriched eszopiclone: The present application describes deuterium-enriched eszopiclone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080318962 - Fungicides based on nitrogen-containing heterocycles: The compound of the general formula (I), wherein W, X, Y, Z, R, R1 and R2 are defined as set forth in the specification, useful as fungicide.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080318966 - Sinomenine derivatives and preparation and uses thereof: The present invention relates to the preparation and pharmacological use of sinomenine derivatives of formula I. The approach disclosed herein is the modification of D ring by-substituting for R. Additional substitutions in the other rings are also provided herein. Several of the sinomenine derivatives have significantly greater anti-inflammation activity when... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20080318967 - Hair growth promoting agents: The present invention is directed to crystalline forms of 6-[[(3S,4R)-3,4-dihydro-3-hydroxy-6-[(3-hydroxyphenyl)sulfonyl]-2,2,3-trimethyl-2H-1-benzopyran-4-yl]oxy]-2-methyl-3(2H)-pyridazinone, formulations containing at least one of these crystalline forms and their use to promote hair growth.... Agent: Pfizer Inc.

20080318968 - Chemical compounds: wherein R1, R2, R3, n, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of... Agent: Morgan Lewis & Bockius LLP

20080318969 - Anti-anginal compounds: This invention relates to novel compounds that partially inhibit fatty acid oxidation and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel compounds that are derivatives of ranolazine. This invention also provides compositions comprising one or more compound of this invention and a carrier and the use of... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080318970 - Treatment of infectious diseases: The present invention is directed to the use of chemosensitising compounds, in particular thioxanthene derivatives and phenothiazine derivatives, for treatment of infectious diseases in combination with an anti-infective agent. The invention furthermore relates to compositions comprising said chemosensitising compounds and anti-infective agents.... Agent: Knobbe Martens Olson & Bear LLP

20080318971 - Treatment of imatinib resistant leukemia: The present invention provides 4-anilino-3-quinolinecarbonitriles compounds useful for treating a subject having an BcrAbl positive leukemia that is resistant to imatinib.... Agent: Wyeth Patent Law Group

20080318972 - 5-ht1a receptor subtype agonist: e

20080318973 - Urotensin ii receptor antagonists:

20080318974 - Compounds useful for inhibiting chk1: Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome... Agent: Eli Lilly & Company

20080318975 - Indolylmaleimide derivatives: y

20080318976 - Alpha-hydroxy amides as bradykinin antagonists or inverse agonists: α-Hydroxy amide derivatives of the general formula (I) are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway. R2a is selected from (1) a group selected from Ra. (2)(CH2)nNRbC(O)Ra. (3)(CH2)nNRbSO2Rd. (4)(CH2)nNRbCO2Ra.(5)(CH2)k-heterocycle optionally substituted with... Agent: Merck And Co., Inc

20080318977 - Condensed pyridines as kinase inhibitors: New compounds of formula (I), wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080318979 - Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators: The invention also provides a composition comprising a pharmaceutically acceptable carrier and at least one of the following: i) a pharmaceutically effective amount of a compound of formula I and ii) a pharmaceutically acceptable salt, ester, or prodrug thereof. The invention also provides a method of preventing or treating a... Agent: Mcdermott, Will & Emery

20080318978 - Heterocyclic compounds and their use as aldosterone synthase inhibitors: The application relates to novel heterocyclic compounds of the general formula (I) in which R, R1, R2, W, X, Y, Z and n have the meanings defined in the description, to a process for their preparation and to the use of these compounds as medicaments, in particular as aldosterone synthase... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080318980 - Use of 7-(pyrimidin-4 yl)-imidazo[1,2-a]pyrimidin-5(1h)-ones as gsk-3beta inhibitors: e

20080318981 - Novel compounds 480: wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080318982 - Pharmaceutical combination for the treatment of luts: This invention relates to the combined use of a PDE5 inhibitor and a muscarinic antagonist in the treatment of lower urinary tract symptoms (LUTS), such as urgency, frequency, nocturia and urge incontinence.... Agent: Pfizer Inc.

20080318983 - A2b adenosine receptor antagonists: Disclosed are methods for treating asthma, inflammatory gastrointestinal tract disorders, cancer, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis using A2B adenosine receptor antagonists having the structure of Formula I or Formula II:... Agent: Cv Therapeutics, Inc.

20080318984 - Compounds having activity in correcting mutant-cftr processing and uses thereof: The invention provides compositions, pharmaceutical preparations and methods for correcting cellular processing (e.g., folding, trafficking, or post-translational modification) of a mutant-cystic fibrosis transmembrane conductance regulator protein (e.g., ΔF508 CFTR) that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one... Agent: Bozicevic, Field & Francis LLP

20080318985 - Novel 2-aminopyrimidinone or 2-aminopyridinone derivatives and their use: This invention relates to novel compounds having the structural formula Ia or Ib below: (Ia); (Ib) and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.... Agent: Pepper Hamilton LLP

20080318986 - Ddc compositions: A composition comprising from 1% to 3% dDC which is aqueous and ophthalmically acceptable is disclosed herein.... Agent: Allergan, Inc.

20080318987 - Methods for modulating bone formation and mineralization: Methods and compositions for modulating bone formation and mineralization are described.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080318989 - Pyrimidine kinase inhibitors: The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula (I) wherein ring A, X, Y, Z, R1, R2, R3, R4, m and n are as defined herein.... Agent: Genentech, Inc.

20080318988 - Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis: The present invention relates to the use of pyrimidylaminobenzamide derivatives for the preparation of a drug for the treatment of non-cancerous, benign brain tumors, especially for the curative and/or prophylactic treatment of NF, and to a method of treating non-cancerous, benign brain tumors, especially for the curative and/or prophylactic treatment... Agent: Novartis Corporate Intellectual Property

20080318991 - Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1: The present invention relates to certain spirocyclic compounds that are inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 (11βHSD1), compositions containing the same, and methods of using the same for the treatment of diabetes, obesity and other diseases.... Agent: Fish & Richardson PC

20080318990 - Spiroindolines as modulators of chemokine receptors: e

20080318992 - Method of using a pkc inhibitor to reverse prefrontal cortical declines: Aging is associated with deficiencies in the prefrontal cortex, including working memory impairment, and compromised integrity of neuronal dendrites. The role of Protein Kinase C(PKC) in age-related prefrontal cortical impairments had not been previously determined. The inventors provides evidence that PKC activity is associated with prefrontal cortical dysfunction in aging.... Agent: Cantor Colburn, LLP

20080318993 - Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for hepatic impairment: The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician that the bioavailability of oxymorphone may be increased in patients with hepatic impairment.... Agent: Mayer Brown LLP

20080318994 - Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment: The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician that the bioavailability of oxymorphone is increased in patients with renal impairment.... Agent: Mayer Brown LLP

20080318995 - N-substituted indenoisoquinolines and syntheses thereof: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.... Agent: Barnes & Thornburg LLP

20080318996 - 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor: The present invention relates to 6-amino(aza)indane compound of the formula (I) Wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R6 and wherein Ar may also carry I or 2 radicals Rb; X is N or CH; E is CR6R7... Agent: Dykema Gossett PLLC

20080318997 - Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof: Compounds are provided that, by way of their selective neurotransmitter binding useful for the treatment of various neurological and psychological disorders, e.g., ADHD. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein.... Agent: Nixon Peabody LLP - Patent Group

20080318998 - Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines: Thiazoloquinolines and thiazolonaphthyridines with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are... Agent: Wolf Greenfield & Sacks, P.C.

20080318999 - Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators: wherein R1, R2, R3, A, B, D, m, n, x, and y are defined as described in the specification. The invention additionally provides a pharmaceutically composition comprising the compound of formula I, together with a method of using the same to treat or prevent neurological and psychiatric disorders. The compounds... Agent: Birch Stewart Kolasch & Birch

20080319000 - Use of 3,1ib-cis-dihydrotetrabenazine for the treatment of symptoms of huntingtons disease: The invention provides 3,11b-cis-dihydrotetrabenazine for use in halting or slowing the progress of one or more symptoms of Huntington's disease in a patient, and more particularly a symptom selected from involuntary movements such as involuntary chorea, tremors and twitches, and degeneration in gait.... Agent: Heslin Rothenberg Farley & Mesiti PC

20080319001 - Cancer treatment using specific 3,6,9-substituted acridines: The present invention relates to a 3,6,9 acridine compound and optionally substituted derivatives thereof that may be useful in the treatment of cancer. The invention also provides compositions comprising the compounds and uses thereof. Formula (I) wherein each of R1, R2, R3, R4 and R5 is either fluorine or is... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080319003 - Cyclic amine compound and pest control agent: e

20080319002 - Xanthine derivatives a useful as muscarinic receptor antagonists: This present invention generally relates to xanthine derivatives as muscarinic receptor antagonists which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions... Agent: Ranbaxy Inc.

20080319004 - Deuterium-enriched clopidogrel: The present application describes deuterium-enriched clopidogrel, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080319005 - Phenylacetamides suitable as protein kinase inhibitors: The invention relates to compounds of the formula (I) wherein the moieties R1, R2, R3, R9, R10 and Q and X, Y and Z are as defined in the specification, and salts thereof, as well as their use, methods of use for them and method of their synthesis, and the... Agent: Novartis Corporate Intellectual Property

20080319006 - Nebulizer formulation: A nebulizer formulation contains levalbuterol and ipratropium in about 2 ml or less of saline and is used for treatment of COPD and asthma and other airways diseases and disorders with increased patient compliance.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080319007 - Deuterium-enriched montelukast: The present application describes deuterium-enriched montelukast, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080319008 - Compounds having activity in increasing ion transport by mutant-cftr and uses thereof: The invention provides compositions, pharmaceutical preparations and methods for increasing activity (e.g., ion transport) of the mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR), e.g., ΔF508 CFTR, G551D-CFTR, G1349D-CFTR, or D1152H-CFTR, that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may... Agent: Bozicevic, Field & Francis LLP

20080319009 - Methylene-bridged selective androgen receptor modulators and methods of use thereof: This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor.... Agent: Pearl Cohen Zedek Latzer, LLP

20080319010 - Use of chloroquine to treat metabolic syndrome: The present invention provides methods and compositions for modulating certain metabolic processes and for treating a variety of disorders associated with metabolic syndrome, including insulin related disorders, ischemia, oxidative stress, atherosclerosis, hypertension, obesity, abnormal lipid metabolism, and stroke by administering an effective dose of a chloroquine compound. The invention also... Agent: St. Jude Children''s Research Hospital C/o Darby & Darby P.C.

20080319012 - 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors: 2-pyridyl-substituted imidazoles which are used advantageously in the treatment of diseases mediated by ALK 5 or ALK 4 receptor or both.... Agent: Dickinson Wright PLLC

20080319013 - 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazole-2-ones and, 4-(substituted cycloalkylmethyl) imidazole-2-ones and related compounds: where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula 1 are useful as... Agent: Allergan, Inc.

20080319011 - Protein tyrosine kinase enzyme inhibitors: e

20080319015 - Insect repellent mixture: The present invention relates to the use of an insect repellent, preferably selected from the group 2-(2-hydroxyethyl)-1-methylpropyl 1-piperidinecarboxylate, N,N-diethyl-3-methylbenzamide, dimethyl phthalate, butopyronoxyl, 2,3,4,5-bis(2-butylene)-tetrahydro-2-furaldehyde, N,N-diethylcaprylamide, N,N-diethylbenzamide, o-chloro-N,N-diethylbenzamide, dimethyl carbate, di-n-propyl isocinchomeronate, 2-ethylhexane-1,3-diol, N-octylbicycloheptenedicarboximide or piperonyl butoxide, particularly preferably 2-(2-hydroxyethyl)-1-methylpropyl 1-piperidinecarboxylate, as action enhancer for a second insect repellent, to corresponding compositions,... Agent: Millen, White, Zelano & Branigan, P.C.

20080319014 - Nitroxides for use in treating or preventing diabetes: Pharmaceutical compositions are provided that are useful in treating diabetes. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of genes related to diabetes. Methods are also provided for the use of the pharmaceutical compositions in the... Agent: Knobbe Martens Olson & Bear LLP

20080319016 - Novel arylamidine derivative, salt thereof, and antifungal containing these: An arylamidine derivative represented by the general formula (wherein R1 represents optionally protected or substituted amidino; and R2 and R3 are the same or different and each represents hydrogen or halogeno) or a salt of the derivative. The derivative and salt have potent activity against fungi including ones having tolerance... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080319018 - Organic compounds: wherein R1, R2, R3, R4 and R5 are as defined in the specification, for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation... Agent: Novartis Institutes For Biomedical Research, Inc.

20080319017 - Non-anilinic derivatives of isothiazol-3(2h)-thione 1,1-dioxides as liver x receptor modulators: to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with... Agent: Pepper Hamilton LLP

20080319020 - 4-oxadiazolyl-piperidine compounds and use thereof: 4-Oxadiazolyl-piperidine compounds of formula (I) and (II), their compositions and use for the treatment of pain and diarrhoea.... Agent: Dechert LLP

20080319019 - Therapeutic agents: O

20080319021 - Inhibition of phosphoinositide 3-kinase beta: The present invention relates to selective inhibitors of phosphoinositide (PI) 3-kinase β, use of the selective inhibitors in anti-thrombotic therapy, and a method for screening compounds useful for the new anti-thrombotic therapy by detecting selective inhibitory activity of PI 3-kinase β of the compound. The invention also relates to novel... Agent: Pepper Hamilton LLP

20080319022 - 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors: 2-pyridyl-substituted imidazoles and their use in inhibiting ALK 5 and/or ALK 4 receptors is disclosed.... Agent: Dickinson Wright PLLC

20080319023 - Insecticidal compositions for control of general household pests: The present invention relates to an insecticidal composition comprising a pyrethroid and a second insecticide selected from the group consisting of imidacloprid, nithiazine, thiamethoxam, dinotefuran, nitenpyram, thiacloprid, clothianidin and chlorfenapyr, with significantly improved knockdown and mortality characteristics when applied to general household pests.... Agent: John M Sheehan Fmc Corporation

20080319024 - Rosiglitazone phosphate and polymorphic forms: The present invention relates to 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione phosphate, a novel salt of rosiglitazone and to novel polymorphic forms thereof. The invention is also directed to processes for preparation of rosiglitazone phosphate and its polymorphs. The compounds of the invention are useful for treatment and/or prophylaxis of diabetes mellitus, conditions associated with... Agent: Sandoz Inc

20080319025 - Therapeutic and diagnostic methods dependent on cyp2a enzymes: Furthermore, it has been discovered that the presence in an individual of a mutant allele of human cytochrome P450 enzyme CYP2A6 (referred to throughout this specification as “CYP2A6” for brevity) is predictive of an individual who: (i) has a decreased risk of becoming a smoker, (ii) will smoke less if... Agent: Bereskin And Parr

20080319027 - Composition and method for treating fibrotic diseases: The present invention discloses 5-methyl-1-(substituted phenyl)-2(1H)-pyridones have enhanced anti-fibrotic activities than 5-methyl-1-(non-substituted phenyl)-2(1H)-pyridones. An representative example of 5-methyl-(1-substituted phenyl)-2(1H)-pyridones is 1-(3′-fluorophenyl)-5-methyl-2(1H)-pyridone. Accordingly, there are provided compositions comprising one or more compounds selected from the group consisting of 5-methyl-1-(substituted phenyl)-2(1H)-pyridones and methods of using the same to treat or prevent fibrosis... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20080319026 - Substituted n-aryl pyridinones: Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080319028 - Dicycloalkylcarbamoyl ureas as glucokinase activators: This invention relates to dicycloalkylcarbamoyl ureas of formula (I), which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080319029 - Bifenthrin/acetamiprid compositions for control of general household pests: The present invention relates to an insecticidal composition of bifenthrin and acetamiprid with significantly improved knockdown and mortality characteristics when applied to general household pests.... Agent: Patent Administrator Fmc Corporation

20080319030 - Sydnonimines - specific dopamine reuptake inhibitors and their use in treating dopamine related disorders: Derivatives of Sydnonimine and its analogues, which bind selectively to dopamine transporter (DAT) proteins are useful for treating and delaying the progression of disorders and illnesses that are alleviated by inhibiting dopamine reuptake.... Agent: Dann, Dorfman, Herrell & Skillman

20080319031 - Novel tyrosine derivatives: The present invention relates to novel tyrosine derivatives of formula (I), their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention more particularly provides novel tyrosine derivatives of the general formula (I).... Agent: Foley And Lardner LLP Suite 500

20080319032 - Tetrahydrobenzothiazole analogues as neuroprotective agents: This invention relates generally to tetrahydrobenzothiazole analogues and tetrahydrobenzooxyzole analogues, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to methods of treatment using these compounds. The invention also encompasses pharmaceutically acceptable esters, amides, and salts of such compounds. The invention further provides a method of... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080319033 - Organic compounds: i

20080319034 - Method for producing precious material for ornamental articles and precious material for ornamental articles which can be obtained in particular by means of this method: Method for producing a precious material for ornamental articles, which envisages introducing, into the plasticization chamber of an extruder at a temperature of between 120 and 220° C., an amount of a Polymer composition and an amount of a metallic powder formed with one or more precious metals having particles... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080319035 - Microbicidal composition: Synergistic microbicidal compositions containing N-methyl-1,2-benzisothiazolin-3-one.... Agent: Rohm And Haas Company Patent Department

20080319036 - Method for treating obesity: The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or... Agent: Knobbe Martens Olson & Bear LLP

20080319037 - 1,2,4-triazol-1-yl bisphenyl derivatives for use in the treatment of endocrine-dependent tumors: wherein R3, R4, R5, R6 and R7 are independently selected from H and —Y—R8; wherein each R8 is independently selected from —OH, hydrocarbyl groups, oxyhydrocarbyl groups, cyano (—CN), nitro (—NO2), H-bond acceptors, and halogens; wherein at least one of R3, R4, R5, R6 and R7 is —Y—R8 wherein R8 is... Agent: Frommer Lawrence & Haug

20080319038 - Preventative or therapeutic agent for acute renal failure: An agent for prevention and treatment of acute renal failure comprising a hydantoin derivative represented by the general formula below as an active ingredient. One example of such compounds is (2S, 4S)-6-fluoro-2′,5′-dioxospiro[chroman-4,4′imidazolidine]-2-carboxamide.... Agent: Patterson, Thuente, Skaar & Christensen, P.A.

20080319039 - Unit dosage forms of temozolomide: This invention relates to unit dosage forms of temozolomide. These unit dosage forms are particularly well-suited for decreasing the pill burden and increasing patient compliance. The invention also relates to methods of treating proliferative disorders in a patient with these unit dosage forms. The invention additionally relates to kits comprising... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080319040 - N-acylic aminoacid derivatives, method for the production thereof, pharmacological composition and the use in the form anti-allergic, anti-inflammatory and hypolipidemic agents: or pharmaceutically acceptable salts thereof, to novel processes for preparing the same, to use thereof as anti-allergic, anti-anaphylactic, anti-inflammatory and hypolipidemic agents as well as to a pharmaceutical composition comprising the indicated compounds in an efficient amount and to a method for treating allergic and inflammatory diseases and lipid metabolism... Agent: Banner & Witcoff, Ltd.

20080319041 - Lofexidine enantiomers for use as a treatment for cns disease and pathologies and its chiral synthesis: The invention relates to methods for treatment of CNS disease and pathologies using non-racemic mixtures of lofexidine enantiomers. The invention also relates to processes for the manufacture of chirally pure enantiomers of lofexidine.... Agent: Frost Brown Todd, LLC

20080319042 - Compositions and methods for treatment of liver disease: The present invention comprises compositions and methods for the treatment of liver disease, particularly treatments for infection by HCV and/or HBV. The present invention comprises antiviral compositions comprising lamiridosin, derivatives of lamiridosin or iridoids that are effective in inhibiting one or more steps in the infection of cells by HCV... Agent: Troutman Sanders LLP

20080319043 - 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists: The present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed... Agent: Ranbaxy Inc.

20080319044 - Compounds and methods of use thereof: Indole boronic acid compounds, and analogs thereof, and pharmaceutical formulations are described, along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof.... Agent: Alston & Bird LLP

20080319045 - Combination of histone deacetylase inhibitors and radiation: d

20080319046 - Substituted sulfonamide-indoles: The present invention relates generally to substituted sulfonamide indoles such as substituted sulfonamide indoles, and methods of using them.... Agent: Wyeth Patent Law Group

20080319047 - Novel glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes: wherein m is an integer selected among 1-3; R1 to R4 each independently is optionally substituted alkyl, etc.; Ar1 is optionally substituted naphthyl; and A is optionally substituted heteroaryl, a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, and... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080319048 - Solubilized formulation of docetaxel without tween 80: Lyophilizates containing docetaxel and the use thereof in preparing concentrated liquid formulations, and ready to use formulations for injection, as well as such concentrates and ready to use formulations themselves are disclosed in which Tween surfactants are avoided so that hypersensitivity reactions to Tween surfactants can be avoided and docetaxel... Agent: Irving M. Fishman C/o Cohen Tauber Spievack & Wagner

20080319049 - Compounds for the treatment of metabolic disorders: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed, wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is... Agent: Wellstat Management Company. LLC

20080319053 - Anthocyanin pigment/dye compositions through corn extraction: Anthocyanin pigments/dyes are extracted from corn kernels by adding corn kernels with less than 5% by weight of corn kernels comprising broken kernels to an aqueous medium to form an aqueous-corn medium. The corn kernels have in excess of 0.1 mg of anthocyanin pigment/dye per gram of corn kernel therein.... Agent: Mark A. Litman & Associates, P.A. York Business Center

20080319052 - Lipopexia inhibitor and food or beverage: [Means for Solving Problems] There is provided a lipopexia inhibitor comprising an effective amount of any of methylated catechins of the following chemical formula (1) obtained by extraction of green tea or Pouchung tea. (1) wherein each of R1, R2, R3 and R4 independently is a hydrogen atom or methyl;... Agent: Knobbe Martens Olson & Bear LLP

20080319051 - Liquiritigenin and derivatives as selective estrogen receptor beta agonists: The disclosure provides compositions comprising liquiritigenin, or derivatives, or prodrugs, useful as estrogen receptor beta selective agonists. The disclosure also provides methods of treating menopausal symptoms, and estrogen-dependent disorders, with said compositions.... Agent: Wilson Sonsini Goodrich & Rosati

20080319050 - Preparation containing oxidized flavonoid derivatives: The invention relates to novel compositions, in particular cosmetic and/or pharmaceutical compositions or food supplements, comprising at least one oxidised flavonoid derivative of the formula I, to novel oxidised flavonoid derivatives, and to novel uses of the oxidised flavonoid derivatives.... Agent: Millen, White, Zelano & Branigan, P.C.

20080319054 - Treatment of cancer: The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions.... Agent: Wilson Sonsini Goodrich & Rosati

20080319055 - Cooling compounds: e

20080319056 - Butylphthalide self-emulsifying drug delivery system, its preparation method and application: The present invention relates to a novel drug delivery and release system, i.e. Self-emulsifying Drug Delivery System (SEDDS), of butylphthalide, to a preparation process thereof, and to a use thereof in a pharmaceutical formulation. The drug delivery system comprises as essential ingredients 1% to 65% of butylphthalide and 10% to... Agent: Fish & Richardson P.C.

20080319057 - 2-phenylethylamino derivatives as calcium and/or sodium channel modulators: 2-Phenylethylamino substituted carboxamide derivatives of formula (I); wherein J, W, R0, R1, R2, R3, and R4 have the meanings as defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing alleviating and... Agent: Dechert LLP

20080319059 - Caffeic acid derivative and composition containing the same: The present invention provides a caffeic acid derivative denoted by a chemical formula 1 as below and a composition containing the same. The preferable composition according to the present invention containing a caffeic acid derivative denoted as below contains a vitamins C further. And the composition can be the formulation... Agent: Park Law Firm

20080319060 - Composition containing vitamin c: The present invention relates to a composition containing vitamin C. The composition according to the present invention includes cationic material and anionic material as a primary stabilizing agent of the vitamin C; and a caffeic acid derivative as a secondary stabilizing agent of the vitamin C. The caffeic acid derivative... Agent: Park Law Firm

20080319058 - Skin care products, as well as foods and beverages containing 6-o-pufa ascorbic esters: where RCO— is an acyl group derived from a polyunsaturated fatty acid, and A is a residue of ascorbic acid that binds by —O— derived from the hydroxyl group in ascorbic acid. The products show improved transfer of ascorbic acid to tissues or cells, allow the functions of ascorbic acid... Agent: Drinker Biddle & Reath (dc)

20080319061 - Process for the preparation of an oxaliplatin preparation: The present invention relates to an improved process for the preparation of oxaliplatin, the obtained oxaliplatin preparation and its use in cancer therapy.... Agent: Dickstein Shapiro LLP

20080319062 - Disinfectant and method of use: A non-toxic environmentally friendly aqueous disinfectant is disclosed for specific use as prevention against contamination by potentially pathogenic bacteria, fungi and virus. The aqueous disinfectant is formulated by electrolytically generating silver ions in water in combination with a citric acid. The aqueous disinfectant has many potential uses including bacteria, fungus... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080319063 - Curing accelerator and method of making: A sterilized cyanoacrylate adhesive composition including a cyanoacrylate composition and a cure speed enhancer, wherein the sterilized cyanoacrylate adhesive composition does not cure upon sterilization. A kit for applying the sterilized cyanoacrylate adhesive composition, including the cyanoacrylate adhesive composition and an applicator. A method of making the sterilized cyanoacrylate adhesive... Agent: Kohn & Associates, PLLC

20080319064 - Deuterium-enriched oseltamivir: The present application describes deuterium-enriched oseltamivir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080319065 - Systemic and intrathecal effects of a novel series of phospholipase a2 inhibitors on hyperalgesia and spinal pge2 release: Phospholipase A2 (PLA2) forins are expressed in spinal cord whose inhibition induces a potent antihyperalgesia. PLA2 inhibitor compounds are provided that include a common motif consisting of a 2-oxoamide with a hydrocarbon tail and a four carbon tether. The compounds block Group IVA calcium dependent PLA2 (cPLA2) and/or Group VIA... Agent: Dla Piper LLP (us)

20080319066 - Jasmonate derivative compounds, pharmaceuticals compounds and methods of use thereof: The present invention provides novel jasmonate derivative compounds, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for treatment of cancers, especially mammalian cancers.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080319067 - 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors: e

20080319068 - Novel polymorph of acetylsalicylic acid, and methods of making and using the same: A polymer of aspirin is provided by the present invention. Methods of making and using the same are also provided.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080319069 - Spider esters in personal care applictions: The present invention is drawn to a process for providing emolliency to the skin using a series so called “spider esters”. These esters are derived from poly-hydroxy functional compounds sequentially reacted with ethylene oxide or propylene oxide, followed by the reaction of the alkoxylate with fatty acid. The resulting products... Agent: Anthony J O'lenick Jr

20080319070 - Sanitizing and cleaning composition and its use for sanitizing and/or cleaning hard surfaces: The present invention relates to acidic sanitizing and/or cleaning compositions comprising a specific quaternary antimicrobial system consisting of C1-C4 hydroxyalkyl carboxylic acids, C5-C18 alkyl monocarboxylic acids, unsubstituted or substituted, saturated or unsaturated C4-dicarboxylic acids and additional inorganic or organic acids. The compositions of the present invention can be present in... Agent: Johnsondiversey, Inc.

20080319071 - Novel nutraceutical and pharmaceutical compositions and use thereof for the treatment, co-treatment or prevention of inflammatory disorders: The present invention relates to new methoxylated aromatic compounds. It also relates to novel compositions comprising methoxylated aromatic compounds as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.... Agent: Nixon & Vanderhye, PC

20080319072 - Composition and method for treating bacterial, viral, fungal diseases, inflammation and pain: The present invention is directed to compositions and methods of treating bacterial, viral, fungal diseases; inflammation or inflammatory-related disorders; pain; and skin conditions. The composition comprises an organic solvent extract, which is prepared by the method comprising the steps of: (a) mixing methionine with water, (b) adding an aqueous hypochlorite... Agent: Howrey LLP-ca

20080319073 - Colonic delivery therapeutic agents for inflammatory bowel disease: The present invention discloses a therapeutic agent for inflammatory bowel disease, which is in the from of delivering 1 to 5 g of glutamine to the large intestine per one administration; and the therapeutic agent for inflammatory bowel disease with which an anti-inflammatory agent(s) is combined. This therapeutic agent for... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080319074 - Glucagon receptor antagonists, preparation and therapeutic uses: The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using... Agent: Eli Lilly & Company

20080319075 - Polymorphic forms of nateglinide: Provides are crystalline forms of nateglinide, labeled Forms A, C, D, F, G, I, J, K, L, M, N, O, P, Q, T, U, V, Y, α, β, γ, δ, ε, σ, θ and Ω, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also... Agent: Kenyon & Kenyon LLP

20080319076 - Compositions comprising creatine salts and methods of use thereof: The invention relates to compositions (e.g., nutritional supplements) comprising, consisting essentially of, or consisting of a creatine bicarbonate, and to methods of making and using said compositions.... Agent: Morse, Barnes-brown & Pendleton, P.C. Attn: Patent Manager

20080319077 - Remedy for diabetes: The present invention relates to a therapeutic agent for diabetes with sulfonylurea secondary failure, which contains a GPR40 agonist. According to the present invention, a therapeutic agent for diabetes with sulfonylurea secondary failure that affords a superior insulin secretion effect and a superior hypoglycemic effect even in diabetic patients for... Agent: Foley And Lardner LLP Suite 500

20080319078 - Triphenylethylene compounds useful as selective estrogen receptor modulators: Triphenylethylene compounds of formula (I) are provided. The compounds are particularly useful for selective estrogen receptor modulation.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080319079 - Method for administering formoterol using a nebulizer: The present invention provides a method of administering formoterol, for example as a fumarate dihydrate, using a nebulizer device for the treatment of bronchoconstriction, such as that caused by asthma and chronic obstructive pulmonary disease. The method of this invention is particularly useful in pediatric, geriatric, handicapped and acutely ill... Agent: Osler, Hoskin & Harcourt LLP (osler Ottawa)

20080319080 - Amide compounds and their use: e

20080319081 - Insecticidal compositions having improved effect: The present invention relates to increasing the activity of crop protection compositions comprising phthalic acid diamides through the addition of ammonium salts and/or phosphonium salts or through the addition of ammonium or phosphonium salts and penetrants, to the corresponding compositions, to processes for preparing them and to their use in... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080319082 - Biphenyl and naphthyl-phenyl hydroxamic acid derivatives: Biphenyl and phenyl-naphthyl compounds bearing a hydroxamic group, which are endowed with antitumour, and anti-angiogenic activity These compounds are therefore particularly useful for the treatment of drug-resistant tumours.... Agent: Lucas & Mercanti, LLP

20080319083 - Medicine for transnasal administration: p

20080319084 - Wrinkling prevention or remedy with adam activity inhibiting substance: A composition contains a substance, which is capable of inhibiting activity of ADAM (a disintegrin and metalloprotease) present in a skin, in a proportion efficient for preventing or remedying wrinkling. Wrinkling is prevented or remedied with a method comprising the step of applying a substance, which is capable of inhibiting... Agent: Rankin, Hill & Clark LLP

20080319085 - Titration dosing regimen for controlled release tramadol: A titration dosing regimen for the administration of controlled release tramadol analgesic to patients. The titration dosing regimen provides a significant reduction in the occurrence of adverse effects from the introduction of controlled released tramadol dosing, thus increasing patient compliance and medication tolerability.... Agent: Duane Morris LLP - Ny Patent Department

20080319086 - Deuterium-enriched salmeterol: The present application describes deuterium-enriched salmeterol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080319087 - Use of ambroxol for the treatment of rhinovirus infections: The invention is directed to the use of ambroxol or pharmaceutically acceptable salts thereof for preparing a medical composition for treating or preventing infections caused by human rhinovirus. Surprisingly it was found that Ambroxol is capable to suppress the replication of human rhinovirus. Therefore, the ambroxol-containing medical composition is suitable... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080319088 - Aldehyde compositions and methods for providing fragrance containing the same: e

20080319089 - Method of colouring carrier materials:

20080319090 - Pearlizer concentrate and its use in personal care compositions: An aqueous pearlescent concentrate, containing a pearlizing agent, an anionic surfactant, and a cationic component, having increased opacity and is useful in modifying the appearance of aqueous liquid compositions, particularly personal care compositions.... Agent: Rhodia, Inc.

20080319091 - Polymer derivatives comprising an imide branching point: The invention provides a water-soluble polymer comprising (i) an imide group comprising a linking nitrogen atom, a first carbonyl group covalently attached to the linking nitrogen atom, and a second carbonyl group covalently attached to the linking nitrogen atom; (ii) a first water-soluble polymer segment covalently attached, either directly or... Agent: Nektar Therapeutics

20080319092 - Transdermal drug delivery formulation: The present invention provides a transdermal formulation for the delivery of at least one active agent. The formulation includes (i) a first compound comprising an organic sulfoxide, and (ii) a second compound selected from the group consisting of a fatty acid ester, a fatty acid, an azone-related compound and mixtures... Agent: Katten Muchin Rosenman LLP (c/o Patent Administrator)

20080312128 - Cellular biomarker antioxidant assay and uses thereof: The invention encompasses cell-based systems comprising biomarkers that respond to oxidative stress (OS) in a quantitative manner, and methods of use thereof. The systems are useful for screening, identifying and testing antioxidant agents, combinations, and formulations thereof for preventing, treating, or reducing symptoms of conditions associated with oxidative damage to... Agent: Margaret J. Mclaren, P.A. Mclaren Legal Services

20080312132 - Composition for animal consumption: This invention is directed generally to compositions (including foods, supplements, treats, toys, etc.) for animal consumption, particularly compositions that tend to aid in weight loss or reduction in weight gain, and particularly compositions that comprise one or more medium chain fatty acid triglycerides (“MCT”). This invention also is directed generally... Agent: Colgate-palmolive Company

20080312130 - Drug delivery vehicle for cancer therapy, process for producing the same, and pharmaceutical preparation using the same: The invention provides a vehicle that can deliver drugs specifically to the body and a pharmaceutical preparation using the same. Disclosed is a drug delivery vehicle for cancer therapy, comprising a cationized viral envelope vector, as well as a pharmaceutical preparation comprising a drug enclosed in the vehicle. The viral... Agent: Fulbright & Jaworski, LLP

20080312127 - Host cell comprising a vector for production of proteins requiring gamma-carboxylation: The present invention relates a host cell comprising an expression vector comprising a nucleic acid molecule encoding a protein requiring gamma-carboxylation and associated expression control sequences and a nucleic acid molecule encoding a vitamin K epoxido reductase and associated expression control sequences and a nucleic acid molecule encoding a γ-glutamyl... Agent: Fish & Richardson P.C.

20080312131 - Regeneration of chromatographic stationary phases: Process for regenerating a chromatographic stationary phase... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080312133 - Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders: An isolated polypeptide comprising any amino acid fragment of unacylated ghrelin or any analog thereof, wherein the polypeptide has an activity selected from the group consisting of a) decreasing blood glucose levels; b) increasing insulin secretion an/or sensitivity; c) binding to insulin-secreting cells; and d) promoting survival of insulin-secreting cells.... Agent: Darby & Darby P.C.

20080312129 - Use of mas g-protein-coupled receptor agonists and antagonists, as apoptotic-activity modulators for study, prevention and treatment of diseases: The present invention is characterized by the use of Mas G-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for study, prevention and treatment of diseases. It is further characterized by the use of Mas G-protein-coupled receptor agonist and antagonists for modulation of the apoptotic activity involving alterations in the... Agent: Nixon & Vanderhye, PC

20080312134 - Vesicles for active macromolecule delivery: Vesicles for delivery of active macromolecules, such as oligoaminoacids, oligonucleotides, microRNA, siRNA, dsRNA, single stranded oligonucleotides, DNA, peptide nucleic acids, peptides, proteins, and some synthetic organic drugs which are made from amphiphilic segmented copolymers where one segment contains the active macromolecule. In one preferred embodiment, the active macromolecule is contained... Agent: Law Office Of Collen A. Beard, LLC

20080312135 - Mixtures of drug-oligomer conjugates comprising polyethylene glycol, uses thereof, and methods of making same: A non-polydispersed mixture of conjugates in which each conjugate in the mixture comprises a drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugates. The mixture may be more effective at surviving... Agent: Moore & Van Allen PLLC

20080312136 - Alpha 1-antitrypsin compositions and treatment methods using such compositions: Alpha 1-antitrypsin compositions and treatment methods using such compositions for treating a variety of pulmonary diseases are provided. The compositions generally contain AAT, a stabilizing carbohydrate such as trehalose, a surfactant such as Polysorbate 80 and an antioxidant to stabilize AAT for use as a therapeutic. The formulations can be... Agent: Heller Ehrman LLP

20080312138 - Erythropoietin complementation or replacement: The present invention provides methods and compositions to replace up to 90% of erythropoietin use in the treatment of anemias and hypoxias. The method employs acid and salt forms of inositol-tripyrophosphate (ITPP) isomers to shift the P50 value of hemoglobin, thereby improving the rate and efficiency of oxygenation by blood... Agent: King & Spalding LLP

20080312137 - Fed batch culture methods for streptococci: This invention relates to the optimization of culture conditions to improve the production of bacterial capsular polysaccharides from Streptococcus strains in fed-batch culture.... Agent: Novartis Vaccines And Diagnostics Inc.

20080312139 - Use of pharmaceutical composition containing epidermal growth factor (egf) for diabetic foot amputation prevention: The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-Injectable pharmaceutical composition which is administered by means of infiltration into and around chronic cutaneous ischaemic lesions in order to prevent diabetic foot amputation. Said composition can be administered to recently-created surgical surfaces damaged by the effect... Agent: Hoffmann & Baron, LLP

20080312140 - Compositions and methods for preventing or treating hiv infection: The present invention is directed to compositions and methods of preventing for treating a retroviral infection, more particularly an HIV (human immunodeficiency virus) infection, and even more particularly an HIV-1 infection. The compositions and methods involve molecules that mimic the active site of the human CD4 protein.... Agent: Winston & Strawn LLP Patent Department

20080312141 - Peptide ligands for prostate specific antigen: The present invention relates to novel peptide ligands for prostate specific antigen (PSA) binding specifically with it and enhancing its enzyme activity, to a process for preparation of these peptides, to diagnostic and pharmaceutical compositions comprising these peptides, to the use of these peptides for pharmaceutical and research preparations, to... Agent: Sughrue Mion, PLLC

20080312154 - Administration of adipocytokine and adiponectin for treating headache and methods of diagnosing headache by measuring adiponectin: Methods for treating a headache, such as a migraine, in a subject comprising administering a therapeutically effective amount of an adipocytokine, for example, adiponectin, to the subject are disclosed. Pharmaceutical compositions comprising adipocytokine, for example, adiponectin, are disclosed. Methods of diagnosing the presence or absence of a headache in a... Agent: Pietragallo Gordon Alfano Bosick & Raspanti LLP

20080312145 - Agent for regulating bone formation: The present invention provides preventive, ameliorating, and/or therapeutic agents for diseases caused by a disturbed balance between bone formation and bone resorption. The decoys of the present invention induce normal bone metabolism by inhibiting the differentiation-inducing factors of cells involved in bone metabolism. For example, bone resorption can be controlled... Agent: Foley And Lardner LLP Suite 500

20080312142 - Composition for increasing body height: This invention provides a composition for increasing a body height of a patient with short stature or an individual other than patients with short stature. More specifically, the invention provides: a composition for increasing the body height of an individual comprising a guanyl cyclase B (GC-B) activator as an active... Agent: Birch Stewart Kolasch & Birch

20080312147 - Compositions and methods for the regulation of hair growth: A novel hair loss prevention and hair restoration composition, is applied topically to the scalp. The composition and methods of application stimulate the hair follicle, encourage angiogenesis, and improve blood circulation throughout the area where the composition is applied. Moreover, formation of di-hydroxytestosterone is inhibited using copper peptides that interfere... Agent: Greenberg Traurig LLP (la)

20080312151 - Compositions and methods including expression and bioactivity of bovine follicle stimulating hormone: The present invention provides methods of producing biologically active recombinant bFSH and methods of increasing reproduction in mammals, particularly bovine, using recombinant bFSH. Also provided are methods of producing single chain recombinant bFSH. The recombinant bFSH of the present invention increases superovulation, embryo development, and reproductive efficiency in cattle and... Agent: Greenlee Winner And Sullivan P C

20080312152 - Glycosylated probnp: The present invention is directed to glycosylated proBNP and pharmaceutical compositions thereof. The present invention also relates to novel assays for measuring the total natriuretic activity that is present in a clinical blood sample.... Agent: Philip S. Johnson Johnson & Johnson

20080312149 - Health food and pharmaceutical composition for amelioration of disease induced by metabolic disorder in cartilage: The invention relates to a health food and a pharmaceutical preparation, containing a composition for treating rheumatoid arthritis. The health food and pharmaceutical preparation in which glucosamine, a collagen and an isoflavone aglycone act synergically, which are useful for relieving symptoms or treatment of diseases related to abnormal cartilage metabolism,... Agent: Sughrue Mion, PLLC

20080312146 - Meth1 and meth2 polynucleotides and polypeptides: The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080312143 - Modified cdna for high expression levels of factor viii and its derivatives: The present invention relates to modified DNA sequences coding for biologically active recombinant human factor VIII and its derivatives, recombinant expression vectors containing such DNA sequences, host cells transformed with such recombinant expression vectors, and processes for the manufacture of the recombinant human factor VIII and its derivatives. The invention... Agent: Birch Stewart Kolasch & Birch

20080312144 - Peptides for the treatment of herpes virus infections: e

20080312153 - Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents a single bond, a C1-6 alkylene group etc.; Z represents CO or SO2; R4 and... Agent: Sughrue Mion, PLLC

20080312148 - Recombinant human interferon-like proteins: This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20080312150 - Treatment and analysis of proliferative disorders: A method of treating a subject having unwanted cell proliferation which includes: inducing differentiation in a cell; providing said cell with a photosensitizer; and activating said PS, thereby the treating unwanted cell proliferation.... Agent: Edwards Angell Palmer & Dodge LLP

20080312157 - Gip analog and hybrid polypeptides with selectable properties: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20080312156 - In-situ crosslinkable elastin-like polypeptides for defect filling in cartilaginous tissue repair: Defects in a cartilaginous tissue are filled by: (a) mixing (i) a first reagent composition preferably comprising an amine-free hydroxyalkyl (preferably hydroxymethyl) phosphine crosslinking agent with (ii) a second reagent composition comprising a bioelastic polymer, the bioelastic polymer preferably comprising elastomeric units, the elastomeric units preferably selected from the group... Agent: Myers Bigel Sibley & Sajovec

20080312155 - Metastin derivatives and use thereof: The invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, etc.). By modifying the constituent amino acids of metastin with specific modifying groups, metastin derivatives having more improved blood stability, etc. than native metastin and showing excellent cancer metastasis suppressing... Agent: Edwards Angell Palmer & Dodge LLP

20080312158 - Semaphorin gene family: A novel class of proteins, semaphorins, nucleic acids encoding semaphorins, semaphorin peptides, and methods of using semaphorins and semaphorin-encoding nucleic acids are disclosed. Semaphorin peptides and receptor agonists and antagonists provide potent modulators of nerve cell growth and regeneration. The invention provides pharmaceutical compositions, methods for screening chemical libraries for... Agent: Townsend And Townsend And Crew, LLP

20080312159 - Dendrimeric peptides, pharmaceutical compositions and methods of using the same: The compounds demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention and treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present peptides are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent... Agent: Klauber & Jackson

20080312160 - Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist: A therapeutic method for treating intestinal damage, enteritis, diarrhea, or a combination thereof caused by a C. difficile is provided. The method includes administration to a patient in need thereof an effective amount of an A2A adenosine receptor agonist, optionally in combination with an effective amount of a stable glutamine... Agent: Schwegman, Lundberg & Woessner, P.A.

20080312161 - Compounds for stabilizing factor vii polypeptide formulations: The invention relates to novel compounds with formula I and their use in stabilization of Factor Vila or other Factor VII polypeptides, particularly in aqueous liquid compositions thereof.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080312162 - Methods and compositions for enzyme-specific activation of carbohydrate-conjugated prodrugs: Methods for the targeted activation of prodrugs by enzymes, which cleave a linkage between a carbohydrate conjugate and a drug. Means to target the activation of prodrugs to specific cells by linking the enzyme to an antibody molecule. Carbohydrate conjugates of geldanamycin.... Agent: Calfee Halter & Griswold, LLP

20080312163 - Treatment of pulmonary hypertension with carbonic anhydrase inhibitors: This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20080312164 - Isothiocyanates and glucosinolate compounds and anti-tumor compositions containing same: The present invention provides glucosinolate and isothiocyante compounds and related methods for synthesizing these compounds and analogs. In certain embodiments, these glucosinolate and isothiocyanate compounds are useful and chemopreventive and or chemotherapeutic agents.... Agent: Intellectual Property Department Dewitt Ross & Stevens S.c.

20080312165 - Process for obtaining pure monosialoganglioside gm1 for medical use: A process for preparing pure monosialoganglioside GM1 in the form of its sodium salt. There is provided a process for the isolation and purification of monosialoganglioside GM1 comprising (a) separation of GM1 from a lipidic mixture containing the monosialoganglioside GM1 as the main ganglioside component by ion exchange column-chromatography using... Agent: Baker & Daniels LLP

20080312166 - Reversal core pharmaceutical system and method: A medication delivery system is disclosed to mitigate or reverse the pharmacologic effect of a medication beyond the desired therapeutic window. The system provides sequential delivery of medications including a first agent which induces a physiologic change, a second agent for reversing the physiologic change, and a medication release delaying... Agent: The Sleep And Breathing Research Institute

20080312167 - 4'' amino linked macrolides useful for the treatment of microbial infections: m

20080312168 - Novel dispersible tablet composition: The present invention relates to a novel dispersible tablet composition, which comprises of a pharmacologically active ingredient and at least one excipient, which reduces the sedimentation rate of active ingredient. This invention further relates to a process for the preparation of a dispersible tablet of a pharmacologically active ingredient.... Agent: Darby & Darby P.C.

20080312172 - Anti-il-6 antibodies, compositions, methods and uses: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions,... Agent: Philip S. Johnson Johnson & Johnson

20080312169 - Cosmetic use of d-ribose: D-ribose is incorporated into a cosmetic composition and applied to the skin to reduce the length and area of wrinkles and to improve the complexion of the skin.... Agent: Kathleen R. Terry

20080312170 - Fibrinolysin of agkistrodon acutus venom and its usage: The present invention relates to a fibrinolysin gene of Agkistrodon acutus, a vector containing the said gene and the host cell which transformed by the vector. The fibrinolysin could be used in treating diseases caused by thrombus. The fibrinolysin FII is purified from the crude venom of Agkistrodon acutus, and... Agent: Brinks Hofer Gilson & Lione

20080312176 - Gene silencing: Methods are disclosed for gene silencing (e.g. post transcriptional gene silencing) in an organism using small RNA molecules.... Agent: Morrison & Foerster LLP

20080312179 - High level expression of recombinant human erythropoietin having a modified 5'-utr: The present invention provides an expression construct capable of producing high levels of erythropoietin in mammalian cells. More particularly, the expression construct includes an erythropoietin coding region fused to a unique 5′-UTR sequence and a truncated 3′-UTR. The present invention also provides methods of synthesizing large amounts of erythropoietin and... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20080312178 - Human g-protein receptor hgber32: Human G-protein coupled receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed were methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080312175 - Methods and compositions for regulating hdac4 activity: The present invention provides methods and compositions for modulating HDAC4 activity and modulating the activity of proteins downstream of HDAC4 in the muscle transcriptional pathway in a cell by modulating HDAC4 activity. Further provided are methods and compositions for treating muscle atrophy and/or inflammation by inhibiting HDAC4 activity.... Agent: Myers Bigel Sibley & Sajovec

20080312177 - Serca2 therapeutic compositions and methods of use: The present invention provides methods for treating urinary incontinence, urethral sphincter dysfunction and/or bladder dysfunction by delivering a therapeutic adeno-associated virus (AAV)-SERCA2 composition to a subject in need thereof.... Agent: Dla Piper LLP (us)

20080312171 - Tetracycline-dependent regulation of rna interference: The present invention relates to a tetracycline dependent gene regulatory system or composition controlling the expression of a target gene in a cell and to methods using said system or composition. The present invention more specifically discloses compositions, vectors and methods allowing tetracycline-controlled expression of short-hairpin RNAs (shRNAs), and demonstrates... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080312173 - Treatment of hsv-related pathologies using plasmids that make ssdna: A composition for treatment of HSV-related pathologies including an expression vector for altering expression of a target sequence in an HSV-infected cell by production of single-stranded cDNA (ssDNA) in the cell in vivo suspended for topical application to an affected site in a suitable delivery vehicle. The expression vector is... Agent: Cytogenix, Inc.

20080312174 - Water soluble crosslinked polymers: Compositions for siRNA delivery are described which include water soluble degradable crosslinked cationic polymers having a water soluble polyethylene glycol component, a cationic polyethyleneimine component and a degradable unit component. The composition may be used to deliver siRNA to cells, particularly cancer cells. The composition may be applied to a... Agent: Knobbe Martens Olson & Bear LLP

20080312180 - Methods to protect skeletal muscle against injury: Disclosed herein are compositions and methods for the treatment of skeletal muscle and/or the protection of skeletal muscle against injury. The adenosine A3 receptor has been identified as a new therapeutic target for the treatment of skeletal muscle. Adenosine A3 receptor agonists are used treat subjects with skeletal muscle ischemia... Agent: Cantor Colburn, LLP

20080312181 - Composition and methods for skin care: Compositions useful in the treatment of skin atrophy and improvement of skin appearance and texture are disclosed. The methods include the topical administration of vitamin D3 or specific vitamin D3 analogs as an essential ingredient either on its own or in combination with cADPR and or nicotinamide. The compositions are... Agent: Winston & Strawn LLP Patent Department

20080312182 - Ophthalmic composition with hyaluronic acid and polymeric biguanide: An ophthalmic composition comprising 0.5 ppm to 3 ppm of poly(hexamethylene biguanide), and 0.002 wt. % to 0.03 wt. % of hyaluronic acid. The weight ratio of hyaluronic acid to poly(hexamethylene biguanide) in the composition is from 45:1 to 120:1. The invention is also directed to a method of cleaning,... Agent: Bausch & Lomb Incorporated

20080312184 - Composition for preventing plant diseases and method for preventing the diseases: A composition for preventing plant diseases comprises Components I and II as active ingredients. The Component I is (RS)—N—[2-(1,3-dimethylbutyl)thiophen-3-yl]-1-methyl-3-tri fluoromethyl-1H-pyrazole-4-carboxamide. As the Component II, there can be exemplified, for example, tetraconazole, flutriafol, imibenconazole, triadimefon, simeconazole, oxpoconazole fumarate, prothioconazole, bupirimate, spiroxamine, metiram, dodine, anilazine, chlozolinate, oxycarboxin, ethaboxam, iprovalicarb, pyrazophos, fluoroimide, diflumetorim,... Agent: Buchanan, Ingersoll & Rooney PC

20080312183 - Dutpase inhibitors: Deoxyuridine derivatives of the formula (I) where R1 is H or various substituents; D is —NHCO—, —CONH—, -0-, —C(═O)—, —CH═CH, —C≡C—, —NR5—; R4 is hydrogen or various substituents; R5 is H, C1-C4 alkyl, C1-C4 alkanoyl; E is Si or C; R6, R7 and R8 are independently selected from C1-C8 alkyl,... Agent: Birch Stewart Kolasch & Birch

20080312186 - Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions: The present invention also pertains to pharmaceutical compositions comprising such compounds. The compounds inhibit osteoclast survival, formation, and/or activity, and inhibit conditions mediated by osteoclasts and/or characterised by bone resorption, and are useful in the treatment of bone disorders such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease,... Agent: Nixon & Vanderhye, PC

20080312185 - Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses: e

20080312187 - Phosphoinositide modulation for the treatment of alzheimer's disease: The present invention relates to methods of treating Alzheimer's Disease which utilize agents that increase neuronal phosphotidylinositol 4,5-biphosphate (PIP2), and to differentiated stem cell-based assay systems that may be used to identify agents that modulate phosphoinositide levels and thereby treat a variety of diseases. It is based, at least in... Agent: Baker Botts L.L.P.

20080312188 - Glycogen synthase kinase-3 inhibitors: Novel compounds designed to allow interactions with binding sites of GSK-3 and hence are capable of inhibiting GSK-3 activity, via inhibition of substrate binding are disclosed. Further disclosed are pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions.... Agent: Martin D. Moynihan Prtsi, Inc.

20080312189 - Cadasil treatment with cholinesterase inhibitors: The invention provides methods for treating and/or preventing cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) in a patient in need thereof by administering a therapeutically effective amount of at least one cholinesterase inhibitor. The invention also provides methods for treating and/or preventing neurovascular diseases caused by one... Agent: Venable LLP

20080312190 - Organophosphoric derivatives useful as anti-parasitic agents: The present invention relates to novel phosphonic acid compounds having the structural formula (I): wherein: (a) R is a group of 1 to 5 substituents independently selected from the group consisting of fluoro, chloro, bromo, C1-4 alkoxy, C1-4 alkyl, hydroxy, formyl, trifluoromethoxy, phenyl, heterocyclic, heterocyclic-substituted methyl, aminomethyl, hydroxy methyl, bromomethyl,... Agent: Clark & Elbing LLP

20080312191 - Novel urokinase inhibitors: The present invention relates to novel compounds with inhibitory activity towards urokinase plasminogen activator (uPA); to methods for preparation of said uPA inhibitor compounds; to pharmaceutical compositions comprising said uPA inhibitor compounds; to the use of said uPA inhibitor compounds as a medicament and the use of said uPA inhibitor... Agent: Clark & Elbing LLP

20080312192 - Diaryl urea derivatives in the treatment of protein kinase dependent diseases: The invention relates to the use of diaryl urea derivatives for the manufacture of pharmaceutical compositions for the treatment of RET dependent disorders, especially RET dependent tumour diseases. The invention further relates to novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N′-phenyl-urea derivatives and their use in the treatment of the animal or human body, especially in... Agent: Novartis Corporate Intellectual Property

20080312194 - Methods and compositions for normalizing meibomian gland secretions: The present invention provides non-aqueous compositions for normalizing meibomian gland secretions, and methods of use thereof. The present invention further provides compositions and methods for treating and/or preventing the signs and/or symptoms of dry eye disease.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080312193 - Substituted tetracycline compounds for treatment of inflammatory skin disorders: Methods and compositions for the treatment of skin disorders (e.g., acne, rosacea) are described.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080312195 - Preservatives: The invention relates to clear, liquid preservatives, which contain a) one or several 1-hydroxy-4-methyl-6-alkyl-2(1H)-pyridones and/or one or several salts thereof. wherein alkyl represents a linear, branched or cyclic alkyl group having 1-12 carbon atoms, and b) one or several alcohols containing one or several aromatic groups.... Agent: Clariant Corporation Intellectual Property Department

20080312196 - Topical wart removal composition: A non-aqueous liquid composition for topical application to warts and other fibroids, papillomas, and other growths for the removal of same is defined by a non-aqueous solution of: (a) at least one keratolytic compound or agent, (b) an adhesive, (c) a dermal regeneration promoter, and (d) a solvent. The composition... Agent: The Weintraub Group, P.L.C

20080312197 - Pharmaceutical products containing hormones and a 25-hydroxy vitamin d compound: The present invention relates to pharmaceutical products containing progestins in combination with the 25 hydroxy Vitamin D compounds. The 25 hydroxy Vitamin D compounds are preferably administered with the progestins. In OC and HRT regimens, the 25 hydroxy Vitamin D compounds can be administered daily, or on a non-daily basis,... Agent: Jenner & Block, LLP

20080312198 - Pharmaceutical products containing hormones and a 25-hydroxy vitamin d compound: The present invention relates to pharmaceutical products containing progestins in combination with the 25 hydroxy Vitamin D compounds. The 25 hydroxy Vitamin D compounds are preferably administered with the progestins. In OC and HRT regimens, the 25 hydroxy Vitamin D compounds can be administered daily, or on a non-daily basis,... Agent: Jenner & Block, LLP

20080312200 - Medicament comprising a hormone combination: The present invention relates to the use of a hormone combination of ethinyl oestradiol or oestradiol as oestrogen component and at least one metabolite of chlormadinone acetate selected from the group consisting of 3α-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-20-one (3α-hydroxychlormadinone acetate), 3β-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-20-one (3β-hydroxychlormadinone acetate), 3α-hydroxy-17α-acetoxy-5β-pregnan-20-one and 3β-hydroxy-17α-acetoxy-5β-pregnan-20-one, optionally mixed with chlormadinone acetate as gestagen component... Agent: Norris, Mclaughlin & Marcus, Pa

20080312199 - Treatments of therapy resistant diseases and drug combinations for treating the same: The present invention provides novel methods and kits for diagnosing the presence of cancer within a patient, and for determining whether a subject who has cancer is susceptible to different types of treatment regimens. The cancers to be tested include, but are not limited to, prostate, breast, lung, gastric, ovarian,... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080312201 - Reduced toxicity methotrexate formulations and methods for using the same: Methods of using methotrexate (MTX) active agents in which reduced host toxicity is observed are provided. In the subject methods, an effective amount of an MTX active agent is administered to the host in conjunction with the administration of an MTX toxicity reducing agent of the present invention. Also provided... Agent: Bozicevic, Field & Francis LLP

20080312202 - 6-substituted estradiol derivatives and methods of use: wherein R1 and Z are as described above, X is selected from the group consisting of: C1-C6 alkyl, a substituted alkyl, a halogen, a halogenated alkyl, a glucuronide, —NH2, —SO2NH2, —COOH, —CN, —CH2CN, —NHCN, —CHO, —COOsalt, —OSO2alkyl, —SH, —SCH3—CH(CH2)nCOOCH3, —(CH2)n—O—CH3, —CH2OH, —(CH2)n—O—NH2, —NH(CH2)nCH3, NH(CH2)nOCH3, —NH(CH2)nCHOH—COOH, —N(CH3)2, —(CH2)n(NH)CH2OH, —NHCOOH, —(CH2)nNHCOOH, —NO2,... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20080312203 - Bicyclic 6-alkylidene-penems as beta-lactamase inhibitors: e

20080312204 - Soluble forms of amoxicillin and treatment of animals: A solid mixture or aqueous solution of amoxicillin antibacterial agent with a material that aids in its dissolution in water to render it ingestive and palatable.... Agent: Crowell & Moring LLP Intellectual Property Group

20080312205 - Method and intermediates for the preparation of derivatives of n (1-benzhydrylazetidin-3-yl)-n-phenylmethylsulfonamide: The invention relates to a novel method for the synthesis of N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080312207 - Compounds: Compounds of Formula (I) wherein: R1 is methyl; R2 is selected from —C (O) NR4R5, SO2NR4R5, S (O) pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from... Agent: Morgan Lewis & Bockius LLP

20080312209 - Piperazine heteroaryl derivatives as gpr38 agonists: m

20080312208 - Pyridine analogues: The present invention relates to certain new pyridin analogues of Formula (I) Chemical formula should be inserted here. Please see paper copy Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-thrombotic agents etc, their use as medicaments in cardiovascular diseases as well... Agent: Pepper Hamilton LLP

20080312206 - Chemical compounds-149: The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula which possess CSF 1R kinase inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the... Agent: Astrazeneca R&d Boston

20080312210 - Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure: The present invention provides the use in a pharmaceutical composition of a specific cyclic amine derivative, or its pharmaceutically acceptable salts, for the treatment of heart failure of any aetiology.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080312211 - Antibacterial pyrrolopyridines, pyrrolopyrimidines and pyrroloazepines-154: Compounds of formula (I) and their pharmaceutically acceptable salts are described: formula (I). Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.... Agent: Astrazeneca R&d Boston

20080312212 - Organic compounds: m

20080312213 - 7-pyrazolylbenzazepines having affinity for d3 receptor: wherein R1 is pyrazolyl substituted by two or three substituents independently selected from halogen, C1-4alkyl and haloC1-4alkyl; R2 is hydrogen or methyl; and R3 is quinolinyl, oxazolyl or phenyl, each of which is optionally substituted by one or two halogen, C1-4alkyl or haloC1-4alkyl. Processes for preparation and uses of the... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080312214 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme: or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Methods of inhibiting 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Methods of treating neuronal degeneration, dysfunction, acute psychosis, anxiety, dementia, depression, non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions... Agent: Paul D. Yasger Abbott Laboratories

20080312217 - Organic compounds:

20080312216 - Piperazine and [1,4]diazepan derivatives as nk antagonists:

20080312215 - Substituted [1,4]-diazepanes as cxcr3 antagonists and their use in the treatment of inflammatory disorders: are disclosed. Inhibition of CXCR3 activation is useful for treating disorders resulting from CXCR3-associated T-cell mediated function, such as inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis and diabetes, as well as in the prevention of allograft rejection. N-ethyl-1,4-diazepane-1-carboxamides in which R1 is substituted or unsubstituted arylalkyl and R3 is substituted... Agent: Heslin Rothenberg Farley & Mesiti PC

20080312218 - Fused tetracyclic mglur1 antagonists as therapeutic agents: In its many embodiments, the present invention provides tetracyclic compounds of formula I or formula II (wherein the various moieties are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080312219 - Biologically active methylene blue derivatives: The compounds are biologically active photosensitisers which are strongly photocytotoxic and have application in the areas of photodynamic therapy (PDT), as well as for the diagnosis and detection of medical conditions and related uses in photochemical internalisation, in the production of cancer vaccines, in the treatment and prevention of microbial... Agent: Nixon & Vanderhye, PC

20080312220 - Oxadiazole derivatives with crth2 receptor activity: Compounds of formula are CRTH2 ligands, useful for treatment of inflammatory, autoimmune, respiratory or allergy disease: wherein R1 is hydrogen or methyl and R2 is optionally substituted cycloalkyl, or optionally substituted non-aromatic heterocyclyl having to 6 ring atoms; or R1 and R2, taken together with the carbon atom to which... Agent: Banner & Witcoff, Ltd.

20080312221 - Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same: wherein X=CH or N; Z=O or S; L=O or S; M=CR10R11, wherein R10 and R11=H, alkyl, or alkoxy, NR12 wherein R12=H or alkyl; R1, R2, and R3=H or optionally substituted alkoxy; R4=H; R5-8=H, halogen, alkoxy or the like; and R9=alkyl optionally substituted by —R14, -T-R15, or —NR16R17 wherein T=O, S,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080312222 - 4-benzyledene-piperidin derivatives: The present invention relates to new 4-benzylidene-piperidin derivatives of formula (I), useful as NMDA, in a particular NR2B subunit containing receptor antagonists and analgesica.... Agent: K.f. Ross P.C.

20080312223 - Thiazole and isothiazole derivatives that modulate the activity of cdk, gsk and aurora kinases: The invention provides a compound of the formula (I): or a salt, N-oxide, tautomer or solvate thereof, wherein X is CR5 or N; each of Q1 and Q2 is a carbon atom; Q3 is selected from S and CH; Q4 is selected from CR2 and S; provided that one of... Agent: Heslin Rothenberg Farley & Mesiti PC

20080312224 - Oxaphenanthrene derivatives: The invention relates to compounds of the formula (I), in which R1, R2, R3, R4, Y and A have the meanings indicated, and to processes for the preparation thereof and to the use thereof for the preparation of medicaments.... Agent: Millen, White, Zelano & Branigan, P.C.

20080312225 - Triazolophthalazines: e

20080312226 - Amide compound: wherein Z is oxygen or sulfur; R1 is aryl which may be substituted, or a heterocyclic group which may be substituted; R1a is a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; R2 is piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; R3 is... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080312228 - Pyrimidine compound and medical use thereof: wherein each symbol is as defined in the specification and a method of therapeutically or prophylactically treating an undesirable cell proliferation, comprising administering such a compound. The compound of the present invention has superior activity in suppressing undesirable cell proliferation, particularly, an antitumor activity, and is useful as an antitumor... Agent: Leydig Voit & Mayer, Ltd

20080312227 - Substituted pyrido(2,3-d) pyrimidine derivatives useful as medicines for the treatment of autoimmune disorders: This invention relates to a group of trisubstituted pyrido(2,3-d)pyrimidine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and as such are useful in the treatment in transplant rejection and/or in the treatment of certain inflammatory diseases.... Agent: Clark & Elbing LLP

20080312229 - Organic compounds: i

20080312230 - Organic compounds:

20080312231 - Substituted sulfonamide compounds:

20080312232 - Substituted amide derivatives and methods of use: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention... Agent: Amgen Inc.

20080312233 - Therapeutic morpholino-substituted compounds: Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers... Agent: Pepper Hamilton LLP

20080312234 - Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same: This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies,... Agent: Heslin Rothenberg Farley & Mesiti PC

20080312235 - Pyridine derivatives: The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds for the treatment of pain.... Agent: Pfizer Inc.

20080312236 - 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimlant activity: e

20080312237 - Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same:

20080312238 - 4-arylazo-3,5-diamino-pyrazole compounds and use thereof: A series of mono- and binuclear 4-arylazo-3,5-diamino-pyrazoles which are useful for inhibition of cyclin-dependent kinases (preferably CDK9). Hence they can be used as antimitotic-, pro-apoptotic and antiinflammatory drugs, in particular, in chemotherapy of cancer and asthma, therapy of psoriasis and parasitoses as those caused by fungi or protists, treatment of... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080312239 - Methods for the treatment of erectile dysfunction using fispemifene: A method of treatment of erectile dysfunction (ED) comprises the step of administering fispemifene to a subject in need thereof in an amount effective to raise the subject's testosterone level. Fispemifene may be used in combination with a PDE-5 inhibitor in individuals who have failed to respond sufficiently to conventional... Agent: Brinks Hofer Gilson & Lione

20080312242 - 7-aryl-3, 9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases: The invention relates to novel 3,9-diazabicyclo[3.3.1]nonene derivatives of formula (I) and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially... Agent: Dickstein Shapiro LLP

20080312240 - Bicyclic piperazines as metabotropic glutatmate receptor antagonists: e

20080312241 - Cicletanine and pkc inhibitors in the treatment of pulmonary and cardiac disorders: Embodiments of the present invention are related to novel therapeutic drugs, drug combinations, and associated methods for treating or preventing pulmonary disease, including pulmonary hypertension, pulmonary fibrosis, asthma and COPD, and heart failure, together with other pulmonary and cardiovascular diseases and their complications. More particularly, aspects of the present invention... Agent: Gilead Sciences Inc

20080312243 - Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions: b

20080312244 - Squaric acid derivatives as protein kinase inhibitors: Compounds of the formula I, in which R, X, R1, R2, R3, R4 and R5 have the meanings indicated in Claim 1, are inhibitors of CHK1 CHK2 and SGK kinases and can be employed, inter alia, for the treatment of cancer.... Agent: Millen, White, Zelano & Branigan, P.C.

20080312246 - Substituted piperazines as metabotropic glutamate receptor antagonists: m

20080312247 - Substituted piperazines: Disclosed herein are substituted piperazine late Na+ channel modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080312248 - Pyrimidinyl aryl urea derivatives being fgf inhibitors: wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of... Agent: Novartis Institutes For Biomedical Research, Inc.

20080312249 - Kmup-1 capable of treating hypertension: A pharmaceutical composition for treating the hypertension is provided. The pharmaceutical composition comprises a chemical compound of 7-[2-[4-(2-Chlorobenzene)piperazinyl]ethyl]-1,3-dimethyl xanthine and one of a pharmaceutical acceptable salt thereof and a solvate thereof, wherein the chemical compound treats the hypertension by cGMP-dependent inhibition on Rho kinase.... Agent: Volpe And Koenig, P.C.

20080312251 - Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof: The present invention provides aminopyrimidine compounds of formula (I) and their salts, wherein R1, R2, R3, R4, R5, R6, Q, Z, L, m, n are defined as the description, the methods for preparation thereof, the uses thereof and the pharmaceutical compositions comprising the effective amount of compounds of formula (I).... Agent: Morris Manning Martin LLP

20080312250 - Combination comprising a bcrp inhibitor and 4- (4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3- (4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl] -benzamide: in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, especially in the delay of progression or treatment of cancer, and to pharmaceutical compositions... Agent: Novartis Corporate Intellectual Property

20080312252 - Combination of organic compounds:

20080312245 - Methods and compositions for treating acne and other infectious diseases: The present invention provides a composition comprising metronidazole, ketoconazole, and lincomycin and methods of treating infectious skin diseases such as acne by topically administering the composition.... Agent: Longyan Xiao

20080312253 - Pharmaceutical compositions containing pyrazole derivatives for treating as serotonin antagonist: The present invention relates to a pharmaceutical composition containing a pyrazole derivative as an active ingredient, which has antagonistic activity against serotonin 5-HT3A and is effective for the prevention and treatment of central nervous system (CNS) diseases, including emesis, nausea, alcoholism, drug abuse, depression, compulsive neurosis, anxiety, seizure, Alzheimer's disease,... Agent: Dickinson Wright PLLC

20080312254 - Process for the preparation of ziprasidone: The invention relates to processes for the preparation of substantially pure ziprasidone. The invention also relates to the preparation of acid addition salts of ziprasidone. More particularly, it relates to the preparation of substantially pure hydrochloride salt of ziprasidone. The invention also relates to pharmaceutical compositions that include the substantially... Agent: Ranbaxy Inc.

20080312255 - Piperdine compounds and uses thereof-911: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.... Agent: Astrazeneca R&d Boston

20080312256 - Organic compounds: m

20080312257 - Triazolopyrimidine derivatives as adp p2y12 receptor antagonists:

20080312258 - Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile: The present invention provides active metablites of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.... Agent: Fish & Richardson PC

20080312259 - Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile: The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.... Agent: Fish & Richardson PC

20080312261 - 4- (4-bromo-2-fluoroanilino) -6- methoxy-7- (1-methylpiperidin-4-ylmethoxy) quinazoline monohydrate: The present invention relates to a ZD6474 monohydrate, to processes for the preparation of a ZD6474 monohydrate, to pharmaceutical compositions comprising a ZD6474 monohydrate as the active ingredient, to the use of a ZD6474 monohydrate in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability... Agent: Morgan Lewis & Bockius LLP

20080312260 - Biological markers predictive of anti-cancer response to kinase inhibitors: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase. Based on the surprising discovery that tumors cells after having undergone an EMT, while being mesenchymal-like, still express characteristics of both epithelial... Agent: Osi Pharmaceuticals, Inc.

20080312262 - Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics: e

20080312263 - Pharmaceutical compositions for the prevention and treatment of atherosclerosis:

20080312264 - Process for the production of an abuse-proofed solid dosage form: The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a synthetic or natural polymer with a breaking strength of =500 N, characterised in that a corresponding mixture is processed by melt extrusion... Agent: Norris, Mclaughlin & Marcus, P.A.

20080312265 - Treatment of drug-resistant tumors: A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of drug-resistant tumors and/or for the administration to patients who show polymorphisms in the gene coding for DNA topoisomerase I.... Agent: Lucas & Mercanti, LLP

20080312266 - Steroidal compounds for inhibiting steroid sulphatase: There is provided a compound having Formula (I) wherein G is H or a substituent, and wherein R1 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group, capable of inhibiting steroid sulphatase.... Agent: Frommer Lawrence & Haug

20080312267 - Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway: The present invention relates to compositions and methods for identifying abnormalities in TSC signaling pathways. In particular, the present invention relates to methods of diagnosing and treating disorders such as tuberous sclerosis, which are caused by mutations in the TSC genes. The present invention further relates to methods and compositions... Agent: Casimir Jones, S.c.

20080312268 - Substituted tricyclic piperidone compounds: e

20080312270 - Compounds and methods useful for treating asthma and allergic inflammation: Compounds, compositions and methods that are useful in the treatment of inflammatory and immune-related diseases and conditions are provided herein. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.... Agent: Jones Day

20080312269 - Therapeutic agents: The present invention relates to 4,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one and 4,5-dihydropyrrolo[3,2-c]pyridin-4-one compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.... Agent: Morgan Lewis & Bockius LLP

20080312272 - Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof: e

20080312271 - Azabenzimidazolyl compounds:

20080312273 - Quinoline derivatives having vegf inhibiting activity: The invention relates to compounds of formula (I) wherein: either any one of G1, G2, G3, G4 and G5 is nitrogen and the other four are —CH— or G1, G2, G3, G4 and G5 are all —CH—; Z is —O—, —NH—, —S—, —CH2— or direct bond; Z is linked to... Agent: Morgan Lewis & Bockius LLP

20080312276 - 4,5 dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators: e

20080312275 - Novel cyanoguanidine compounds: Novel pyridyl cyanoguanidine compounds of general formula I (I) wherein R1, X, R2 and R3 are as defined herein, exhibit a high antiproliferative activity and may be used in the treatment of hyperproliferative and neo-plastic diseases.... Agent: Wilmerhale/boston

20080312274 - Quinoline derivatives as neurokinin receptor antagonists: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors, such as schizophrenia.... Agent: Merck And Co., Inc

20080312277 - Gpr41 and modulators thereof for the treatment of insulin-related disorders: The present invention relates to a method for identifying a glycemic stabilizing compound by: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is modulated, where a modulation in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. In addition, the invention... Agent: Bozicevic, Field & Francis LLP (arena Pharmaceuticals, Inc.)

20080312278 - Hydroxyquinoline derivatives: Compounds of the formula I in which X, Y, R1, R1′, R2, R3 have the meanings indicated in claim 1, are inhibitors of cell proliferation and can be employed for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20080312279 - Compositions for treating fragile x and other disorders methods of use thereof, and screening for compounds for fragile x and other disorders: Methods of screening compounds, active compositions, pharmaceutical compositions, methods of treating disorders, methods of preventing disorders, and kits to screen a library of compounds, are disclosed.... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20080312280 - 3- (4-{ [4- (4-{ [3-(3, 3-dimethyl-1-piperidinyl) propyl] oxy} phenyl) -1-piperidinyl] carbonyl}-1-naphthalenyl) propanoic or propenoic acid as h1 and h3 receptor antagonists for the treatment of inflammatory and/or allergic disorders: wherein the naphthalene ring is substituted in the 2, 3, 4, 5, 6, 7 or 8 position by R1, and R1 represents —CH2CH2COOH or —CH═C(CH3)COOH, and to processes for their preparation, to compositions containing them and to their use in the treatment of various inflammatory and/or allergic diseases, such as... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080312281 - G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes: Compounds of formula (I), or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes.... Agent: Osi Pharmaceuticals

20080312282 - Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme: m

20080312283 - Use of hydroxylamine derivates for inhibiting vitrectomy-induced cataracts: Methods to prevent, inhibit, or slow the development of vitrectomy-induced cataracts are disclosed. The methods comprise administering to the eye of a subject a composition comprising an opthalmologically acceptable carrier or diluent and at least one hydroxylamine compound in a therapeutically sufficient amount to prevent, inhibit, or slow the development... Agent: Woodcock Washburn LLP

20080312284 - Amorphous form of 1,2-dihydropyridine compound: An amorphous form of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridine-2-one.... Agent: Birch Stewart Kolasch & Birch

20080312285 - Substituted indazoles as inhibitors of phosphodiesterase type-iv: The present invention relates to isoxazoline derivatives of structure Ia, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. Compounds disclosed herein can be useful in the treatment of CNS disorders, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's... Agent: Ranbaxy Inc.

20080312286 - Indanone potentiators of metabotropic glutamate receptors: The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed... Agent: Merck And Co., Inc

20080312287 - Compound and methods for the treatment of cancer and malaria: Formula (I): Where R1 is an optionally substituted C3-C12 hydrocarbyl group (preferably a cyclic alkyl group), an optionally substituted heterocyclic group, an optionally substituted aromatic group or an optionally substituted heteroaromatic group; R is a C(O)yR′ group (preferably forming an optionally substituted C2-C5 acyl group), or a S(O)xR′ group, where... Agent: Coleman Sudol Sapone, P.C.

20080312290 - Oil based suspension concentrates: Agrochemical formulation comprising at least one room-temperature-solid active substance from the class of the neonicotinoids, at least one room-temperature-solid active substance from the class of the pyrethroids, at least one penetrant, at least one vegetable oil, cyclohexanone, at least one nonionic surfactant and/or at least one anionic surfactant, and one... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080312288 - Solid forms of 2-chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1h-imidazol-4-ylethynyl]-pyridine: The present invention relates to the mono-sulfate salt, crystalline forms A and B of the mono-sulfate salt, an amorphous form of the mono-sulfate salt, hemi-sulfate salts, and a crystalline form A of the hemi-sulfate salt of the compound 2-chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080312289 - Use of cni-sl formulations for controlling white fly: Method of controlling eggs and nymphal stages of whitefly by the spray application of agrochemical formulations containing at least one insecticide from the series of the neonicotinyls, at least one fatty alcohol ethoxylate of the formula (I), at least one solvent from the group consisting of dimethyl sulphoxide, N-methylpyrrolidone and... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080312291 - Heterocyclic gaba-b modulators: The present invention relates to novel thiazole and oxazole derivatives having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of... Agent: White & Case LLP Patent Department

20080312292 - Antipruritics: It is intended to provide antipruritics (drugs to control itching, antiitch agents and drugs to stop itching). It is found out that a compound having an agonistic activity to the cannabinoid receptor shows an antipruritics effect.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080312293 - 2-arylpropionic acid derivatives and pharmaceutical compositions containing them: The present invention relates to selected (R)-2-phenyl-propionamides and (R)-2-phenyl-sulfonamides with a hydrogen bond acceptor atom/group in a well defined position in the chemical space. These compounds show a surprising potent inhibitory effect on C5a induced human PMN chemotaxis. The compounds of the invention absolutely lack of CXCL8 inhibitory activity. Said... Agent: Birch Stewart Kolasch & Birch

20080312294 - Tricyclic compounds, compositions, and methods: e

20080312295 - Pesticidal mixtures:

20080312296 - Bifunctional synthetic molecules: The synthesis and use of bifunctional molecules to improve the topical and transdermal delivery efficiency of various types of therapeutic agents or agents designed to promote the transdermal delivery of those therapeutic agents either into the skin tissue or into the systemic circulation. Three major classes of molecules are covalently... Agent: Nields & Lemack

20080312298 - Methods for identification of modulators of carm1 methyl transferase activity: This invention relates to CARM1, CARM1 binding pockets, or CARM1-like binding pockets. The invention relates to a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. The invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080312297 - Substituted oxyguanidines: i

20080312299 - Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them: Imidazole derivatives of formula (I) wherein R1, R2a, R2b, A, V and W are as defined in the description, as inhibitors of fructose-1,6-bisphosphatase, their preparation process and their use in the prevention or treatment of diabetes, and other diseases where the inhibition of gluconeogenesis, control of blood glucose levels, reduction... Agent: Millen, White, Zelano & Branigan, P.C.

20080312300 - Processes for the preparation of stable polymorphic form i of ritonavir: The invention relates to processes for the preparation of a polymorphic form of ritonavir. More particularly, it relates to the preparation of a stable polymorphic Form I of ritonavir. The invention also relates to pharmaceutical compositions that include the stable Form I of ritonavir and use of the compositions for... Agent: Ranbaxy Inc.

20080312301 - Substituted n-benzo[d]isoxazol-3-yl-amine compounds as inhibitors of mglur5, serotonin (5-ht) and noradrenaline receptors, and uses thereof: The invention relates to substituted N-benzo[d]isoxazol-3-yl-amine derivatives of formula (I) wherein R1, R2, R3, R4 and R5 are defined as in patent claim 1. The invention also relates to the use of said compounds for producing medicaments.... Agent: Crowell & Moring LLP Intellectual Property Group

20080312302 - Desferasirox dispersible tablets: The invention pertains to dispersible tablets comprising as active ingredient 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid or pharmaceutically acceptable salt thereof in an amount of from 5 to 40% in weight by weight of the total tablet.... Agent: Novartis Corporate Intellectual Property

20080312303 - Imidazole derivatives and their use for modulating the gabaa receptor complex: e

20080312305 - Imidazoles as gaba- b receptor modulators: The present invention relates to novel imidazole derivatives having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux... Agent: White & Case LLP Patent Department

20080312304 - Topical compositions containing metronidazole: Aqueous compositions containing solubilized metronidazole at a concentration of about 0.75% by weight or greater are able to be obtained by using the combination of solubility enhancing agents, first one is niacinamide, second one is urea, and third one is hydroxyalkyl urea. Related methods are also disclosed.... Agent: Jerry Zhang

20080312306 - Polymorphs, solvates, and hydrate of 5-(4'-fluoro-2'-oxo-1',2'-dihydrospiro[cyclopropane-1,3'-indol]-5'-yl)-1-methyl-1h-pyrrole-2-carbonitrile: Novel polymorph Form II and III, solvate Forms I, II, III, and IV, and the hydrate of 5-(4′-fluoro-2′-oxo-1′,2′-dihydrospiro[cyclopropane-1,3′-indol]-5′-yl)-1-methyl-1H-pyrrole-2-carbonitrile are provided, as are methods for preparing the same. Pharmaceutical compositions and kits containing these novel polymorphs, solvates, and hydrate, and combinations thereof are further provided, as are methods of contraception; treating... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20080312307 - Mapk/erk kinase inhibitors: v

20080312308 - Substituted acetic acid derivatives: The present invention relates generally to substituted acetic acid derivatives and methods of using them.... Agent: Wyeth Patent Law Group

20080312309 - Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia: The present invention provides methods of treating and preventing arrhythmia and other diseases or disorders, using ion channel modulating compounds, including vernakalant hydrochloride. The present invention further provides controlled release oral formulations and dosages of vernakalant hydrochloride, which are effective in preventing arrhythmia. Certain methods and formulations of the present... Agent: Seed Intellectual Property Law Group PLLC

20080312310 - Compounds, compositions and methods: Compounds, compositions and methods useful for treating cellular proliferative diseases and disorders, for example, by modulating the activity of KSP, are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080312311 - Crystalline forms of 3-(2r-tetrahydrofuryl-methyl)-2-thioxanthine: The present invention relates to novel crystalline forms of 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine. Further the present invention also relates to compositions comprising them and their use in therapy.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080312312 - Substituted benzopyrans as selective estrogen receptor-beta agonists: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof useful as Estrogen Receptor beta agonists for treating Estrogen Receptor beta mediated diseases such as benign prostatic hyperplasia.... Agent: Eli Lilly & Company

20080312313 - Inhibitors of ccr9 activity: A compound of formula (I), wherein the residues have various meanings, useful as pharmaceuticals.... Agent: Novartis Corporate Intellectual Property

20080312314 - Alpha crystalline form of strontium ranelate: c

20080312315 - Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use: Multifunctional compounds are provided that readily crosslink in situ to provide crosslinked biomaterials. The multifunctional compounds contain a single component having at least three reactive functional groups thereon, with the functional groups selected so as to be non-reactive in an initial environment and inter-reactive in a modified environment. Reaction of... Agent: Seed Intellectual Property Law Group PLLC

20080312316 - Chromone derivatives useful as antagonists of vr1 receptors: l

20080312317 - 12 membered-ring macrolactam derivatives: There provided a 12-membered-ring macrolactam derivative having antitumor activity: A compound represented by Formula (1) or a salt thereof. In this Formula, R1 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group or a C6-14 arylcarbonyl group; R2 is a hydrogen atom or a C1-6 alkyl group;... Agent: Birch Stewart Kolasch & Birch

20080312318 - Deuterium-enriched escitalopram: The present application describes deuterium-enriched escitalopram, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080312319 - Modulation of bacterial quorum sensing with synthetic ligands: The present invention provides compounds and methods for modulation of the quorum sensing of bacteria. In an embodiment, the compounds of the present invention are able to act as replacements for naturally occurring bacterial quorum sensing ligands in a ligand-protein binding system; that is, they imitate the effect of natural... Agent: Greenlee Winner And Sullivan P C

20080312320 - Non-dusty, free flowing, storage stable solid composition and a process for its preparation: A solid water dispersible granular composition of pesticide comprising up to 50% of at least one pesticide from pyrethroid class, more particularly a highly viscous liquid pyrethroid insecticide, permethrin, having the properties of excellent dispersibility and suspensibility, as well as the process of preparation of the composition are disclosed. Also... Agent: Jones, Tullar & Cooper, P.C.

20080312321 - Therapeutic substituted cyclopentanes: Therapeutic compounds are disclosed herein.... Agent: Allergan, Inc.

20080312322 - Organic compounds: A compound of formula (I); in free or pharmaceutically acceptable salt form, where R1, R2, R3, R4, R5, m, n, w, X, Y and Q have the meanings as indicated in the specification, are useful for treating conditions mediated by the CRTh2 receptor, especially inflammatory or obstructive airways diseases.... Agent: Novartis Corporate Intellectual Property

20080312323 - Inhibition of tnf-alpha-initiated response: The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNFα)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically stable LX analogs. At concentrations as low as 1-10 nM, the LXA4 and ATL analogs each inhibited TNFα-stimulated superoxide anion generation and IL-1β release... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080312324 - Treatment of lung cells with histone deacetylase inhibitors: Lung disease, such as cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), asthma or acute and chronic bronchitis, can be treated with an oxyamide-containing compound.... Agent: Steptoe & Johnson LLP

20080312325 - Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins: Methods of detecting and treating rapidly growing exogenous cells, such as Protista, or parasites, that preferentially accumulate a photoactivatable porphyrin in which 5-aminolevulinic acid or precursor thereof is administered to the patient, or contacted to the exogenous cells, in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of... Agent: Foley And Lardner LLP Suite 500

20080312326 - Method for the prevention and/or treatment of neurodegenerative diseases characterized by administering and ep1 receptor antagonist: The present invention relates to the use of EP1 receptor antagonists for the treatment of neurodegenerative diseases, for example, Alzheimer's disease, Parkinson's disease, Parkinson syndrome, dementia, amyotrophic lateral sclerosis, progressive supranuclear palsy, Huntington's disease, spinocerebellar ataxia, etc.... Agent: Banner & Witcoff, Ltd.

20080312327 - Organic compositions: Provided is an improved liquid composition for the treatment of surfaces, preferably the skin and/or hair in order to provide a cleaning and/or sanitizing effect thereto, which necessarily comprises: one or more detersive surfactants selected from anionic, nonionic, cationic, and amphoteric surfactants; a first biocidal constituent(s) which provide a biocidal... Agent: Norris, Mclaughlin & Marcus

20080312328 - Deuterium-enriched tamsulosin: The present application describes deuterium-enriched tamsulosin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080312329 - Nonpeptide inhibitors of matrix metalloproteinases: wherein X is (CH2)nO, (CH2)nS, (CH2)nNR1, (CH2)n(CH2), or CH═CH, wherein n=0, 1, or 2; R and R1 are, independently, a substituted or unsubstitued alkyl, alkenyl, alkynyl, aryl, heteroaryl group, cycloalkyl, heterocycloalkyl, cycloalkenyl, or heterocycloalkenyl; and Z is NH or CH2; or a pharmaceutically acceptable salt thereof. Also disclosed are methods... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080312330 - Methods for reducing mortality and morbidity by postoperative administration of a pharmacologic cardiovascular agent: The present invention relates to methods for reducing mortality and cardiovascular morbidity following surgery. In particular, the invention relates to the intensive postoperative administration of a pharmacologic cardiovascular agent to reduce mortality and cardiovascular complications. The invention is illustrated by way of working examples which demonstrate that in patients with,... Agent: Sutherland Asbill & Brennan LLP

20080312331 - Method of treating dailysis-induced hypotension: A method is described for the treatment of hypotension, e.g., intra-dialytic hypotension, which is based on the administration to a patient, e.g. a dialysis patient during dialysis, of midodrine or a midodrine metabolite which will increase a lowered blood pressure in the patient or relieve a symptom caused by the... Agent: Accu-break Technologies, Inc.

20080312332 - G protein-coupled receptor antagonist and its use for preventing and treating alzheimer's disease: A method for screening a reagent for treating or preventing Alzheimer's disease or related neurological pathology includes the steps of: (a) activating a receptor and determining a first extent of endocytosis of the receptor, wherein the receptor is a G-protein coupled receptor that associates with presenilin-1; (b) activating the receptor... Agent: Osha Liang L.L.P.

20080312333 - Agent for preventing/ameliorating life style-related diseases containing turmeric essential oil component: The agent for preventing and/or ameliorating life style-related diseases according to the invention contains, as an active ingredient, at least one compound selected from the group consisting of ar-turmerone, α-turmerone, β-turmerone, curlone, bisacumol and β-sesquiphellandrene, or at least one compound selected from among the bisabolane type sesquiterpenoids derived from Curcuma... Agent: Connolly Bove Lodge & Hutz LLP

20080312334 - Cyclohexenone compounds from antrodia camphorata to treat autoimmune diseases: The present invention relates to a compound of Antrodia camphorata used to treat autoimmune diseases, in particular to an extract, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone, isolated from Antrodia camphorata, and its use in alleviating symptoms of autoimmune diseases such as systemic lupus erythematosus (SLE). The cyclohexenone compound according to the present invention helps to... Agent: Rabin & Berdo, PC

20080312335 - Liver protection compounds of the cyclohexenone type from antrodia camphorata: The present invention relates to a compound of Antrodia camphorata used for liver protection, in particular to an extract, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone which is isolated from Antrodia camphorate. The cyclohexenone compound according to the invention helps to alleviate liver injury and fibrosis induced by chemicals and reduces the levels of alanine aminotransferase... Agent: Birch Stewart Kolasch & Birch

20080312336 - Preventive and/or therapeutic agent for diabetic vascular disorder and respiratory disorder: e

20080312337 - Anticancer composition comprising obovatol or obovatal: Disclosed herein is an anticancer composition, comprising obovatol, represented by the following Chemical Formula 1, obovatal, represented by the following Chemical Formula 2, and/or pharmaceutical salts thereof. The composition exhibits the activity of inhibiting the growth of cancer cells and suppressing the expression and activity of matrix metalloproteinases (MMPs), and... Agent: Casimir Jones, S.c.

20080312338 - Formulation: The invention relates to sterile pharmaceutical compositions for parenteral administration which comprise an oil-in-water emulsion in which a free radical scavenging sedative agent dissolved in an omega-3 rich water-immiscible solvent, is emulsified with water and stabilised by means for a surfactant, the composition being suitable either directly or after dilution... Agent: Morrison & Foerster LLP

20080312339 - Fluorine-substituted alkyl phenol compounds and their uses: The present invention relates to the synthesis of fluorinated forms of alkyl phenol compounds and their subsequent use as pharmaceutical agents. More specifically, alkyl phenol compounds are fluorinated to increase compound volatility such that the compound may be administered to a mammal, such as a human being, by inhalation. The... Agent: Edwards Angell Palmer & Dodge LLP

20080312340 - Process for preparing dispersions: The invention provides a process for preparing a dispersion of particles, by reducing in particle size at least one component by agitating the component in the presence of (i) a plurality of beads; (ii) a powder; (iii) a surfactant; and (iv) a liquid medium to form a dispersion, wherein the... Agent: The Lubrizol Corporation Attn: Docket Clerk, Patent Dept.

20080312341 - Mono-, di- and polyol phosphate esters in personal care formulations: A hydrophilized personal care formulation, which can be in the form of a hand or body soap (liquid or bar), lipstick, body wash, makeup remover, skin cleaner, hair conditioner, skin or hair moisturizer. The formulation employs an organophosphorus material or a mixture of an organophosphorus material, for example, mono-, di-,... Agent: Novak Druce + Quigg, LLP

20080312342 - Process for the production of diacylglycerol: The present invention provides a process for producing a diacylglycerol, which comprises, reacting triacylglycerol with water and an enzyme preparation to obtain a mixture comprising of diacylglycerol, monoacylglycerol and free fatty acid; removing water content in the mixture by way of dehydration; and separating monoacylglycerol, free fatty acid and residual... Agent: The H.t. Than Law Group

20080312344 - Dendrimers multivalently substituted with active groups: e

20080312343 - Novel concentrated inverse latex, process for preparing it and industrial use thereof: wherein the radicals R1, R2 and R3, which are the same or different, independently represent a hydrogen atom or a linear or branched alkyl radical comprising between 1 and 4 carbon atoms, the radical R4 represents a linear or branched, saturated or unsaturated, aliphatic radical comprising between 6 and 30... Agent: Young & Thompson

20080312345 - Aqueous film coating composition containing sodium alginate and preparation thereof: A coating composition comprising sodium alginate and plasticizer, optionally detackifying agents, opacifers and colorants. The coating composition of the present invention may be applied to a pharmaceutical and veterinary tablet, caplets, pellets, granules, neutraceuticals, food, confectionery, seeds, animal feed, fertilizers and pesticide tablets and provides an elegant, glossy, prompt release... Agent: Merchant & Gould PC

20080305985 - Isosteric transormation: A method of generating an isosteric structure of a polypeptide at least partially containing D-amino acids from 3D-coordinates and sequence information of an L-configurated precursor having an N-terminal amino group or substituted amino group, a C-terminal carboxy group or a carboxy derivative, a backbone and L-amino acid side chains, and... Agent: Venable LLP

20080305986 - Multimers of peptides: Described are compounds useful for trimerising chemical entities, methods of trimerising chemical entities, and trimerised entities. In one aspect, the entities are peptides.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080305987 - Sex-specific regulation of aging and apoptosis: The invention provides anti-apoptotic agents and therapies and uses thereof. Specifically, the anti-apoptotic agents and therapies involve human Xist gene, Xist RNA, Xist gene product, and antagonists and small molecule mimics of these nucleic acids and proteins.... Agent: Hogan & Hartson L.L.P.

20080305988 - V-like domain binding molecules: The present invention relates to binding moieties comprising at least one monomeric V-like domain (VLD) derived from a non-antibody ligand, the at least one monomeric V-like domain being characterised in that at least one CDR loop structure or part thereof is modified or replaced such that the solubility of the... Agent: Frommer Lawrence & Haug

20080305989 - Transdermal delivery peptides and method of use thereof: Transdermal delivery peptides for the treatment of skin diseases and/or facilitation or enhancement of transdermal delivery of pharmaceutically active agents are provided. Compositions comprising the transdermal delivery peptides and methods of therapeutic use, including the improvement of transdermal delivery of drugs or other pharmaceutically active agents, are also disclosed. Nucleic... Agent: Sutherland Asbill & Brennan LLP

20080305991 - Factor ix: remodeling and glycoconjugation of factor ix: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.... Agent: Morgan, Lewis & Bockius LLP (sf)

20080305992 - Glycopegylated erythropoietin: The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified... Agent: Morgan, Lewis & Bockius LLP (sf)

20080305990 - Method of producing fully carbamylated erythropoietin: The present invention relates to a method of carbamylating an erythropoietin such that the resulting carbamylated erythropoietin has less that about 10% free primary amines on the lysines and the N-terminal amino acids, is not digested when exposed to Lys-C proteolysis, exhibits no erythropoietic activity in a TF-1 or UT-7/EPOR... Agent: Jones Day

20080305993 - Use of c1 inhibitor for the prevention of ischemia-reperfusion injury: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080305994 - Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye: A composition for treating, reducing, ameliorating, alleviating, or preventing a dry eye condition or an opthalmologic disorder that has an etiology in inflammation comprises an inhibitor of activity of poly(ADP-ribose) polymerase (“PARP”). The composition can also include a modulator of pro-inflammatory gene expression.... Agent: Bausch & Lomb Incorporated

20080306002 - Combination therapy for preventing angiogenesis: The present invention is directed to a combination therapy for inhibiting angiogenesis in a subject having, or at risk of having, an angiogenic disease/disorder. The method comprises both administering to the mammal an inhibitor of HIF-I and administering a second compound or agent that inhibits angiogenesis such as an inhibitor... Agent: David S. Resnick

20080305998 - Ligand to gpr8 and dna thereof: e

20080306004 - Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptides. In particular, the invention relates to novel stem cell growth factor-like polypeptides, including novel proteins named SCGF3248Fk081_aa2, SCGF3248Fk081_aa1, SCGFFk081_aa3, and SCGF323401Fe131_aa1. Other... Agent: Robins & Pasternak

20080306006 - Microrna-based methods and compositions for the diagnosis, prognosis and treatment of solid cancers: The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provide methods of identifying inhibitors of tumorigenesis.... Agent: Macmillan Sobanski & Todd, LLC

20080305997 - Modulation of cd4+ t cell responses by a tick saliva protein, salp15 and polypeptides derived therefrom: Salp15, biologically functional equivalents and fragments thereof, and nucleic acid molecules encoding the same are disclosed. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed. Salp15 gene products and Salp15 polypeptide fragments have biological activity in modulating CD4+ T cell activation through specific binding to CD4. Thus,... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080306003 - Novel compositions and methods for promoting, inhibiting and detecting protein entry into cells: The invention features methods for identifying compounds that inhibit cell death, and methods for identifying compounds that promote cell death, by blocking or accelerating, respectively, the translocation of the catalytic domain of toxins or transcription factors through the endosomal membrane into the cytosol of a cell. Also featured are methods... Agent: Clark & Elbing LLP

20080305996 - Novel tumor necrosis factor receptor homologs and nucleic acids encoding the same: The present invention is directed to novel polypeptides having homology to members of the tumor necrosis factor receptor family and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention... Agent: Audrey Goddard

20080305995 - Royal jelly peptide and composition containing the same: A royal jelly peptide which has a function as a queen bee's attraction cofactor and can enhance the biological defense system of an animal (an immunopotentiating effect); and a composition containing the same.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080305999 - Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia: Vascular endothelial growth factor (VEGF) has utility in the treatment of intimal hyperplasia, hypertension and atherosclerosis, and of conditions susceptible to treatment with agents that produce nitric oxide or prostacyclin. Instead of VEGF, an equivalent agent such as an agonist of VEGF receptors may be given, as may nucleic acid... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080306000 - Three-dimensional structures of tall-1 and its cognate receptors and modified proteins and methods related thereto: Disclosed are TALL-1 and TALL-1 receptor protein homologues (agonists and antagonists) designed based on the three-dimensional structure of sTALL-1, eBCMA and eBAFF-R; agonist homologues of APRIL; methods of using wild-type APRIL to inhibit the activity of TALL-1; compositions comprising such homologues, nucleic acid molecules encoding such homologues, and therapeutic methods... Agent: Sheridan Ross PC

20080306001 - Transcriptional modulation of extracellular matrix (ecm) of dermal fibroblasts: The present invention includes peptides, compositions as well as their use for the prevention or treatment of various age related or pathological conditions of skin or other tissues including skin wrinkles, wounds, different types of fibrosis and methods of reconstructing different tissues such as techniques used in regenerative medicine. The... Agent: Biotech Beach Law Group , PC

20080306005 - Treatment of bone disorders with skeletal anabolic drugs: Disclosed herein are methods for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass, including osteoporosis. The present invention provides methods of using PTHrP, or analogs thereof, for the treatment of metabolic bone disorders that are both effective and have an increased safety.... Agent: Foley & Lardner LLP

20080306007 - Agents for prophylaxis or treatment of neurological related diseases and conditions: Inhibitors of syndapin I binding to dynamin I (DynI) are provided. Examples include mimetics of a region of DynI including the serine residues S774 and S778 or phosphorylatable amino acids in homologous positions. Typically, the mimetics exclude or do not imitate at least one phosphorylation site provided by the serine... Agent: Fulbright & Jaworski, LLP

20080306008 - Peptides for use in the treatment of obesity: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080306009 - Immunoregulatory compositions: wherein AAL is a substituted or unsubstituted non-polar amino acid selected from the group consisting of Ala and Leu; wherein AAQ is a substituted or unsubstituted amino acid selected from the group consisting of Gln, Pro, and Ala; wherein AAG is a substituted or unsubstituted amino acid Gly, and wherein... Agent: Trask Britt

20080306010 - Vaccine composition containing irradiated ovalbumin for the prevention and treatment of allergic disease: The present invention relates to a vaccine composition for the prevention and treatment of allergic disease comprising irradiated ovalbumin as an effective ingredient, more precisely a method for preparing an immunogen of a vaccine for the prevention and treatment of allergic disease using the irradiated ovalbumin which is separated and... Agent: Lucas & Mercanti, LLP

20080306011 - Method of controlling the proliferation of vascular endothelial cells and inhibiting lumen formation: [MEANS FOR SOLVING PROBLEMS] A method of controlling the proliferation of vascular endothelial cells characterized by utilizing the vascular endothelial cell proliferation-controlling effect of D-mannose, D-allose, 2-deoxy-D-glucose, 3-deoxy-D-glucose, L-sorbose, 2-deoxy-D-ribose and/or 2-deoxy-L-ribose. A method of inhibiting lumen formation of vascular endothelial cells characterized by utilizing the vascular endothelial cell lumen... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20080306012 - Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates: The invention relates to compounds capable of releasing nitric oxide wherein the compounds comprise a saccharide and at least one nitric oxide-releasing diazeniumdiolate [N2O2] functional group, which is bonded directly to a carbon atom of the saccharide, and methods for preparing the same. The invention further comprises the treatment of... Agent: Leydig, Voit & Mayer, Ltd.

20080306013 - Illudin analogs useful as antitumor agents: e

20080306014 - Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial: The present invention provides agents which are capable of regulating the function of a micro-RNA component which can be used to regulate an AChE-associated biological pathway. In addition, the present invention provides methods and pharmaceutical compositions for the treatment of various pathologies related to AChE-associated biological pathways such as apoptosis,... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20080306018 - Micro-rna expression abnormalities of pancreatic, endocrine and acinar tumors: The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of pancreatic cancer. The invention also provides methods of identifying anti-pancreatic cancer agent.... Agent: Macmillan Sobanski & Todd, LLC

20080306017 - Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer: The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of lung cancer. The invention also provide methods of identifying anti-lung cancer agents.... Agent: Macmillan Sobanski & Todd, LLC

20080306016 - Nucleic acid functionalized nanoparticles for therapeutic applications: Materials and Methods for modulating cellular uptake of functionalized nanoparticles are provided. Also provided are materials and methods for modulating the effectiveness of a therapeutic agent with a functionalized nanoparticle.... Agent: Marshall, Gerstein & Borun LLP

20080306015 - Sirna targeting proprotein convertase subtilisin/kexin type 9 (pcsk9): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20080306019 - Dopamine receptor agonists in the treatment and prevention of hiv-induced dementia: Provided herein is a method of protecting a neuron from dysfunction induced by an HIV neurotoxin, comprising contacting the cell with a therapeutically effective dose of a dopamine D1 receptor agonist. Also provided is a method of treating or preventing HIV-1 associated dementia (HAD) in a subject in need of... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080306022 - Agent for applying to mucosa and method for the production thereof: An agent for applying to mucosa capable of persistently exerting a therapeutic effect on disorders such as inflammation and lesions in the mucosa even by a lower frequency of administration because the agent can stay at a diseased site for a long period of time by exhibiting a high staying... Agent: Husch Blackwell Sanders, LLP Welsh & Katz

20080306021 - Cosmetic preparation comprising hyaluronic acid: The present invention relates to cosmetic preparations with an active substance combination of hyaluronic acid and saponins.... Agent: Greenblum & Bernstein, P.L.C

20080306023 - Derivatives of hyaluronic acid, their preparation process and their uses: The present invention relates to the use of a compound having the formula (I) wherein: n represents an integer varying from 720 to 6 200, and i varies from 1 to n, Ri represents in particular OH, or a group of the formula (III) wherein k represents an integer varying... Agent: Young & Thompson

20080306024 - Method for micro-incision cataract surgery, a method of evaluation of a viscoelastic material , a composition for evaluation of a viscoelastic material and a method for evaluation using the composition: A method for micro-incision cataract surgery, wherein a solution containing hyaluronic acid having a weight average molecular weight of from 600,000 to 1,200,000 or a salt thereof is injected into the anterior chamber, and flow rate of a perfusion liquid in the anterior chamber is set to about be 35... Agent: Sughrue-265550

20080306020 - Skin-protecting alkalinity-controlling composition and the use thereof: A skin-protecting alkalinity-controlling composition comprises one or more carboxylic acid polysaccharides. Said compositions are capable of providing buffering, and thus avoiding a major increase in the pH of an aqueous system and/or are capable of reducing the pH of aqueous systems, in which alkalinity is formed as a result of... Agent: J M Huber Corporation

20080306025 - N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use: The present invention relates to an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof, the N-(phosphonoalkyl)-amino acid, related compound or derivative thereof being in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, other than N-(phosphonomethyl)-glycine or N,N-bis(phosphonomethyl)-glycine. Also... Agent: Panitch Schwarze Belisario & Nadel LLP

20080306026 - Capsule formulation: An encapsulated composition of (a) a pesticide at least active via ingestion that is photolabile, and (b) at least one photoprotectant, wherein the encapsulating polymeric barrier is base triggerable is disclosed. A method for controlling damage of a material by a pest by the use of such encapsulated compositions is... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080306027 - Fluoroalkoxycombretastatin derivatives, method for producing the same and use thereof: Combretastatin derivatives of formula (I), preparation and use thereof are disclosed, wherein: Rf is alkyl with 1-8 carbon atoms and 1-17 fluorine atoms, R is amino, substituted amino, hydroxyl, nitro, halo, alkyloxy, phosphate or amino acid side chain. Said derivatives have a capability to inhibit the polymerization of microtubules and... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080306028 - Erianin salts, their preparation methods and pharmaceutical compositions containing the same: This invention relates to a kind of Erianin salt and the preparing process thereof. The said Erianin salt is a compound with the following general formula (I), wherein R is the salt formed by monobasic acid radical of inorganic oxacid combining with metals, ammonium salts, organic amine. This invention also... Agent: Occhiuti Rohlicek & Tsao, LLP

20080306031 - Methods of inhibiting poxvirus growth: This disclosure ascribes new functions to derivatives of tetralin, anthraquinone, naphthylamine, tri-amino-pyrimidine, xanthen-3-one, and/or cinnamic acid (including, for example, NSC270718R, NSC117285R, NSC170008Y, NSC306711P, NSC119913X, NSC119915Z, NSC119911V, NSC119910U, NSC128437O, NSC125908P, NSC9600Q, or NSC13778J, each obtained from the Structure Diversity Set, National Institutes of Health, National Cancer Institute, Developmental Therapeutics Program). These... Agent: Klarquist Sparkman, LLP

20080306029 - Prevention, treatment, and amelioration of radiation induced enteritis: The present invention provides a new method of ameliorating and/or treating enteritis induced by radiation therapy, alone or in combination with other therapies, for the treatment of, for example, gastrointestinal malignancies, including colorectal, appendiceal, anal, or small bowel cancers; urogenital malignancies, including prostate, ladder, testicular, or penile cancers; gynecologic malignancies,... Agent: Edwards Angell Palmer & Dodge LLP

20080306030 - Use of a trpm5 inhibitor to regulate insulin and glp-1 release: The present invention is directed to methods of enhancing insulin release, GLP-1 release, and insulin sensitivity, methods of increasing insulin gene expression, methods of decreasing gastric secretion and emptying and glucagons secretion, and methods of inhibiting food intake, and methods of treating diabetes mellitus, insulin resistance syndrome, hyperglycemia, and obesity... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080306032 - 7-phenyl-substituted tetracycline compounds: 7-phenyl-substituted tetracycline compounds which are substantially free of positional isomers, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-phenyl-substituted tetracycline compounds are described. 7-substituted tetracycline compounds which are substantially free of positional isomers, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted tetracycline compounds... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080306033 - Use of non-steroidal anti-inflammatory drugs by inhalation in the treatment of acute and chronic bronchitis: This invention claims the use of non-steroidal anti-inflammatory drugs, and in particular lysine acetylsalicylate, delivered by nebuliser, to treat non-asthmatic bronchitis, namely acute bronchitis, chronic bronchitis, emphysema and chronic obstructive pulmonary disease.... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20080306034 - Method of administering a therapeutic: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a hormonal treatment such as... Agent: Michael R. Schramm Juneau Biosciences, LLC

20080306035 - Methods and compositions for treating female infertility using clomiphene: The present invention relates to the use of compositions comprising clomiphene for treating female infertility. The invention is also directed to a regimen of treatment for female infertility using trans-clomiphene, a mixture of cis- and trans-clomiphene, and cis-clomiphene.... Agent: Howrey LLP - Dc

20080306037 - Product for use in the prevention and treatment of cardiovascular diseases, cancer and chronic inflammatory diseases: The invention relates to a product that contains at least lycopene and oleic acid together with antioxidants of natural origin, such as β-carotenes, retinol, phytosterols, tyrosol and fatty acids, which is administered orally and which is specially indicated in the prevention of cardiovascular disease and in pathologies mediated by an... Agent: Sturm & Fix LLP

20080306036 - Triphenylethylene compounds useful as selective estrogen modulators: Triphenylethylene compounds of formula (I) are provided. The compounds are particularly useful for selective estrogen receptor modulation.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080306038 - Compositions and methods for modulating inflammation using fluoroquinolones: Compositions for modulating an inflammation comprise a fluoroquinolone having one of Formulae I-VIII. Methods for modulating an inflammation comprise administering such compositions to a subject in need thereof. The compositions and methods are suitable for modulating an ocular or ophthalmic inflammation, including uveitis, vernal keratoconjunctivitis, or inflammation associated with contact... Agent: Bausch & Lomb Incorporated

20080306039 - Loteprednol etabonate aqueous suspension: m

20080306040 - Antibacterial amide macrocycles vii: The invention relates to antibacterial amide macrocycles and methods for their preparation, their use for the treatment and/or prophylaxis of diseases as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially bacterial infections.... Agent: Morrison & Foerster LLP

20080306041 - Cardiovascular compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use: The invention describes compositions and kits comprising at least one cardiovascular compound comprising at least one heterocyclic nitric oxide donor group, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases;... Agent: Wilmerhale/nitromed

20080306042 - Triazole derivatives: Novel triazole derivatives are inhibitors of TGF-beta receptor I kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20080306043 - Sabcomeline alone or combined with a mood stabilising or antimanic agent to treat bipolar disorders: The invention relates to the use of sabcomeline or a pharmaceutically acceptable salt thereof in monotherapy for the treatment of bipolar disorder or mania or and to adjunctive and simultaneous combination therapies for the treatment of bipolar disorder or mania in which sabcomeline or a pharmaceutically acceptable salt thereof and... Agent: Nixon & Vanderhye, PC

20080306044 - Spirobenzoazepanes as vasopressin antagonists: e

20080306045 - 1-benzazepine-3-sulfonylamino-2-pyrroridones as factor xa inhibitors: and/or pharmaceutically acceptable derivative(s) thereof. The invention also relates to processes for the preparation of compounds of formula (I), pharmaceutical compositions containing compounds of formula (I) and to the use of compounds of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080306046 - Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative: [Means for Solution] We have found that a novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative and its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative of the present invention has an excellent effect for increasing an effective bladder capacity, an excellent effect for relieving... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080306047 - Use of aza-phenylalanine compounds for treating cardiac arrhythmia: The present invention relates to the use of certain aza-phenylalanine compounds of formula (I) wherein R1 denotes amino, alkylamino, dialkylamino, amidino, alkylamidino, N-hydroxyamidino, or N-alkoxyamidino, Y denotes sulfonyl or carbonyl and R2 and R4 independently represent various organic residues, in the treatment or prevention of cardiac arrhythmia and/or in treatment... Agent: Manelli Denison & Selter

20080306049 - Therapeutic pyrazoloquinoline derivatives: e

20080306048 - Therapeutic pyrazoloquinoline urea derivatives:

20080306050 - Aminodiazepines as toll-like receptor modulators: Provided are compositions and methods useful for modulation signaling through the Toll-like receptor TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.... Agent: Viksnins Harris & Padys Pllp

20080306051 - Hiv integrase inhibitors: The invention encompasses a series pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080306052 - 3, 6-dihydro-2-oxo-6h-1,3,4,-thiadiazine derivatives: Compounds of the formula I, in which R1, R2, Q and B have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20080306053 - Modulation of chemosensory receptors and ligands associated therewith: The present invention provides screening methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors as well as modifiers capable of modulating chemosensory receptors... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080306054 - Pharmaceutical compounds: or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; C1-5 hydrocarbyl and C1-5 hydrocarbyloxy; wherein the C1-5 hydrocarbyl and C1-5 hydrocarbyloxy moieties... Agent: Frommer Lawrence & Haug

20080306055 - Heterocyclic mchr1 antagonists and their use in therapy: Compounds of formula I depicted below, pharmaceutical compositions containing them, processes for preparing the compounds, and their use in the treatment of obesity, type II diabetes, metabolic syndrome, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy and related conditions, neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea... Agent: Pepper Hamilton LLP

20080306056 - Pyrazole-derivatives as factor xa inhibitors: in which R0; R1; R2; R3; R4; Q; V, G and M have the meanings indicated in the claims. the compound of formula I is valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic... Agent: Ronald G. Ort. Aventis Pharmaceuticals Inc.

20080306058 - Combinations comprising a vegf receptor inhibitor: A composition comprising a VEGF receptor inhibitor and a penetration enhancer and uses thereof.... Agent: Novartis Institutes For Biomedical Research, Inc.

20080306057 - P13k inhibitors for the treatment of endometriosis: This invention relates to a method of treating and/or preventing endometriosis comprising administering a PI3K inhibitor. The PI3K inhibitor can also be administered combined with a hormonal suppressor. The invention further relates to the treatment of endometriosis-related infertility.... Agent: Baker & Daniels LLP

20080306059 - Pyrimido [4,5-b] -oxazines for use as dgat inhibitors: Compounds of formula (I) or salts thereof, wherein A, and R1 to R5 are as defined in the specification, are DGAT-1 inhibitors and are thereby useful in the treatment of, for example, obesity. Processes to make compounds of formula (I) are also described.... Agent: Morgan Lewis & Bockius LLP

20080306061 - Aminophenylsulfonamide derivatives as hiv protease inhibitor: The present invention concerns substituted aminophenylsulfonamide compounds and derivatives, their use as protease inhibitors, in particular as broadspectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. The present invention also concerns combinations of the present substituted aminophenylsulfonamide compounds and derivatives with... Agent: Philip S. Johnson Johnson & Johnson

20080306060 - Fused thiazole derivatives as kinase inhibitors: A series of 5,6-dihydro-1,3-benzothiazol-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PD kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080306062 - Modulators of atp-binding cassette transporters: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Vertex Pharmaceuticals Inc.

20080306063 - Phenylamino isothiazole carboxamidines as mek inhibitors: The invention concerns compounds which inhibit MEK and which have activity as anti-neoplastic agents. These compounds include N-substituted-3-hydroxy-5-arylamino-isothiazole-4-carboxamidines. Also included are the tautomeric isothiazol-3(2H)-ones.... Agent: Wilson Sonsini Goodrich & Rosati

20080306064 - Benzimidazole derivatives: Benzimidazole derivatives, methods of preparing the same and their pharmaceutical uses for the treatment of inflammatory diseases including COPD.... Agent: Novartis Corporate Intellectual Property

20080306065 - Metalloproteinase inhibitors: Compounds of the formula (I) wherein z is SO2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.... Agent: Fish & Richardson P.C.

20080306066 - Non-imidazole heterocyclic compounds: Certain non-imidazole heterocyclic compounds are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20080306067 - Modulators of chemokine receptor activity: A compound of formula (I), wherein substituents are as given above, useful in the treatment of a disease mediated by the action of CCR3, in particular inflammatory or obstructive airway diseases.... Agent: Novartis Institutes For Biomedical Research, Inc.

20080306068 - Kinase inhibitors: The present invention provides kinase inhibitors of Formula I:... Agent: Eli Lilly & Company

20080306069 - Pyrazole derivatives for the inhibition of cdk's and gsk's: The invention provides compounds of the formula (I), or salts, tautomers, N-oxides or solvates thereof wherein: R1 is selected from: (a) 2,6-dichlorophenyl; (b) 2,6-difluorophenyl; (c) a 2,3,6-trisubstituted phenyl group wherein the substituents for the phenyl group are selected from fluorine, chlorine, methyl and methoxy; (d) a group RO; (e) a... Agent: Heslin Rothenberg Farley & Mesiti PC

20080306070 - Combination therapy comprising substituted oxazolidinones for the prevention and treatment of cerebral circulatory disorders: e

20080306071 - Substituted piperidine compounds and methods of their use: Novel 3,4-disubstituted-4-aryl-piperidine compounds are disclosed. Pharmaceutical compositions containing the 3,4-disubstituted-4-aryl-piperidine compounds and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as antagonists of opioid receptors.... Agent: Feldmangale, P.A.

20080306072 - Organic compounds: The present invention relates to compounds selected from the group consisting of 14-0-[((Mono- or dialkylamino)-cycloalkylsulfanyl- or -cycloalkyl-oxy)-acetyl, -thioacetyl or -imino-oxy]-mutilins, 14-O-[((Cycloalkyl- or heterocyclylamino)-cy-cloalkylsulfanyl- or -cycloalkyl-oxy)-acetyl, -thioaceyl or -imino-oxy]-mutilins, 14-O-[((Heterocyc-N-yl-cycloalkyl)-sulfanyl- or -oxy)-acetyl, -thioacetyl or -imino-oxy]-mutilins, 14-O-[(((Mono- or dialkylamino)-cycloalkyl)-alkylsulfanyl- or -alkyl-oxy)-acetyl, -thioacetyl or -imino-oxy]-mutilins, 14-O-[(((Cycloalkyl- or heterocyclylamino)-cycloalkyl)-alkylsulfanyl- or -alkyl-oxy)-acetyl, -thioacetyl or -imino-oxy]-mutilins,... Agent: Workman Nydegger

20080306073 - Antitumor effect potentiator, antitumor preparation, and method for treating cancer: An antitumor effect fortifier comprising as an active ingredient an effective amount of platinum (II) cis-oxalato(1R,2R-diaminocyclohexane) so as to enhance the antitumor activity of antitumor agent containing a therapeutically effective amount of tegafur, an amount, effective for the enhancement of antitumor effect, of gimeracil and an amount, effective for the... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080306078 - 3,9-diazabicyclo [3.3.1] nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors:

20080306074 - Compositions comprising addl receptors, related compositions, and related methods: Disclosed and claimed herein are compositions comprising ADDL receptors, related compositions, and related methods. ADDL receptors are typically, but perhaps not exclusively, localized at the post-synaptic density (PSD) of neuronal cells. Related compositions include, but are not limited to, compounds that affect, positively or negatively, ADDL binding to neuronal cells,... Agent: Licata & Tyrrell P.C.

20080306079 - External preparation for allergic diseases: The invention presents an external preparation for allergic diseases containing 3′-hydroxymethyl-4-hydroxypyrrolido [1,2-f]2′,5′-pipera-zinedione as an active ingredient. This compound has a prophylactic and therapeutic effect of allergic diseases, and the external preparation of the invention can be used in prophylaxis and treatment of various allergic diseases (for example, atopic dermatitis, urticaria,... Agent: Birch Stewart Kolasch & Birch

20080306076 - Modulation of chemosensory receptors and ligands associated therewith: The present invention provides screening methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors as well as modifiers capable of modulating chemosensory receptors... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080306077 - Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators 842: e

20080306075 - Pharmaceutical compositions for transdermal delivery: The present invention relates to a pharmaceutical composition for transdermal administration comprising a conjugate of methotrexate and PTD (protein transduction domain). In accordance with the present invention, the methotrexate, which is widely used for the treatment of psoriasis, rheumatoid and inflammation, etc., can be delivered transdermally to a local part... Agent: Edwards Angell Palmer & Dodge LLP

20080306080 - Neutrophilia inhibitor: An antineutrophilia agent containing a 3(2H)-pyridazinone compound represented by the formula (I) or a pharmaceutically acceptable salt thereof [wherein each of R1, R2 and R3 is independently a hydrogen atom or a C1-6 is alkyl group, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080306081 - Combinations of nicotinic acetylcholine alpha 7 receptor antagonists: Combinations which comprise at least one nicotinic acetylcholine alpha 7 receptor agonist and at least one compound selected from the group consisting of (a) conventional antipsychotics (b) atypical antipsychotics (c) cognition, attention and/or memory enhancers (d) and to use of these combinations in the treatment of psychiatric disorders.... Agent: Novartis Corporate Intellectual Property

20080306082 - [4-(benzo[b]thiophen-2-yl) pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases: The present invention provides compounds of Formula I: useful in the treatment of cancer and inflammatory diseases.... Agent: Eli Lilly & Company

20080306085 - Non-imidazole aryloxyalkylamines: Substituted aryloxyalkylamines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.... Agent: Philip S. Johnson Johnson & Johnson

20080306084 - Substituted amide compounds: b

20080306086 - Prolinamide derivatives as nk3 antagonists:

20080306083 - Biaryl compounds useful as agonists of the gpr38 receptor: The present invention relates to novel biaryl derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of gastrointestinal disorders.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080306087 - Therapeutic agents: The present invention relates to compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080306088 - Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841: e

20080306089 - Prolinamide-tetrazole derivatives as nk3 receptor antagonists:

20080306090 - Thiourea derivatives:

20080306091 - Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation:

20080306092 - Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (crf) receptor antagonists: The present invention generally relates to the polymorph Form 2 of [3-(4-methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-[(S)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-propyl]-amine. The present invention also relates to pharmaceutical compositions comprising the same and methods of using the same.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080306093 - Modulation of chemosensory receptors and ligands associated therewith: The present invention provides screening methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors as well as modifiers capable of modulating chemosensory receptors... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080306094 - Combination of azd2171 and pemetrexed: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,... Agent: Morgan Lewis & Bockius LLP

20080306096 - Quinazoline derivatives, process for their preparation and their use as anti-cancer agents: The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the... Agent: Astrazeneca R&d Boston

20080306097 - Cancer treatment method: Disclosed herein is a method of treating breast cancer that has metastasized to the brain in a mammal by administration of 4-quinazolinamines and pharmaceutical compositions containing the same. In particular, the method relates to methods of treating breast cancer brain metastases which overexpress erbB2 by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080306095 - Control of ectoparasites: Disclosed is a method of controlling ectoparasites that infest companion and livestock animals by applying to the animal an effective amount of 4-tert-butylphenethyl quinazolin-4-yl ether or 4-chloro-5-ethyl-2-methyl-N-[(4-tert-butylphenyl)methyl]pyrazole-3-carboxamide or 5-chloro-N-[2-[4-(2-ethoxyethyl)-2,3-dimethylphenoxy]ethyl]-6-ethyl-4-pyrimidinamine or 4-chloro-3-ethyl-1-methyl-N-[4-(p-tolyloxy)benzyl]pyrazole-5-carboxamide.... Agent: Fish & Richardson PC

20080306098 - Pharmacokinetics of protease inhibitors and other drugs: A method for modulating at least one pharmacokinetic property of a protease inhibitor upon administration to a host is provided. One administers to the host an effective amount of a bifunctional compound of less than about 5000 daltons comprising the protease inhibitor or an active derivative thereof and a pharmacokinetic... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20080306099 - Compositions and methods for inhibition of the jak pathway: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.... Agent: Rigel Pharmaceuticals Inc.

20080306100 - Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase: This invention relates to a process for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (formula (I)) starting from 4-methyl-2-nitro-aniline (formula (II)) through intermediates (3-trifluoromethylsulfonyl)-N-[4-methyl-3-nitrophenyl]-benzamide (formula (III)), (3-trifluoromethylsulfonyl)-N-[3-amino-4-methylphenyl]-benzamide (formula (IV)) and (3-trifluoromethylsulfonyl)-N-[3-guanidino-4-methylphenyl]-benzamide (formula (V)). This invention also relates to processes for the preparation of these intermediates. The compound of formula (I), also known as... Agent: Merchant & Gould PC

20080306101 - Insecticidal spironindane derivatives: An insecticidal compound of formula I wherein X is O or NR11 where R11 is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; Y is a single bond, C═O, C═S or S(O)m where m is 0, 1 or 2; R1, R2, R3, R4, R8 and Ra are... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080306103 - Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor: There are provided methods for the treatment of diseases involving dysfunction of the peripheral and central nervous system comprising administering one or more spiro compounds. Also provided are pharmaceutical compositions useful in such methods, compounds for use in the preparation of such pharmaceutical compositions, processes for preparing compounds useful in... Agent: Foley & Lardner LLP

20080306102 - Novel spirooxyindole compounds and drugs containing same: A Spiro oxindole compound represented by formula (1) of the present invention or salt thereof, or their solvate shows a superior inhibitory effect of 11β-hydroxysteroid dehydrogenasel, and is useful as an agent for preventing or treating a disease that involves 11β-hydroxysteroid dehydrogenasel (in particular, diabetes, insulin resistance, diabetes complication, obesity,... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20080306104 - Tamper-resistant oral opioid agonist formulations: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the... Agent: Davidson, Davidson & Kappel, LLC

20080306106 - 1-heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20080306105 - Deuterium-enriched moxifloxacin: The present application describes deuterium-enriched moxifloxacin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080306107 - Compounds: The present invention relates to new compounds of formula (I) wherein R1 to R9, X, p and n are defined as in claim 1, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080306108 - Substituted pyridoxines as anti-platelet agents: Compounds with antiplatelet aggregation characteristics for the treatment of cardiovascular and cardiovascular related disease, are described. The methods are directed to administering pharmaceutical compositions comprising a pyridoxine analogue.... Agent: Merchant & Gould PC

20080306109 - Indolizine derivatives as ligands of the crth2 receptor: Compounds of formula (I) are CRTH2 antagonists, useful in the treatment of, for example, asthma, chronic obstructive pulmonary disease, rhinitis, allergic airway syndrome, and allergic rhinobronchitis. Formula (I) wherein R1, R2. R3 and R4 each independently are hydrogen, C1-C6alkyl, fully or partially fluorinated C1-C6alkyl, halo, —S(O)nR10, —SO2N(R10)2, —N(R10)2, —C(O)N(R10)2, —NR10C(O)R9,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080306110 - Alkylnitrile quinolines as nk-3 receptor ligands: m

20080306111 - Tricyclic delta- opioid modulators: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.... Agent: Philip S. Johnson Johnson & Johnson

20080306112 - Benzimidazolones which have activity at m1 receptor: wherein R6 is selected from hydrogen, halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano, and Q is hydrogen or C1-6alkyl. The compounds are M1 agonists and... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080306113 - Methods for treating macular degeneration using 4-(amino)-2-(2,6-dioxo(3-piperidyle))-isoindoline-1,3-dione: Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, alone or in combination with a second active agent and/or surgery.... Agent: Jones Day

20080306116 - Aryloxazole, aryloxadiazole and benzimidazole derivatives: wherein X is O or NR8, Y is CR7 or N, and R1 to R8 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080306114 - Human g protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders: The present invention relates to methods of identifying whether one or more candidate compounds is a modulator of a G protein-coupled receptor (GPCR) or a modulator of blood glucose concentration. In certain embodiments, the GPCR is human. The present invention also relates to methods of using a modulator of the... Agent: Bozicevic, Field & Francis LLP (arena Pharmaceuticals, Inc.)

20080306115 - Midazole-4-carboxamide derivatives for use as cb1 modulators: e

20080306117 - Ep4 receptor antagonists:

20080306118 - Process for the crystallization of (r) - or (s) - lansoprazole: The present invention relates to a production method of a crystal of (R)-lansoprazole or (S)-lansoprazole, which includes crystallization at a temperature of about 0° C. to about 35° C. from a C1-4 alkyl acetate solution containing (R)-lansoprazole or (S)-lansoprazole at a concentration of about 0.1 g/mL to about 0.5 g/mL... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080306120 - Azaindole inhibitors of aurora kinases: e

20080306119 - Method for the protection of materials: The present invention relates to the use of the compound A) 4-(2,2-difluoro-1,3-benzodioxol-4-yl)pyrrole-3-carbonitrile(fludioxonil) as a microbicide for the protection of engineering or industrial materials, to mixtures containing such compound, and to the use of such mixtures for the protection of engineering or industrial materials.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080306121 - Bisheterocycle tandem compounds useful as antiviral agents, the uses thereof and the compositions comprising such compounds: The present invention provides small molecule compounds of bisheterocycle in tandem having the structural formula of P1-P2, and the use thereof as well as a composition containing the compounds, each of P1 and P2 is an unsaturated 5-member heterocyclic ring having one or two heteroatoms. This compound may effectively inhibit... Agent: Nixon & Vanderhye, PC

20080306122 - Novel compounds: Compounds of formula (I) wherein the variables are defined herein, pharmaceutical compositions thereof and methods for treatment using the same.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080306123 - Novel compounds: and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein R1 is H, C1-6alkyl, —C(X)Y, C3-8cycloalkyl, aryl, het, aryl-C1-4alkyl or het-C1-4alkyl, wherein the cycloalkyl, aryl or het groups are optionally substituted by at least one substituent independently selected from C1-8alkyl, C1-8alkoxy, OH, halo, CF3, OCF3, SCF3, hydroxy-C1-6alkyl, C1-4alkoxy-C1-6alkyl and C1-4alkyl-S—C1-4alkyl; R2 is... Agent: Pharmacia & Upjohn

20080306125 - Compounds and methods for modulating fx-receptors: Compounds of formula. wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.... Agent: Eli Lilly & Company

20080306124 - Polycyclic oxadiazoles or i soxazoles and their use as sip receptor ligands: m

20080306126 - Peroxisome proliferator activated receptor treatment of hyperhomocysteinemia and its complications: A method of lowering homocysteine level of an individual and of reducing the vascular pathology associated therewith, by administering a ligand of the peroxisome proliferator activate receptor gamma. The peroxisome proliferator activated receptor preferably may be rosiglitazone.... Agent: Vivian A. Fonseca

20080306127 - Compounds and methods for inhibiting the interaction of bcl proteins with binding partners: One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080306128 - Preparation of hydrochloride salts of tetrazole derivative: The present invention relates to sesquihydrate hydrochloride salt of irbesartan and anhydrous hydrochloride salts of irbesartan. Irbesartan used as the starting material for the preparation of the described hydrochlorides of irbesartan can be in any form, e.g. it can be used when contained in a reaction solution, in crude form,... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20080306129 - Benzimidazoles useful as modulators of ion channels: e

20080306130 - Inhibitors of ubiquitin e1: The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention.... Agent: Edwards Angell Palmer & Dodge LLP

20080306131 - Progesterone receptor modulator and uses thereof: e

20080306132 - Novel oral compositions of carporen: An improved semisolid composition for an oral veterinary application and a method of making it. A carprofen paste composition is made for orally administering to animals using calibrated syringe dispensers for exact dosages.... Agent: Jay R Akhave

20080306133 - Intranasal administration of asenapine and pharmaceutical compositions therefor: Asenapine or a pharmaceutically acceptable salt thereof can be administered intranasally, typically via an intranasal dosage formulation having a water-containing liquid carrier.... Agent: SynthonIPInc

20080306134 - Thalidomide analogs for treating vascular abnormalities: are described. R1 is selected from a group comprising of hydroxy, hydrogen, and amino. Also described is a method for treating vascular abnormalities, such as neovascularization and vascular leakage. A therapeutically effective amount of a composition containing the thalidomide analog compound is administered to a patient. The composition may further... Agent: Greenberg Traurig LLP (la)

20080306135 - Process for the preparation of crystalline perindopril: The present invention relates to a new process for the preparation of crystalline perindopril. The present invention also relates to new alkyl ammonium salts of perindopril and the processes for the preparation thereof.... Agent: Sandoz Inc

20080306136 - Substituted ureas and carbamates: useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080306137 - Pharmaceutical compositions comprising docetaxel and methods for preparation thereof: A pharmaceutical composition of docetaxel comprising an effective amount of docetaxel, a polysorbate (TWEEN® compound) and a co-solvent, wherein the co-solvent is at least one member selected from the group consisting of glycerol and polyethylene glycol. The composition is an injectable solution or a freeze-dried powder for injection. The solubility... Agent: Matthias Scholl

20080306138 - Stable non-aqueous pour-on compositions: The present invention relates to a stable, antiparasitic, non-aqueous pour-on parasiticidal composition which comprises an effective amount of amitraz, optionally a macrocyclic lactone, a stabilizer and a carrier system having no active hydroxyl group.... Agent: Wyeth Patent Law Group

20080306139 - Antibiotic compounds: Fermentation of a nutrient medium with a eubacterium Streptomyces sp. yields a novel antibacterial compound of structure (I).... Agent: Merck And Co., Inc

20080306140 - Isoflavonoid dimers: Novel compounds based on phenyl-substituted naphtho[1,2-g]chrysene compounds (A) are described. The compounds are obtainable by dimerisation of 3-phenylchroman (isoflavonoid) ring systems (B). Methods of synthesis of the novel dimeric compounds, compositions containing same and use of the dimers as therapeutic agents are also described.... Agent: Sughrue Mion, PLLC

20080306143 - Cathechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders: A method of treating an amyloid disease, or a disease characterized by alpha-synuclein or NAC fibrillogenesis, in a mammalian subject. The method includes administering to the mammal a therapeutically effective amount of a various disclosed catechins or green tea extract. A pharmaceutical composition comprising a therapeutically effective amount of a... Agent: Proteotech, Inc.

20080306142 - Isolation, purification and synthesis of procyanidin b2 and uses thereof: Methods for the synthesis, isolation, and purification of procyanidin B2 are disclosed. The synthetic methods utilize epicatechin as a starting material and produce procyanidin B2 in high yields. The isolation methods extract procyanidin B2 from a sample of bark powder from plant matter of the genus Uncaria. The isolated and/or... Agent: Proteotech, Inc.

20080306141 - Method of extraction of catechin type-a proanthocyanidins: Catechin type-A proanthocyanidins are recovered from cinnamon bark or other sources rich in catechin type-A proanthocyanidins by extraction with a first organic solvent to provide an extract rich in catechin type-A proanthocyanidins. This extract is combined with water and the organic solvent is removed by distillation so that proanthocyanidins are... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20080306144 - Hydroxybenzyl or hydroxypyranonemethyl esters as tyrosinase inhibitors: Method for the preparation of ester compounds for use as skin brightening agents and compositions for brightening skin containing the ester compounds.... Agent: Eastman Chemical Company

20080306145 - Preparation of ginkgolide and f-seco-ginkgolide lactols: The present invention relates to synthesis of C11 natural ginkgolide derivatives and C11 f-seco-gingkolide derivatives from the corresponding lactols which are selectively obtained using NaBH4.... Agent: Cooper & Dunham, LLP

20080306146 - Dosing regimens for cox-2 inhibitor: The present invention relates to a potent cyclooxygenase-2 inhibitor and dosing regimens thereof to safely treat cyclooxygenase-2 mediated disorders.... Agent: Baker & Hostetler LLP Attn: Jim Coffman

20080306147 - Illudin analogs useful as anticancer agents: Acylfulvene analogs, which inhibit tumor growth, especially solid tumor growth, and which have an adequate therapeutic index to be effective for in vivo treatment are provided herein. The compounds described herein are useful as anti-neoplastic agents, i.e., to inhibit tumor cell growth in vitro or in vivo, in mammalian hosts,... Agent: Schwegman, Lundberg & Woessner, P.A.

20080306148 - Anti-cancer compositions and methods: Anti-cancer compositions and methods are described including one or more isothiocyanates and/or isoselenocyanates. Methods of treating a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a composition including an isothiocyanate and/or isoselenocyanate to a subject having a condition characterized by... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080306149 - Use for a composition comprising chloroprocaine hcl, a new composition comprising chloroprocaine hcl and a method for its manufacture: The present invention concerns a new use for a composition comprising chloroprocaine HCl, and in particular its use for the manufacture of a drug for intrathecal narcosis. The present invention also concerns a new composition comprising chloroprocaine HCl, being particularly suited to this new use, as well as a new... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20080306150 - Compounds for the treatment of metabolic disorders: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I), wherein n is 1 or 2; m is 0, 1, 2, 3, or 4; q is 0 or 1;... Agent: Wellstat Management Company. LLC

20080306151 - Deuterium-enriched fenofibrate: The present application describes deuterium-enriched fenofibrate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080306152 - Compositions containing prodrugs of florfenicol and methods of use: The present invention provides compositions and methods for administering florfenicol to mammals. The compositions contain a prodrug of florfenicol in a pharmaceutically acceptable carrier. In one embodiment the prodrug is an esterized form of florfenicol. Examples of suitable prodrugs include one or a combination of one or a combination of... Agent: Townsend And Townsend And Crew, LLP

20080306153 - Lipids and lipid assemblies comprising transfection enhancer elements: e

20080306155 - Method for treating renal disease: A method preserving renal medullary blood flow in a renal disorder in a human or non-human animal is disclosed. The method involves administering 20-HETE or a 20-HETE analog to the human or non-human animal in an amount sufficient to attenuate a fall in renal medullary blood flow following a renal... Agent: Quarles & Brady LLP

20080306156 - Method of using catalpic acid to treat and prevent type 2 diabetes and associated disorders: A method of treating and preventing type 2 diabetes and obesity an animal, including mammals and humans, in which a therapeutically effective amount of catalpic acid to the animal is administered orally or parentally.... Agent: Intellectual Property Dept. Dewitt Ross & Stevens Sc

20080306157 - Therapeutic intervention to mimic the effect of caloric restriction: Methods are provided for promoting longevity and decreasing the incidence of aging associated pathologies (e.g., cancer) by the administration of one or more of the following LFFA: linoleic, oleic and palmitic acid. Secondary LFFA derived from this set, as well as their CoA derivatives and synthetic analogs, are effective also... Agent: Hunton & Williams LLP Intellectual Property Department

20080306154 - Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering omega-3 fatty acids: Omega-3 fatty acid compositions comprising eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are provided, where the compositions are useful for treating, reducing the occurrence of, or preventing major adverse cardiovascular events or major coronary events in patients who have established cardiovascular disease without prior myocardial infarction, preventing their further progression,... Agent: Arent Fox LLP

20080306158 - Methods to prevent cytotoxicity using n-acetyl-cysteine: Compositions and methods to inhibit adverse physiological effects caused by resin-based and resin-containing materials are disclosed. More specifically, the use of N-acetyl-cysteine (NAC) to inhibit hydroxyethyl methacrylate (HEMA)-mediated cell death and cytotoxicity.... Agent: K&l Gates LLP

20080306159 - Enteric coated, soluble creatine and polyethylene glycol composition for enhanced skeletal uptake of oral creatine: An oral creatine formulation includes soluble creatine and polyethylene glycol, coated with an enteric coating. The most preferred soluble creatine is creatine HCl. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight... Agent: Hogan & Hartson LLP

20080306160 - Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid: The present invention provides pharmaceuticals for the prevention or treatment of diseases associated with decrease in tear. That is, the present invention provides pharmaceuticals for the prevention or treatment of diseases associated with decrease in tear such as dry eye, dry disorders of cornea and conjunctiva, disorders of the keratoconjunctival... Agent: Stuart D. Frenkel Frenkel & Associates, P.C.

20080306161 - Use of axomadol for treatment of arthrosis pain: The use of axomadol for the treatment of pain in arthrosis.... Agent: Crowell & Moring LLP Intellectual Property Group

20080306162 - Treatment of inflammatory disorders and pain: A compound that is useful for the treatment or prevention of a condition such as pain, that is associated with T-cell proliferation or that is mediated by pro- and/or anti-inflammatory cytokines, is of formula (I) wherein R1 is aryl or heteroaryl optionally substituted with R5; R2 is H, alkyl or... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080306163 - Agent for treatment of allergic eye disease: wherein R1 is an unsubstituted or substituted C1 to C8 alkyl group provided that an unsubstituted methyl group is excluded, a C3 to C7 cycloalkyl group, a C6 to C10 bicycloalkyl group or an indanyl group, etc., R2 is a C1 to C4 alkyl group, R3 is a hydrogen atom,... Agent: Christie, Parker & Hale, LLP

20080306164 - New 2-substituted d-homo-estra-1,3,5(10)-trienes as inhibitors of 17beta-hydroxy steroid dehydrogenase type 1: e

20080306165 - Compounds for the treatment of metabolic disorders: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, poly-cystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. wherein n is 1 or 2; m is 0, 1, 2, 3, or 4; q is 0 or 1; t is... Agent: Wellstat Management Company. LLC

20080306166 - Compositions and methods for treatment of disorders of protein aggregation: The invention provides compositions, methods and uses comprising a scyllo-inositol compound that provide beneficial effects in the treatment of a disorder and/or disease including a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080306167 - Metal pigment composition: e

20080306168 - Dental compositions with a water scavenger: The present invention relates to polymerizable dental compositions that contain a water scavenger, such as a molecular sieve, to increase the shelf life of the composition.... Agent: 3m Innovative Properties Company

20080306169 - Method for preparing a living polymer comprising methacrylic and/or methacrylate units: The invention relates to a method for preparing a living polymer comprising methacrylic and/or methacrylate units using a monofunctional or polyfunctional alkoxyamine consisting in polymerising one or several types of methacrylic an/or methacrylate units.... Agent: Arkema Inc. Patent Department - 26th Floor

20080306170 - Organic compounds: The use of 2-phenyl-2-alkene nitriles as fragrance ingredients and fragrance applications comprising them. These fragrance applications can be e.g. perfumes, household products, laundry products, body care products and cosmetics.... Agent: Norris, Mclaughlin & Marcus

20080300164 - Calixarene-based peptide conformation mimetics, methods of use, and methods of making: A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity, antiangiogenic activity, and/or antitumor activity. Methods of use and methods of designing calixarene-based peptide mimetics are described.... Agent: Mueting, Raasch & Gebhardt, P.A.

20080300169 - Development of novel antibiotic alternatives: The present invention relates to two recombinant colicin expression systems, one utilizing a yeast expression system that produces a protein that is inexpensive to purify, and the other utilizing a plasmid expression system to be used as a probiotic culture. The recombinant colicins provide effective alternatives to conventional antibiotics and... Agent: Mckee, Voorhees & Sease, P.L.C

20080300168 - Inhibition of migration and induction of cell death by the type ii collagen amino propeptides: The present invention provides combinations and methods for inducing cell death, inhibiting angiogenesis, and inhibiting cell migration. In particular, the present invention provides methods for inducing cell death in a cell expressing an αvβ3 and/or an αvβ5 integrin.... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20080300163 - Modified human four helical bundle polypeptides and their uses: Modified human four helical bundle (4HB) polypeptides and uses thereof are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20080300167 - Patched genes and uses related thereto: Methods for isolating patched genes, including the mouse and human patched genes, as well as invertebrate patched genes and sequences, are provided. Decreased expression of patched is associated with the occurrence of human cancers, particularly basal cell carcinomas of the skin. The patched and hedgehog genes are useful in creating... Agent: Ropes & Gray LLP

20080300165 - Purposeful movement of human migratory cells away from an agent source: This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response.... Agent: Ewards Angell Palmer & Dodge LLP

20080300166 - Treatment of melanoma with alpha thymosin peptides: A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080300170 - Compositions and methods for diagnosis and treatment for type 2 diabetes: The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo Attn: Patent Intake Customer No. 35437

20080300172 - Method and compositions for the treatment of diabetes and related complications: The present invention relates to administration of relaxin and related polypeptides to treat a variety of conditions, including diabetes, diabetes-related conditions, Alzheimer's disease, and menopause and related conditions.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080300171 - Use of dpp-iv inhibitor to reduce hypoglycemic events: The invention relates to a method to reduce the hypoglycemic events, especially sever hypoglycemic events resulting from insulin treatment, wherein the patient is treated with a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof.... Agent: Novartis Corporate Intellectual Property

20080300173 - Branched peg remodeling and glycosylation of glucagon-like peptides-1 [glp-1]: The present invention provides polypeptides that include an O-linked glycoconjugate in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. The polypeptides of the invention include wild-type peptides and mutant peptides that include... Agent: Morgan, Lewis & Bockius LLP (sf)

20080300174 - Compositions and methods for enhancing factor viii heavy chain secretion: FVIII heavy chain mutants are provided which exhibit enhanced secretion from transfected cells and robust anti-coagulation activity.... Agent: Dann, Dorfman, Herrell & Skillman

20080300175 - Glycopegylated erythropoietin: The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified... Agent: Morgan, Lewis & Bockius LLP (sf)

20080300176 - Methods of treating neurodegenerative diseases: The invention relates to the discovery that in an animal model of Parkinson's disease (PD), administration of granulocyte colony-stimulating factor (G-CSF) to rodents having 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD restored the function of dopamine neurons. In these animals, G-CSF treatment increased the number of dopamine neurons in the substantia nigra (SN), G-CSF... Agent: Akerman Senterfitt

20080300177 - Cyclic peptide cxcr4 antagonists: Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.... Agent: Eli Lilly & Company

20080300178 - Method for treating huntington's disease by inhibiting dephosphorylation of huntingtin at s421: The present invention relates to a method for treating patients having Huntington's disease by a drug increasing the phosphorylation of huntingtin at position S421, thereby decreasing the polyQ-huntingtin-induced toxicity.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080300179 - Bowman-birk inhibitor compositions for treatment of muscular atrophy and degenerative muscle disease: Methods for use of a composition comprising Bowman-Birk Inhibitor (BBI) or a derivative thereof in the treatment and/or prevention of skeletal muscle atrophy, to improve of skeletal muscle function, and to alleviate symptoms and/or slow progression of degenerative skeletal muscle diseases or disorders are provided.... Agent: Licata & Tyrrell P.C.

20080300182 - Eye disease treating agent and method for treating eye disease: An eye disease treating agent and a method for treating an eye disease, which use a compound having an interleukin 6 production accelerating activity, are provided.... Agent: Sughrue-265550

20080300183 - Gastrointestinal proliferative factor and uses thereof: The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor (GIPF) polynucleotides and polypeptides. The invention further relates to the therapeutic use of GIPF to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa.... Agent: Robins & Pasternak

20080300180 - Growth hormone secretagogue receptor 1a ligands: The present invention relates to new growth hormone secretagogue receptor 1A (GHS-R 1A) ligands, and pharmaceutical compositions comprising any of the new GHS-R1 A ligands. The ligands are suitable for a wide range of applications, and thus the present invention also relates to use of the GHS-R1 A ligands according... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080300188 - Immunoglobulin fusion proteins: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a... Agent: Sughrue Mion, PLLC

20080300181 - Methods of using il-1 antagonists to treat neointimal hyperplasia: Methods of using interleukin-1 (IL-1) antagonists to prevent or treat restenosis and other neointimal hyperplasia conditions, including atherosclerosis, vascular access dysfunction, hypertension and related vascular diseases are provided.... Agent: Regeneron Pharmaceuticals, Inc

20080300187 - Mutated hoxb4 proteins with improved stability, and methods of use thereof: A polypeptide, the amino acid sequence of which comprises a sequence as set forth in SEQ ID NO:2, including at least one mutation within the degron domain of the polypeptide encompassed between positions 1 and 35 of the sequence, wherein said at least one mutation reduces the susceptibility of the... Agent: Goudreau Gage Dubuc

20080300189 - Pharmaceutical compositions and methods for restoring beta-cell mass and function: Pharmaceutical compositions and methods for using are provided for restoring β-cell mass and function in a mammal in need thereof. The pharmaceutical compositions have a biological response modifier and a β-cell growth factor in admixture with a pharmaceutically acceptable carrier, adjuvant or vehicle.... Agent: Nixon & Vanderhye, PC

20080300186 - Process to produce fibrillar proteins and method of treatment using fibrillar proteins: A method for changing a globular protein structure into a fibrillar protein structure. The method comprising the steps of providing a globular protein, forming a solution containing the globular protein, adding a detergent to the solution containing the globular protein, applying the solution to a molecular sizing column with a... Agent: Greenberg Traurig LLP (la)

20080300184 - Transgenic tieg non-human animals: Materials and Methods related to a transgenic non-human animal (e.g., a transgenic non-human mammal) whose genome comprises a disrupted TIEG allele are provided. Methods for making such transgenic non-human animals, and using them to identify and characterize agents that affect conditions related to TIEG activity, such as cardiac hypertrophy and... Agent: Fish & Richardson P.C.

20080300185 - Use of il-1 antagonists to treat gout and pseudogout: Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout or pseudogout in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein gout or pseudogout are inhibited or ameliorated. Preferably, the IL-1 antagonist is... Agent: Regeneron Pharmaceuticals, Inc

20080300190 - Peptides, derivatives and analogs thereof, and methods of using same: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment... Agent: Pepper Hamilton LLP

20080300192 - Auristatins having an aminobenzoic acid unit at the n terminus: Auristatin-type peptides are disclosed which are highly cytotoxic, synthetically accessible, and can be conjugated to antibodies and other ligands.... Agent: Townsend And Townsend And Crew, LLP

20080300191 - Protease inhibitors for coronaviruses and sars-cov and the use thereof: Disclosed are protease inhibitors for coronaviruses and SARS-CoV, or picornaviruses, and the use of these protease inhibitors for preventing, reducing, ameliorating and treating a disease or condition caused by coronaviruses and SARS-CoV, or picornaviruses. Also disclosed are methods of reducing or preventing the spread of coronavirus, or picornaviruses, and preventing... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080300193 - Composition and method for the treatment of diseases affected by a peptide receptor: The present invention includes peptidomimetic compound compositions and methods of making and using peptidomimetic compounds to modulate the activity of a peptide receptor for the treatment of one or more of hyperglycemia, insulin resistance, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia or other symptoms that relate to the function of the targeted receptor.... Agent: Chalker Flores, LLP

20080300194 - Methods of treating emesis using growth hormone secretagogues: The present invention relates to methods of treating or preventing emesis and improving a subject's ASAS score by administering to the subject an effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.... Agent: Edwards Angell Palmer & Dodge LLP

20080300195 - Metabolic imprinting: The present invention generally relates to the field of nutrition. In particular the present invention relates to infant nutrition in the post natal period and in early life, more particular during the age period of 6-36 months or during a part thereof. One embodiment of the present invention is a... Agent: Bell, Boyd & Lloyd LLP

20080300196 - Monosaccharide derivatives: The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory, cancer, cardiovascular and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type-I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative... Agent: Ranbaxy Inc.

20080300197 - Pharmaceutical composition having virucidal and spermicidal activity: Acaciaside-B (Ac-B) has emerged as a prospective candidate molecule for prevention of HIV infection along with potential for use as/in vaginal contraceptive/formulation. It possesses anti-HIV property at a tolerably low concentration, is non-mutagenic and does not harm the niche of Lactobacilli. Thus Ac-B appears to be a superior ingredient for... Agent: Ladas & Parry LLP

20080300198 - Olive compositions and methods for treating inflammatory conditions: A method of treating an inflammatory condition with a hydroxytyrosol-rich composition. Improvement is monitored as a reduction in the levels of a biochemical marker such as homocysteine or C-reactive protein. The composition may be administered in an amount and for a period sufficient to effect a drop in the level... Agent: King & Spalding LLP

20080300199 - Antibacterial 1,4,5-substituted aminoglycoside analogs: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.... Agent: Seed Intellectual Property Law Group PLLC

20080300200 - Therapeutic furopyrimidines and thienopyrimidines: The invention provides compounds of formula I, II, and III as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of formula I, II, and III are useful as anti-viral agents and/or as anti-cancer agents.... Agent: Viksnins Harris & Padys Pllp

20080300204 - Alpha-synuclein antibodies and methods related thereto: Disclosed are antibodies specific for alpha-synuclein conformers and methods related thereto. For example, disclosed are methods of diagnosing a neurodegenerative monitoring a neurodegenerative disease treatment using the disclosed antibodies. Assays, kits, and solid supports related to alpha-synuclein and antibodies specific for alpha-synuclein are also disclosed.... Agent: Clark G. Sullivan Arnall Golden Gregory LLP

20080300206 - Alpha-synuclein kinase: The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase.... Agent: Townsend And Townsend And Crew, LLP

20080300201 - Cell cycle arrest and apoptosis: The HIV-1 accessory gene vpr encodes a conserved 96-amino acid protein that is necessary and sufficient for the HIV-1-induced block of cellular proliferation and induction of apoptosis. Expression of vpr in CD4+ lymphocytes results in G2 arrest, followed by apoptosis. ATR, as a cellular factor that mediates Vpr-induced cell cycle... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080300205 - Epigenetic mechanisms re-establish access to long-term memory after neuronal loss: The invention relates to methods and products for enhancing and improving recovery of lost memories. In particular the methods are accomplished through the increase of histone acetylation.... Agent: Wolf Greenfield & Sacks, P.C.

20080300209 - Gene expression and pain: The present invention relates to double-stranded oligonucleotides, pharmaceutical compositions thereof, and use of such double-stranded oligonucleotides and pharmaceutical compositions to modulate nociceptive signaling in a cell or prevent and/or treat pain in a patient.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080300208 - Isociatrate dehydrogenase and uses therof: The present invention discloses uses for the IDH gene and/or polypeptide and/or modulators thereof in the diagnosis and treatment of apoptosis-related diseases.... Agent: Cooper & Dunham LLP

20080300210 - Method of controlling insects and virus transmission: The present invention provides methods and compositions for controlling insects and virus transmission, including a genetic construct for inhibiting virus transmission by an arthropod, a transgenic plant, plant cell or plant tissue, a method of preventing transmission of an arthropod-dependent viral plant disease, a method of delivering an active toxic... Agent: Quarles & Brady LLP

20080300211 - Microrna inhibition for the treatment of inflammation and myeloproliferative disorders: The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing and treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of... Agent: Knobbe Martens Olson & Bear LLP

20080300207 - Protein production: The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080300203 - Stable quantitation and detection of immune response levels with non-zero background peptides: The invention relates to a kit comprising MHC Class I and Class II HLA-coated beads containing specific antigenic peptides for binding to antigen-specific T cells and the appropriate negative control peptides. Also provided are methods for making the coated beads and methods for use. The application of these beads go... Agent: James Remenick Novak Druce & Quigg, LLP

20080300202 - Subtractive transgenics: Described herein are methods for predictable, highly selective expression of a transgene in a human or non-human animal. The methods comprise subtractive transgenics, wherein the expression pattern of one selective promoter is subtracted from the expression pattern of a second selective promoter. Provided are non-human transgenic animals exhibiting a highly... Agent: Klarquist Sparkman, LLP

20080300212 - Treatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotide inhibition of human replication-initiation proteins: Antisense oligonucleotides that inhibit expression of human replication- initiation protein as well as methods of preventing or treating hyperproliferative conditions using said oligonucleotides are disclosed. One aspect provides an antisense oligonucleotide that inhibits the expression of human replication-initiation protein and has a sequence complementary to at least a portion of... Agent: Wilkinson & Grist

20080300214 - Compounds for the treatment of marihuana dependence, withdrawal, and usage: The invention provides methods for treating or suppressing marihuana usage, withdrawal, or dependence involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, uridine-containing compound, creatine-containing compound, adenosine-containing, or adenosine-elevating compound to a mammal.... Agent: Clark & Elbing LLP

20080300213 - Use of a3 adenosine receptor agonist in osteoarthritis treatment: The present invention provides the use of an A3 adenosine receptor agonist (A3AR agonist) for the preparation of a pharmaceutical composition for the treatment of a mammal subject having osteoarthritis (OA), as well as to a method for the treatment of OA in a mammal subject, the method comprises administering... Agent: Nath & Associates

20080300215 - Prodrugs activated by rna-dependent dna-polymerases: Herein described are prodrugs activated by RNA-dependent DNA-polymerases, such as telomerase and retroviral reverse transcriptases, their use for the treatment of haematological tumours and of blood and blood derivatives from patients affected by retroviral infections, and their use for the preparation of pharmaceutical compositions, to be used for the treatment... Agent: Clark & Elbing LLP

20080300216 - Dutpase inhibitors: Deoxyuridine derivatives of Formula (I′); where A is O, S or CH2; B is O, S or CHR3; R1 is H, or various substituents; R2 is H, F; R3 is H, F, OH, NH2; or R2 and R3 together form a chemical bond; D is —NHCO—, —CONH—, —O—, —C(═O)—, —CH═CH,... Agent: Birch Stewart Kolasch & Birch

20080300217 - Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders: The present invention relates to compositions, kits and methods for administration of a first component of fumaric acid ester(s), or a pharmaceutically acceptable salt thereof, and a second component which is a substance that reduces or eliminates flushing.... Agent: Darby & Darby P.C.

20080300218 - Crosslinkable polysaccharide derivative, process for producing the same, crosslinkable polysaccharide composition, and medical treatment material: A process for producing an uncrosslinked, crosslinkable polysaccharide derivative having an active ester group, said process including: dissolving an acid-containing polysaccharide having a carboxy group and/or a carboxyalkyl group which are originally possessed or which have been introduced, in its non-salt form, into an aprotic polar solvent at a temperature... Agent: Buchanan, Ingersoll & Rooney PC

20080300219 - Novel interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis: The present invention relates to a disorder of the lower urinary tract, and in particular, reducing the symptoms (including treatment) of interstitial cystitis in vivo. In a preferred embodiment, the present invention relates to treatment formulations and methods for reducing interstitial cystitis in patients.... Agent: Foley & Lardner LLP

20080300220 - Linkable lewis x analogs: Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLeX) and related analogs. These compounds have conjugatable nucleophilic groups, making them useful in preparing multimeric SLeX compositions. In particular, the disclosed SLeX compounds can be used to prepare selectin binding... Agent: Kramer Levin Naftalis & Frankel LLP

20080300221 - Contact lens care composition: The present invention relates to ophthalmic compositions such as contact lens care solutions, containing miltefosine. The present invention further relates to ophthalmic compositions or contact lens care systems containing miltefosine in combination with additional other active microbiocidal substances or proteases. Furthermore, the invention relates to the use of the compositions... Agent: Chalker Flores, LLP

20080300222 - Phosphoantigen salts of organic bases and methods for their crystallization: The invention provides novel phosphoantigen salts and novel crystalline phases of phosphoantigens salts, that the latter including non-solvated polymorphs, and solvates useful as pharmaceuticals. The invention also provides pharmaceutical compositions comprising, and processes for making, novel phosphoantigen crystalline phases. Methods of using such compositions for the treatment of disease, immunostimulatory... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080300223 - (20r)-2a-methyl-19,26,27-trinor-vitamin d analogs: This invention discloses (20R)-2α-methyl-19,26,27-trinor-vitamin D analogs, and specifically (20R)-2α-methyl-19,26,27-trinor-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall, LLP

20080300224 - Treatment of conditions relating to hormone deficiencies by administration of progestins: The present invention includes methods for preventing endometrial hyperplasia associated with estrogen therapy through the administration of a progestin agent. The methods presented may include starting the administration of a progestin agent at a high dose, and then lowering the dose.... Agent: Myers Bigel Sibley & Sajovec

20080300226 - Combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd: The present invention describes the combination of topically inhaled medicinal formulations comprising an anticholinergic component and a glucocorticosteroid component and its use in the symptomatic and prophylactic treatment of diseases of the respiratory tract, especially with an obstructive component or underlying inflammation like asthma and chronic obstructive pulmonary disease (COPD).... Agent: Venable LLP

20080300227 - Drugs for treating hypertension combined with hyperuricemia and/or hypercholesterolemia: The invention is directed to a drug for treating hypertension combined with serum hyperuricemia and/or hypercholesterolemia, with the active ingredients being 2-propyl-3-{[21-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-5,6,7, 8-tetrahydrocyclohepta imidazole-4-(3H)-one and a prodrug or salt thereof. Pratosartan can be used in combination with one or more diuretics chosen from sulfonamide-, phenoxyacetic acid- and thiazide-type diuretics, triamterene,... Agent: Flynn Thiel Boutell & Tanis, P.C.

20080300225 - Pesticidal formulation containing oxymatrine or matrine: Compositions and methods are provided for a water-soluble insecticidal or pesticidal comprising at least one alkaloid, particularly at least one tetracyclo-quinolizindine alkaloid derived from sophora roots, particularly matrine and/or oxymatrine.... Agent: Cheryl H Agris Phd

20080300228 - Crystalline rostafuroxin: New crystalline forms of 17β-(3-Furyl)-5-βandrostane-3β,14β,17α-triol are described together with pharmaceutical composition containing the same and methods for their preparation. In particular new Forms B, C, D, E and H are here described.... Agent: Lucas & Mercanti, LLP

20080300229 - Sprayable pharmaceutical compositions comprising a corticoid and an oily phase: Anhydrous sprayable pharmaceutical/dermatological compositions containing, as active pharmaceutical agent, a corticoid, preferably clobetasol propionate, and an oily phase, are formulated in a physiologically acceptable medium, and are useful for the treatment of a variety of conditions and afflictions, notably psoriasis.... Agent: Buchanan, Ingersoll & Rooney PC

20080300230 - Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary tract caused by sex hormones: The present invention relates to extracts from Cimicifuga species and particularly from Cimicifuga racemosa, which are suited for producing a ready-formulated drug for the selective treatment and/or prophylaxis of sexual hormone-related disorders of the uro-genital tract. The extracts in accordance with the invention are moreover suited for the treatment and/or... Agent: Catalyst Law Group, Apc

20080300231 - Antibacterial amide macrocycles vi: The invention relates to antibacterial amide macrocycles and methods for their preparation, their use for the treatment and/or prophylaxis of diseases, as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular of bacterial infections.... Agent: Morrison & Foerster LLP

20080300233 - Pharmaceutical composition comprising simvastatin and ezetimibe: The present invention relates to the field of pharmaceutical technology and in particular to novel dosage forms of medicaments containing as active ingredients simvastatin and ezetimibe, or pharmaceutically acceptable salts thereof. The present pharmaceutical compositions are characterized in that the contact of the compositions with oxygen is substantially reduced, such... Agent: Bell, Boyd & Lloyd, LLP

20080300232 - N-piperidine derivatives as ccr3 modulators: Compounds of formula I, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions... Agent: Pepper Hamilton LLP

20080300234 - Pyrimidine derivatives for the treatment of abnormal cell growth: wherein R1-R4 are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions... Agent: Pfizer Inc

20080300235 - Fxr agonists for reducing lox-1 expression: Provided are certain methods of treating at least one disease state characterized by elevated expression of the Lectin-like Oxidized Low-density Lipoprotein Receptor 1 (LOX-1) in a patient with farnesoid X receptor agonists. Also provided are certain methods of reducing expression of LOX-1 in a cell with farnesoid X receptor agonists.... Agent: Wyeth/finnegan Henderson, LLP

20080300236 - Quinoline-derived amide modulators of vanilloid vr1 receptor: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to quinoline-derived amides that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.... Agent: Philip S. Johnson Johnson & Johnson

20080300237 - Pharmaceutically active diazepanes: Leukocyte Function-Associated Antigen One (LFA-1) is a cell adhesion molecule selectively expressed on leukocytes, and plays a major role in the activation and trafficking of T lymphocytes in the tissue at sites of inflammation. In the last decade a large body of preclinical data has accumulated to establish the importance... Agent: Novartis Corporate Intellectual Property

20080300238 - Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic: The invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and a diuretic and to a method of using such composition for the treatment of cardiovascular disease.... Agent: Novartis Corporate Intellectual Property

20080300239 - Quinoline derivatives as pi3 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080300240 - Pde10 inhibitors and related compositions and methods: wherein m, n, p, x, R, R1, R2, R3, R4, R5, A and B, are defined herein, including pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the... Agent: Seed Intellectual Property Law Group PLLC

20080300241 - Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods: Non-steroidal tricyclic quinolinone and tricyclic quinoline compounds and compositions that are agonists, partial agonists and/or antagonists for androgen receptors (AR), their preparation and their uses are described.... Agent: Bell, Boyd & Lloyd LLP

20080300242 - Imidazopyridine kinase inhibitors: The present invention provides imidazopyridine compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.... Agent: Glaxosmithkline Corporate Intellectual Property

20080300243 - Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same: Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.... Agent: Jones Day

20080300244 - Novel compounds: m

20080300245 - Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors:

20080300246 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, BMX, BTK, CHK2, b-RAF, c-RAF,... Agent: Genomics Institute Of The Novartis Research Foundation

20080300247 - Benzimidazole thiophene compounds: The present invention provides benzimidazole thiophene compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080300248 - Quinazoline derivatives, preparation methods and uses thereof: The present invention has disclosed a compound of formula I and a pharmaceutically acceptable salt or a solvate thereof, wherein the substituents are as defined in the description. The invention has also disclosed a method for preparing the compound of formula I, the pharmaceutical compositions comprising the same and their... Agent: Scully Scott Murphy & Presser, PC

20080300249 - Isothiazole derivatives useful as anticancer agents: and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X1, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.... Agent: Scully Scott Murphy & Presser, PC

20080300250 - Acetylenyl-pyrazolo-pyrimidine derivatives: d

20080300251 - Derivatives of 3-azabicyclo[3.1.0] hexane as dipeptidyl peptidase-iv inhibitors: The present invention relates to novel 3-azabicyclo[3.1.0]hexane derivatives as dipeptidyl peptidase-IV inhibitors and the processes for the synthesis of the said compounds. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating diabetes, especially type 2 diabetes, as well as prediabetes, diabetic... Agent: Ranbaxy Inc.

20080300252 - Embedding antibiotic compounds in solid polymers: The present invention is directed to providing antimicrobial compositions consisting of a polymeric material and, embedded therein, an antimicrobial compound. The antimicrobial compound contains at least one quaternary ammonium group, at least one hydrocarbon chain comprising a minimum of 10 carbon atoms and a maximum of 24 carbon atoms, and... Agent: Hoffmann & Baron, LLP

20080300253 - Treatment of inflammatory disorders with praziquantel: Methods of treating and/or preventing disorders mediated by one or more of TNF-α, NF-κB, IKK-α, IKK-β, ATF-2 and p38 kinase by administration of praziquantel, or a pharmaceutically acceptable salt, prodrug, ester or amide thereof. These disorders include inflammatory disorders such as autoimmune diseases.... Agent: Knobbe Martens Olson & Bear LLP

20080300254 - Tylophorine analogs as antitumor agents: Compounds of Formula I are described: preferably subject to the proviso that either (a) R2 and R3 together form —O—CH(R10)—O—, or (b) R5 and R6 together form —O—CH(R10)—O—, wherein R10 is H, halo, or loweralkyl. Pharmaceutical salts, formulations, and methods of using the same in the treatment of cancer are... Agent: Myers Bigel Sibley & Sajovec

20080300255 - Substituted pyrazoles: Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S.... Agent: Philip S. Johnson Johnson & Johnson

20080300257 - 3-(imidazolyl)-pyrazolo[3,4-b]pyridines: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.... Agent: Townsend And Townsend And Crew, LLP

20080300256 - Substituted 5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-ylamine compounds and their use for producing drugs: Substituted 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-ylamine compounds corresponding to formula I, methods for the preparation thereof, pharmaceutical compositions containing said compounds, the use of said compounds for preparing pharmaceutical compositions and related treatment methods.... Agent: Crowell & Moring LLP Intellectual Property Group

20080300258 - Anhydrous ciprofloxacin hydrochloride: The present invention provides a new anhydrous crystalline form of ciprofloxacin hydrochloride that is substantially free from solvent molecules, and processes of preparation thereof.... Agent: Lang Michener

20080300259 - Multimediator 5-ht6 receptor antagonists, and uses related thereto: The invention provides a class of 5HT6—D3/DAT compounds, packaged pharmaceuticals comprising such compounds, and their uses in treating, or manufacturing medicaments for treating disease conditions, including a movement disorder, anxiety, depression or psychotic disorder (e.g. Bipolar Disorder, Bipolar Depression or Unipolar Depression, etc.). Related business methods such as marketing the... Agent: Ropes & Gray LLP

20080300260 - Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor): The present invention relates to heterocyclic compounds which are positive modulators of metabotropic glutamate receptor. The present invention also relates to the use of these compounds for preparing a pharmaceutical composition and to a method of treating a medical disorder, selected from neurological and psychiatric disorders associated with glutamate dysfunction.... Agent: Dykema Gossett PLLC

20080300261 - Arylacetic acids and related compounds for treatment of alzheimer's disease: e

20080300262 - Combination therapy for relief of pain: The present invention relates to analgesic compositions comprising a non-peptidyl N-type calcium channel blocker, and at least one other analgesic compound, and to methods of using N-type calcium channel blockers in combination with at least one other pain-relieving compound that alleviates pain through a mechanism other than N-type calcium channel... Agent: Morrison & Foerster LLP

20080300263 - Pyrazolo [1,5-a] pyrimidine compounds and pharmaceutical compositions containing them: The present invention relates to certain pyrazolo[1,5a]pyrimidine compounds, to processes for their preparation, compositions comprising them and methods of using them. The compounds are useful in the treatment of cancer. Novel screening methods are also provided.... Agent: Edwards Angell Palmer & Dodge LLP

20080300264 - Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors: e

20080300265 - Antiviral drugs for treatment of arenavrus infection: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20080300266 - 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mglur3 antagonists: The present invention relates to compounds of the Formula (I) which are useful for treating conditions associated with mGluR3 receptors, such as depression, schizophrenia and migraine, pharmaceutical compositions thereof, and methods of using the same.... Agent: Eli Lilly & Company

20080300267 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the CDKs, Aurora, Jak2, Rock, CAMKII, FLT3, Tie2,... Agent: Genomics Institute Of The Novartis Research Foundation

20080300268 - Heterocyclic compounds and uses thereof: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.... Agent: Choate, Hall & Stewart LLP

20080300269 - Therapeutic compounds: e

20080300270 - 4-phenyl-5-oxo-1,4,5,6,7,8,- hexahydroquinoline derivatives as medicaments for the treatment of infertility: The invention relates to a 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivative according to Formula (I), wherein the substituents are defined as in the description, or a pharmaceutically salt thereof. The compounds of this invention are potent FSH receptor activators and may be used for treating fertility disorders in e.g. controlled ovarian hyperstimulation and IVF... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20080300271 - Novel compounds and a novel process for their preparation: The present invention is directed to a procedure for making an enantidimerically enriched compound containing a hydronaphthalene ring structure. The process involves reacting oxabenzonorbornadienes with nuclophiles using rhodium as a catalyst and in the presence of a phosphine ligand. The compounds synthesized may be used in pharmaceutical preparations for the... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080300272 - Alcohol free formulation of argatroban: An aqueous formulation of argatroban and of related compounds is disclosed along with a reconstitutable formulation, each of which is substantially, if not totally alcohol free. The formulations are also substantially free, if not totally free, of mono-, di-, and oligo-saccharides. An especially preferred embodiment is a ready-to-administer 1 mg/ml... Agent: Irving M. Fishman C/o Cohen, Tauber, Spievack & Wagner

20080300273 - Method of treating abnormal cell growth: The present invention relates to the use of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine, a novel c-Met/HGFR inhibitor, for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer.... Agent: Pfizer Inc

20080300274 - Novel pyrrolidino-1,4-naphthoquinone deriviatives and their use for treating malignancies and cardiovascular diseases: The invention provides pyrrolidino-substituted 1,4-naphthoquinone derivatives that modulate the activity of protein kinases, and it relates to the use of the derivatives in pharmaceutical compositions for treating cardiovascular disorders and malignancies. The invention particularly provides medicaments for treating disorders associated with MAPKs signaling, ERKs signaling, p38 signaling, and JNKs signaling.... Agent: Kevin D. Mccarthy Roach Brown Mccarthy & Grber P.C.

20080300275 - Novel benzothiazolone derivatives: The present invention provides compounds of formula (I) wherein e, R1, R2, R3, R4, R5, R4, R5, R6, R7, R7a, R7b, A, D, m and n are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Fish & Richardson P.C.

20080300276 - Heterocyclic carboxylic acide amide derivatives: The invention relates to new heterocyclic carboxylic acid amide derivatives of formula (I)—wherein the meaning of X is hydrogen or halogen atom, hydroxy, cyano, C1-C4 alkylsulfonamido optionally substituted by a halogen atom or halogen atoms, C1-C4 alkanoylamido optionally substituted by a halogen atom or halogen atoms, arylsulfonamido groups, is —CH═... Agent: K.f. Ross P.C.

20080300277 - Process to improve stability of a pharmaceutical composition: The present invention describes in particular a method for stabilizing a pharmaceutical composition by contacting said composition with a polymeric material comprising in particular an ethylene oxide sterilization step.... Agent: Novartis Corporate Intellectual Property

20080300279 - Piperidine-amide derivatives: e

20080300278 - Prodrugs of pyrazoline compounds, their preparation and use as medicaments: The present invention relates to prodrugs of pyrazoline compounds of formula I, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.... Agent: Banner & Witcoff, Ltd.

20080300280 - Cyanobenzene compounds for combating animal pests: The present invention relates to a method of combating animal pests which comprises contacting the animal pests, their habit, breeding ground, food supply, plant, seed, soil, area, material or environment in which the animal pests are growing or may grow, or the materials, plants, seeds, soils, surfaces or spaces to... Agent: Brinks, Hofer, Gilson & Lione

20080300281 - Inhibition of p38 kinase activity using aryl and heteroaryl substituted heterocyclic ureas: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.... Agent: Millen, White, Zelano & Branigan, P.C.

20080300282 - Novel process to prepare pioglitazone via several novel intermediates: A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine.... Agent: Nixon & Vanderhye, PC

20080300283 - Microbicidal preparations based on 1, 2-benzisothiazonlin-3-one with a content of aromatic alcohol: The invention relates to microbicidal preparations which comprise a) at least one of 1,2-benzisothiazolin-3-one and its derivatives, b) at least one of 2-mercaptopyridine N-oxide, its salts and derivatives, c) at least one aromatic alcohol and d) at least one alkalinizing agent, or which are prepared by mixing components a) to... Agent: Young & Thompson

20080300284 - Nicotinic acid compositions for treating hyperlipidemia and related methods therefor: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic... Agent: Dykema Gossett PLLC

20080300285 - Chemical compounds: The use of a compound of formula (I) wherein X is (i), (ii) or (iii), formula (i), formula (ii), formula (iii) Y is O, S(O)m, NR3, CR5R6, CR5R6—CR7R8, O—CR7R8, S(O)m—CR7R8, NR3—CR7R8, CR5R6—O, CR5R6—S(O)m, CR5R6—NR3, SO2—NR3, NR3—SO2, NR3—O or O—NR3; m is 0, 1, or 2; the ring (T) formula (T)... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080300287 - Peptidic compounds: The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are... Agent: Darby & Darby P.C.

20080300286 - Tyrosine derivatives substituted by n-arylacryloyl as agonists of hppar alpha and/or hppar gamma: The present invention relates to a compound of formula I, racemates, optically active isomers, or pharmaceutically acceptable salts or solvates thereof, and a pharmaceutical composition comprising the compound, the various radicals in the formula I are the same as defined in the claims. The present invention also relates to a... Agent: Ladas & Parry LLP

20080300288 - Alkenyldiarylmethanes, fused analogs and syntheses thereof: Non-nucleoside inhibitors of HIV-1 reverse transcriptase are described. Such inhibitors may be used as part of a combination therapy to treat HIV infection. Compounds described herein exhibit antiviral potency. In addition, compounds described herein exhibit metabolic stability. Also described herein are processes for preparing Non-nucleoside inhibitors of HIV-1 reverse transcriptase.... Agent: Barnes & Thornburg LLP

20080300289 - Glucagon receptor antagonists, preparation and therapeutic uses: The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using... Agent: Eli Lilly & Company

20080300290 - Novel beta-agonists, process for their preparation and their use as medicaments: e

20080300291 - Potent indole-3-carbinol-derived antitumor agents: wherein X is hydroxyl or amino; Y is carboxyl or sulfonyl; R1, R2, R3, and R4 can be the same or different and are selected from hydrogen, halogen, methoxy, trifluoromethyl, hydroxyl and combinations thereof, R5, R6, and R7 may be the same or different and are selected from hydrogen, chloro,... Agent: Calfee Halter & Griswold, LLP

20080300292 - Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders: The invention describes novel nitrosated and/or nitrosylated compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one... Agent: Wilmerhale/nitromed

20080300293 - Combination of an dpp-iv inhibitor and a ppar-alpha compound: The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further PPARα compound, preferably selected from the group consisting of fenofibrate, micronized fenofibrate, bezafibrate, gemfibrazil and ciprofibrate for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by... Agent: Novartis Corporate Intellectual Property

20080300294 - Novel thiophene derivatives: The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.... Agent: Dickstein Shapiro LLP

20080300295 - Inhibitors of ccr9 activity: Compounds of formula I, wherein one of R1 and R2 is thienyl which is substituted by halogen and the other of R1 and R2 is substituted phenyl, wherein the substituents are as defined in the claims, with the proviso that the phenyl group is substituted by at least a cyano,... Agent: Novartis Institutes For Biomedical Research, Inc.

20080300296 - Coating agent for drug releasing stent, preparation method thereof and drug releasing stent coated therewith: Disclosed are a coating agent for drug releasing stents, a method for preparing the same and a drug releasing stent coated therewith. The coating agent comprises a biologically active material and a coating material selected from among pullulan acetate, represented by the following Chemical Formula 1, and a polyurethane-surfactant mixture.... Agent: Ladas & Parry LLP

20080300297 - Taxane derivative containing pharmaceutical composition with improved therapeutic efficacy: The invention relates to a pharmaceutical combination comprising a mixture of (a) at least one taxane derivative and (b) at least one ω-3 poly-unsaturated acid or a derivative thereof wherein the molar ratio of (b) to (a) is not higher than 2. The invention further relates to a liquid pharmaceutical... Agent: Abelman, Frayne & Schwab

20080300298 - Honokiol derivates for the treatment of proliferative disorders: The present invention provides novel honokiol derivatives, as well as pharmaceutical compositions containing the honokiol derivatives. These compounds and pharmaceutical compositions can be used in the prevention and/or treatment of cancer. In particular, honokiol derivatives, pharmaceutical compositions comprising the derivatives, and methods for their use in the treatment of myeloma... Agent: Intellectual Property / Technology Law

20080300299 - Application of eriocalyxin b in the manufacture of medicaments for treating leukemia: The use of eriocalyxin B in the manufacture of medicaments for treating leukemia, wherein the leukemia include leukemia containing AML1-ETO fusion protein, acute promyelocytic leukemia, acute myelocytic leukemia and lymphocytic leukemia. Eriocalyxin B increases the level of peroxidate and influences the phosphorylation and degradation of IκBα to prevent NF-κB from... Agent: Kirton And Mcconkie

20080300300 - Use of alpha-mangostin as a mosquito larvicide: Methods of killing mosquito larvae and controlling an adult mosquito population by using α-mangostin, 3,6,8-yrihydroxy-2-methoxy-1,7-bis(3-methylbut-2-enyl)xanthen-9-one, or a salt, solute, hydrate or solvate thereof. Mosquito larvae are killed by contacting a lethal dose of α-mangostin with mosquito larvae. Adult mosquito populations are controlled by treating a mosquito larvae population with a... Agent: Quarles & Brady LLP

20080300301 - Composition for promoting production of hyaluronic acid containing kaempferol and quercetin: Disclosed is a composition for promoting a production of hyaluronic acid containing at least one of kaempferol and quercetin. Kaempferol and quercetin of the invention increase an expression of a hyaluronic acid synthase (HAS) gene existing in a skin cell line of human epidermis, thereby promoting a production of hyaluronic... Agent: Merchant & Gould PC

20080300302 - Stabilized 3-hydroxyflavan compositions and methods therefor: Compositions and methods are directed to covalent adducts between reducing agents and optionally substituted 3-hydroxyflavans, wherein the reducing agent is covalently bound to the B-ring of the 3-hydroxyflavan. Such adducts exhibit markedly increased stability towards oxidation as compared to the unmodified 3-hydroxyflavan. Particularly preferred 3-hydroxyflavans include green tea catechins, and... Agent: Fish & Associates, PC Robert D. Fish

20080300303 - Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use as anti-fungal agents: The present invention pertains to substances of the formula (I) wherein X is O or S; and R1-R4 are defined in the claims as inhibitors of glyoxalase I and/or II, pharmaceutical compositions comprising one or more compounds according to formula (I) and the use of one or more compounds according... Agent: Gudrun E. Huckett Draudt

20080300304 - Ginger fraction for inhibiting human cyp enzymes: The present invention relates to a process for preparing a ginger fraction, the fraction prepared by this process and the use thereof on its own or combined with drugs for inhibiting human cytochrome P450 (CYP) enzymes (particularly cytochrome P450 3A4, CYP3A4) for positively influencing the oral bioavailability and pharmacokinetics of... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080300305 - Method of purifying pravastatin: The present invention provides pure pravastatin compositions and pure compactin compositions, and methods for the preparation thereof.... Agent: Kenyon & Kenyon LLP

20080300306 - Novel compounds: e

20080300307 - Stable gabapentin compositions: Stable compositions containing gabapentin compositions, methods of preparing such compositions, and methods of using such compositions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080300308 - Glucagon receptor antagonists, preparation and therapeutic uses: The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using... Agent: Eli Lilly & Company

20080300309 - Creatine hydroxycitric acids salts and methods for their production and use in individuals: Methods of production for Tricreatine Hydroxycitrate are disclosed. Tricreatine hydroxycitrate can be used as supplemental dietary ingredient for the purposes of reducing adiposity, suppression of appetite, improvement of muscle and exercise performance and recovery. The salts are useful in the dietetic, food supplement and food industries.... Agent: Iovate Health Science Research Inc.

20080300311 - Diclofenac gel: The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.... Agent: Townsend And Townsend And Crew, LLP

20080300310 - Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne: A method of treating at least one dermatological disorder selected from the group consisting of photodamage-induced wrinkles, rosacea, and acne, includes: (a) providing a composition containing 1-3 wt. % diclofenac or a salt thereof, 0.5-1.5 wt. % benzyl alcohol, 10-30 wt. % PEG monomethyl ether, 0.1-3.0 wt. % sodium hyaluronate;... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080300312 - Treatment of cancer with specific rxr agonists: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080300313 - Solvent mixture for preparing water-dilutable liquid concentrate formulation of organic pesticide compounds: The present invention relates to a solvent mixture SM for preparing a water-dilutable liquid concentrate formulation of sparingly soluble organic pesticide compounds C having a water solubilty of not more than 5 g/l at 25° C./1013 mbar. The present invention also relates to water-dilutable liquid concentrate formulation, which comprises said... Agent: Brinks, Hofer, Gilson & Lione

20080300314 - Cooling compounds: e

20080300315 - Stabilized compositions comprising a therapeutically active agent, and an oxidizing preservative: Citric acid and conjugate bases thereof are useful for stabilizing stabilized chlorine dioxide in the presence of therapeutically active agents and excipients in a composition. Ophthalmic compositions and methods related thereto are also disclosed herein.... Agent: Allergan, Inc.

20080300316 - Substituted phenethylamines: Disclosed herein are substituted phenethylamine alpha adrenergic receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080300317 - Diamondoid derivatives possessing therapeutic activity in the treatment of viral disorders: This invention relates to diamondoid derivatives which exhibit therapeutic activity. Specifically, the diamondoid derivatives herein exhibit therapeutic effects in the treatment of viral disorders. Also provided are methods of treatment, prevention and inhibition of viral disorders in a subject in need.... Agent: Crowell & Moring LLP Intellectual Property Group

20080300318 - Cinnamaldehyde formulations and methods of use: The invention generally relates to various cinnamaldehyde (cinnamic aldehyde) formulations for protecting plants from nematodes and other pathogens. The invention provides specific formulations which do not require the use of chemical additives. These formulations have low phytotoxicity and low volatility. Also, methods of applying the formulations for agricultural use are... Agent: Wood, Phillips, Katz, Clark & Mortimer

20080300319 - Methods for preventing or inhibiting post-surgical adhesions: In accordance with one aspect of the invention, a method is provided in which post-surgical adhesions at a surgical site in a patient are prevented or inhibited. The method comprises topically applying a liquid composition comprising a hydrophobic species, which has a melting point above normal body temperature, to tissue... Agent: Mayer & Williams PC

20080300320 - Use of polyvinyl lactam-polyalkylene block copolymers as solubilisers for poorly water-soluble compounds: Use of polyvinyllactam-polyalkylene oxide block copolymers as solubilizers for sub-stances which are sparingly soluble in water.... Agent: Connolly Bove Lodge & Hutz LLP

20080300321 - Multicolor component adhesive system: The present invention relates to a multicolor component adhesive system based on at least two miscible polymerizable components and a curative component, said system being suitable for providing an adhesive having any desired color. The present invention further relates to the use of the adhesive produced on the basis of... Agent: Ostrolenk Faber Gerb & Soffen

20080300322 - Delivery vehicles containing rosin resins: Compositions containing a vehicle containing a rosin resin or derivative and a non-volatilized solvent or plasticizer. The compositions may be used to deliver a biologically active substance such as an active pharmaceutical ingredient. The concentration of rosin resin or derivative in the vehicle is sufficient to alter the release rate... Agent: Howard Eisenberg, Esq.